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Abstract 
       The work described in this thesis relates to gastro-oesophageal reflux (GOR) and 
extra-oesophageal reflux (EOR) in the cystic fibrosis (CF) population. This thesis 
describes the characteristics of GOR and EOR and their association with pulmonary 
function, gastric aspiration and inflammation in the airway. In particular the study 
explores the increasing prevalence of overweight/obesity in CF and its association with 
GOR/EOR. In a sub group of patients (n=12) a longitudinal investigation took place to 
observe the effects of a new CFTR potentiator (Ivacaftor 150 mg/12h) on GOR/EOR 
symptoms. 
         72 CF adults recruited from a CF outpatient clinic consented to the study (39M/33F; 
median age 21 (16-60) years) and completed questionnaires to characterise symptoms of 
GOR (DeMeester score 0-9; < 1 normal) and EOR (Reflux Symptom Index (RSI) score 0-
45; < 13 normal). Patients were measured for BMI kg/m
2
 and grouped according to the 
following BMI categories: underweight <18.5 kg/m
2
, normal weight 18.5-25.0 kg/m
2
, 
overweight 25.1-30.0 kg/m
2
 and obese >30.0 kg/m
2
. An expectorated sputum sample was 
provided and analysed for biomarkers of reflux (pepsin n=69 ELISA) and inflammation 
(IL-6 n=62 and IL-8 n=64 ELISA). Pulmonary function (FEV1 and FVC % predicted) and 
genotype were recorded at the time of data collection. Statistical relationships were 
assessed using the Kruskal-Wallis statistical test followed by the Mann Whitney U test.  
          GOR symptoms (DeMeester) were identified in 42% of patients and EOR 
symptoms (RSI) in 63% of patients.  Pepsin was detected in 48 (70%) patient samples 
(median: 330ng/ml; range 80-1150ng/ml) and not correlated with GOR/EOR symptoms. 
GOR/EOR symptoms and gastric aspiration did not associate with pulmonary function, 
nor was GOR associated with inflammation of the airways. CF patients can be 
overweight/obese (16.7%), and this was associated with better lung function; they have 
less reflux. Obesity didn't show a relationship to F508del/F508del status or to gender. 
Ivacaftor treatment was associated with reduced symptoms of GOR and EOR (6 weeks to 
12 month post medication) accompanied by positive effects on pulmonary function. 
          GOR is common in CF patients and EOR symptoms are very prevalent in CF and 
more so than GOR. Microaspiration of gastric content into the airway was not correlated 
with pulmonary function and occurred across the spectrum of disease severity. 
Overweight/obese patients experience less EOR symptoms. The CFTR potentiator 
Ivacaftor reduced GOR and EOR symptoms after 6 weeks of treatment. 
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Chapter 1.0 
 
General introduction 
1.1 Cystic Fibrosis from the beginning 
     Cystic Fibrosis (CF) was first described in 1938 by Dr Dorothy Andersen who was 
working at the New York Babies Hospital as a pathologist (Orenstein et al., 2000). It was 
known that salty skin was problematic for babies for many years but it was Paul di 
Sant’Agnese who discovered in 1953 that babies with CF had increased salt content in 
their sweat. This knowledge lead to the invention of the diagnostic tool of non-invasive 
sweat testing (di Sant'Agnese et al., 1953). The name ‘cystic fibrosis’ came about due to 
the changes to the pancreas caused by the disease whereby the damaged pancreas becomes 
filled with fluid filled spaces (cysts) and scar tissue (fibrosis) (Thomson and Harris, 2008). 
The 1960’s brought further prospect for the future of CF research with the opening of the 
Cystic Fibrosis Research Foundation Trust charity. This was one of many charities raising 
funds and awareness of the disease (Hodson et al., 2007). In 1985 Professor Lap-Chi Tsui, 
Dr Francis Collins and Professor Jack Riordan identified the specific gene responsible for 
CF found on chromosome 7 and called it the cystic fibrosis transmembrane conductance 
regulator (CFTR) (Tsui et al., 1985). The 20
th
 century witnessed historical key scientific 
mile stones in CF research  resulting in improved life expectancy and quality of life for CF 
patients (and their families) today and for the future (Simmonds, 2013).  
1.2 Epidemiology of Cystic Fibrosis  
     CF is the most common fatal autosomal recessive disease in the Caucasian population 
(Wilson and Pencharz, 1998), one of the most common life-shortening diseases in white 
populations (Orenstein et al., 2000) with expected life expectancy of 40 or 50 years today 
(Thomson and Harris, 2008; Salvatore et al., 2012; Simmonds, 2013). About 1 in 25 
people are a carrier of the recessive mutated CFTR gene with an estimated  1 in every 
2500 live births affected by a mother’s and father’s mutated CFTR gene being carried onto 
their child (Bourke and Burns, 2011). 
     Seventy percent of babies born with CF when it was first described in 1938 were not 
expected to live beyond the age of 1 year (Orenstein et al., 2000; Simmonds et al., 2009). 
In the 1960’s survival rates had increased to 14 years of age due to careful clinical 
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observation and comprehensive treatment programs of diagnostic advances and antibiotic 
treatment (Orenstein et al., 2000; Simmonds, 2013). Reports from the Cystic Fibrosis 
Foundation in 2005 reported median survival to be 36.8 years. A study in 2009 reported 
that n=112 CF patients at their clinic in London were over 40 years of age without lung 
transplantation (median 43.1; range 40-71)  (Simmonds et al., 2009). Research supports 
the predicted median survival age of 50 years for patients born in the year 2000 through 
the observations of continued improvement in the survival of CF patients (Dodge et al., 
2007). 
 1.3 Genetic defects of Cystic Fibrosis 
     CF is caused by mutations on both alleles of the CF transmembrane conductance 
regulator (CFTR) gene that codes for the CFTR protein and there are approximately 2000 
CFTR mutations described to date (Bell et al., 2014; Kotha and Clancy, 2013). CFTR is a 
chloride channel and the role is to regulate salt, fluid and pH balance in multiple organs 
(Van Goor et al., 2013). Protein Kinase A (PKA) phosphorylates CFTR to allow ATP 
binding and hydrolysis which in turn opens and closes the channel across cell membranes 
(channel gating) to allow chloride, and bicarbonate ions to be transported. CFTR 
mutations result in abnormal chloride and bicarbonate ion transport. There are 5 classes of 
CFTR mutations, classes I-III are non-functional CFTR proteins whereas class IV-V 
CFTR proteins do have some function (Figure 1.1). The most common mutation affecting 
80% of patients is the F508del in class II. Class II mutations bring about improper protein 
folding and the CFTR protein remains in the endoplasmic reticulum instead of the plasma 
membrane therefore there is minimal CFTR protein at the cell surface (trafficking). Class 
III mutations differ to class II because the CFTR protein is present at the cell surface but 
displays a defective channel gating resulting in minimal chloride transport. Class III 
mutations occur in approximately 4-5% of patients, the most common mutation in this 
class is G551D (Kotha and Clancy, 2013; Flume, et al., 2012; Yu, et al., 2012). The loss of 
chloride transport leads to elevated sweat chloride concentration, the accumulation of 
thick, sticky mucus in the bronchi, loss of pancreatic function, impaired intestinal 
absorption and reproductive dysfunction (Van Goor, et al., 2013; Yu, et al., 2012). The 
CFTR protein is predominantly expressed in exocrine tissues. These include the airways, 
intestines, pancreatic ducts and sweat glands (Van Goor et al., 2009; 2013; Kotha and 
Clancy, 2013). 
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Figure 1.1 The classification of CFTR mutations. The following illustration represents the 
location of the mutated CFTR in comparison to the normal CFTR (cell at the top left) 
showing the mutation class and a description of the nature of the defect. The normal 
mature CFTR protein (top left) is present at the cell surface and allows for the 
transportation of chloride ions. The class I mutation results in an unstable truncated CFTR 
mRNA leading to total or partial absence in CFTR protein production. The class II 
mutation causes misfolding of the CFTR protein and the protein remains inside of the 
endoplasmic reticulum of the cell leading to an absent functioning CFTR at the cell 
surface. The class III mutation results in the CFTR protein to be defective in channel 
regulation, it is present at the cell surface but the protein is resistant to activation. The 
CFTR class mutation I, II and III result in a non-functional CFTR channel. The class IV 
mutation results in a CFTR channel present at the cell surface but altered conduction of the 
CFTR protein reduces activity. The class V mutation leads to scarce CFTR protein at the 
cell surface caused by the splicing of the CFTR m-RNA. The class IV and V mutations 
cause a reduction in function of the CFTR protein. (Boyle and De Boeck, 2013; Fanen et 
al., 2014). 
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1.4 Diagnosis of Cystic Fibrosis 
       A classical feature in CF is salty skin which results from a high salt content in the 
sweat (di Sant'Agnese et al., 1953). This is due to the failure of the ion channel to reabsorb 
chloride ions from the sweat and results in a sweat sample containing high amounts of 
chloride and sodium concentrations. CF patients show abnormal sweat chloride levels (CF 
unlikely <39mmol/L; CF possible 40-59mmol/L; CF likely >60mmol/L) (Cystic Fibrosis 
Foundation, 2011).  A non-invasive sweat test is the gold standard biomarker to diagnose 
CF disease used to diagnose CF in association with typical clinical features including 
recurrent chest infections and pancreatic insufficiency (Veeze, 1995; Bourke and Burns, 
2011). For reliable sweat testing the Gibson and Cooke method is advised (Gibson and 
Cooke, 1959). 
     Due to advances in genetic testing the CF mutation can be defined by confirming two 
CF mutations on each allele from approximately 1900 mutations (Kotha and Clancy, 2013) 
but it can be difficult to exclude CF from rare mutations. The advances in CFTR mutation 
discovery has highlighted patients with CFTR mutations accompanied by mild clinical 
features, thus less severely affected patients. These patients are classed as atypical or non-
classic CF patients. They do not experience pancreatic insufficiency or recurrent 
pulmonary infection (Bourke and Burns, 2011). 
1.5 Pulmonary complications in Cystic Fibrosis 
      The CF population have poor respiratory function due to thickened mucus in the lungs. 
Reduced chloride secretion and increased sodium reabsorption causes an increased risk of 
pathogen colonisation (Orenstein et al., 2000). Mucus builds up on the outside of the cells 
expressing CFTR caused by the faulty chloride channel at the surface of the cell (Thomas 
and Bishop, 2007). The abundance of resulting mucus in the airways creates an 
environment suitable for bacteria to colonise and grow causing infections within the 
airway. The epithelial surface of the lungs normally have antimicrobial defences but the 
high salt content of the airway surface fluid causes an unnatural environment and results in 
inactivation of antimicrobial defences. Impaired internalization of the CFTR occurs when 
the CFTR is not present at the apical membrane. The defective internalization of 
respiratory pathogens limits bacterium clearing (Pier et al., 1996).  Furthermore, the CF 
surface of airway epithelium possesses increased apical receptors such as asialylated 
gangliosides receptors to allow bacteria to adhere and proliferate (Saiman and Prince, 
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1993; de Bentzmann et al., 1996). Thus, mechanistically defective CFTR leads to repeated, 
cyclical chest infection reoccurrence and this leads to further lung problems and 
progressive lung disease with associated morbidity and mortality. (Navarro et al., 2001; 
Steinkamp and Wiedemann, 2002; Konstan et al., 2007; Thomas and Bishop, 2007; 
Bourke and Burns, 2011). The impaired mucociliary clearance of sputum within the 
airways and bacterial infection lead to pulmonary exacerbations which may lead to 
hospitalisation and required intravenous antibiotics (Banner et al., 2009). It is lung disease 
which leads to premature mortality in most patients with CF. 
      The inflammatory system responds to the bacterial infection by producing 
inflammatory mediators at the site of infection. The mediators recruit neutrophils to attack 
the infection in order to eliminate it. The inflammatory response in the CF airway does not 
function effectively and cannot clear recurrent infections within the airways. Inflammation 
develops in the airways excessively in relation to the bacteria present and continues as the 
infection cannot be cleared (Bourke and Burns, 2011). This leads to a vicious cycle of 
excessive inflammation influx in the CF airway resulting in airway damage. Viral 
infections within the CF lung may potentially damage the epithelium (Banner et al., 2009). 
Progressive pulmonary disease is a leading cause of mortality for the CF population 
(Anthony et al., 1999; Sagel et al., 2007). 
1.6 Gastrointestinal complications in cystic fibrosis  
      A consequence of CF is the blockage and obstruction of the pancreatic ductules by 
thickened mucus produced by abnormal ion transport leading to the gland being 
progressively destroyed. This leads to the inhibition of the pancreatic enzyme lipase into 
the small intestine and results in fat malabsorption, steatorrhoea and failure to gain weight. 
This creates further problems involving the metabolism of fat soluble nutrients, vitamin 
A,D,E and K (Bourke and Burns., 2011; Thomas and Bishop, 2007; Orenstein et al., 2000). 
This is treated with pancreatic enzyme replacement therapy (PERT) taken with all food 
and drink to provide the patient with artificial pancreatic enzymes which breaks down 
dietary fat in the intestines to achieve optimum growth and nutritional status (Littlewood, 
1992; Anthony, et al., 1999;  Morton, et al., 2009). Patients with this complication are 
termed pancreatic insufficient and these patients have been accompanied with worse 
respiratory function. This was put down as a consequence of the pancreatic insufficiency 
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but now thought to be attributed to the mutation severity of the CFTR (Anthony, et al., 
1995).  
      It is well documented that gastro-oesophageal reflux (GOR) characterised by the 
retrograde movement of gastric contents up the oesophagus (Armstrong, et al., 2005; Chen, 
et al., 2010) is a problem in the CF population.  GOR leads to symptoms such as heartburn 
and/or acid regurgitation, in some cases GOR may cause oesophageal mucosal damage, 
which may lead to longer term complications. Reflux reaching the proximal oesophagus 
and extra-oesophageal areas termed extra oesophageal reflux (EOR) has been shown to be 
implicated in multiple respiratory disorders and may result in coughing, sore throat, 
excessive clearing of the throat, post nasal drip, chest wheezing and tightness (Button et 
al., 2005). These symptoms have been shown to reduce quality of life (Bendig et al., 
1982). It is reported that GOR adversely impacts lung function in CF due to the action of 
potent agents in refluxate (Gustafsson, et al.,1991; Navarro, et al., 2001; Blondeau, et al., 
2008a;  Pauwels et al., 2013). 
1.7 New treatments used in cystic fibrosis - CFTR therapeutic agents 
         The pace of clinical and scientific advances in CF research in the late 20th Century 
has been outstanding. During the first 14 years of the 21st century we already observe 
further scientific advances that have the potential to repair the loss of chloride transport by 
targeting the class defect of the CFTR. A group of CFTR modulators have been studied, 
these are pharmacological therapeutic strategy agents that repair the CFTR defect to 
restore function. On January 31st 2012 the approval of the first CFTR potentiator 
(Ivacaftor) took place after successful clinical trial outcomes in the class III G551D 
mutation. This CFTR modulator is a CFTR potentiator which induces channel opening to 
enable chloride ions to be transported through the CFTR present at the cell surface (Van 
Goor, et al., 2009; Kotha and Clancy, 2013).  Administration of 150 mg every 12 hours 
during clinical trials lowered the CFTR biomarker sweat chloride concentrations to below 
the CF diagnostic threshold (60mmol/L). Significant improvements were observed in 
pulmonary function and weight and interestingly pulmonary exacerbations and patient 
hospitalisation were reduced as a result of Ivacaftor treatment compared with placebo 
controls (Ramsey, et al., 2011; Accurso, et al., 2013). Ivacaftor treatment has been shown 
to continue its unprecedented success for the G551D CF patient population in CF clinics 
around the world (Reznikov, et al.2014; Davies, et al., 2013; Harrison, et al., 2013; 
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Hebestreit, et al., 2013; Polenakovik and Sanville, 2013; Barry et al., 2014). In excitable 
anticipation the CF community await further CFTR modulators for other CF patient 
populations with primary or secondary gating defects. More work is needed before we are 
likely to see the same results for the most common mutation, class II F508del defect that 
requires a CFTR corrector agent. The CFTR corrector increases the delivery of CFTR 
protein to the cell surface therefore increasing the flow of chloride ions. A combination 
approach of a CFTR corrector (Lumacaftor) with Ivacaftor for patients with the phe508del 
CFTR has shown encouraging results in clinical trials illustrating modest decreases in 
sweat chloride, and these studies are being consolidated and extended in  ongoing trials 
(Boyle, et al., 2014; Eckford et al., 2014; Quintana-Gallego et al., 2014). 
1.8 The future of CF and arising concerns 
      The CF population are living longer due to advances in health care, clinical treatment 
and continuing scientific research. The numbers of CF children are now being 
outnumbered by the increasing number of adults in  many clinics (Quon and Aitken, 2012; 
Simmonds, et al., 2013) and it has been reported that CF patients are living into their 50’s 
(Simmonds, et al., 2013). Furthermore, those that are born today with the CFTR mutations 
are predicted to have normal life expectancy due to future therapies that treat the basic 
defect (O'Sullivan and Freedman, 2009). Positivity surrounds the increase in life 
expectancy for the CF aging population, although the increasing survival statistics brings 
challenges with it that are now forming a focus for study. The concern of CF age 
associated co-morbidities and age related chronic diseases of the general population is an 
arising challenge (Dennersten, et al., 2009; Simmonds, et al., 2009; Quon and Aitken, 
2012; Simmonds, et al., 2013; Lerín, et al., 2014). GORD has been observed to be higher 
in the adult CF population (Ledson et al., 1998; Blondeau et al., 2008; Sabati et al., 2010; 
Phitidis et al., 2014).  
      It was reported that CF BMI status has increased beyond an ideal status (BMI 
25.0kg/m
2
) and this could be attributed to nutritional interventions of a high fat and calorie 
diet. There is an increasing prevalence of CF overweight and obese BMI status (Kastner-
Cole et al., 2005; Stack et al., 2007; Munck et al., 2007; Coderre et al., 2012; 
Panagopoulou et al., 2014); Stephenson et al., 2013; Kochavi et al., 2014) which has been 
associated with increased risks of GORD in the general population (El-Serag, et al., 2005, 
Dore et al., 2008; Hampel, et al., 2005).  
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1.9 Overall aims of the thesis    
      The importance of long-term health is increasingly recognised for the aging CF 
population, but further research is required.  This thesis focused on the prevalence of GOR 
and EOR in the CF population at the Royal Victoria Infirmary chest clinic, Newcastle 
upon Tyne.  
      The characteristics of GOR and EOR were explored and each was determined using 
validated questionnaires. Gastric aspiration of reflux contents were determined by 
analysing GOR biomarkers in the expectorated sputum of CF patients. The association 
with pulmonary function was explored. In addition, the presence of inflammation within 
the airway was measured in expectorated sputum to assess the role gastric aspiration may 
play in the inflammatory response.  
      Assessment was made of the role a CFTR potentiator, Ivacaftor, may have on the 
presence of reflux (symptoms and gastric aspiration). This was measured by the 
longitudinal investigations over a 12 month period in 12 patients with the G551D mutation 
receiving Ivacaftor for the first time.  
      The prevalence of overweight and obesity was investigated and its association with 
GOR in the CF population and their association with gender and genotype were assessed. 
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Chapter 2.0 
Methodology 
2.1 Project specific materials 
Dulbecco A Phosphate buffered saline, pH 7.3, Oxoid Limited, Basingstoke, Hampshire, 
England. 
TWEEN® 20, SIGMA life Science, SIGMA-ALDRICH Co, 3050 Spruce Street, St Louis, 
MO 63103, USA. 
Sputolysin® - Dithiothreitol (DTT), Calbiochem, Merck KGaA, Darmstadt, Germany. 
Maxisorp NUNC-Immuno 96 well plate, Thermo Scientific NUNC™ F96, Kamstrupvej, 
90 P.O.BOX 280, DK-4000, Roskilde, Denmark. 
Pre-cut transparent microplate sealers, Grelner Bio-One Limited, Brunel way, Stroudwater 
Business Park, Stunehouse, Glossier UK. 
Sodium Dodecyl Sulphate, BDH Laboratory Supplies, Poole, UK. 
Bovine Serum Albumin, Cohn Fraction V Powder pH 7.0, VWR International Ltd, Hunter 
Boulevard, Magna Park, Lutlerworth, Leicestershire, UK. 
Pepsin, Porcine gastric mucosa, SIGMA life Science, SIGMA-ALDRICH Co, 3050 
Spruce Street, St Louis, MO 63103, USA. 
Pepsin primary antibody monoclonal anti-pepsin antibody, W59117G, Biodesign Int. 
US/AMS Biotechnology, UK.  
Secondary horseradish peroxidise conjugated polyclonal anti-goat/sheep antibody, Sigma, 
UK. 
R&D systems human and recombinant IL-8 and IL-6 kit (catalog number: DY208 
&DY206) containing: 
Capture antibody mouse anti-human IL-8 and IL-6 
Detection antibody biotinylated goat anti-human IL-8 and IL-6 
Standard recombinant human IL-8 and IL-6 
Streptavidin conjugated to horseradish peroxidase (HRP) 
(R&D Systems Europe, Ltd. Abingdon, UK) 
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2.2 Ethics and consent 
     Full ethical approval was granted for this study by the County Durham & Tees Valley 2 
Research Ethics Committee (REC NO: 10/H0908/8) (Appendix 8.1). The ethical 
application process of this study was carried out by Mr Amaran Krishnan. Each patient 
recruited signed the consent form to agree to take part in the study. 
2.3 Patient Recruitment 
     Seventy two patients 16 years or older with clinical cystic fibrosis undergoing routine 
clinical appointments at the outpatient chest clinic in the Royal Victoria Infirmary (RVI) 
were recruited to participate in the study. Eleven patients were recruited by telephone call 
and attended scheduled appointments with Mr Amaran Krishnan for oesophageal studies 
in the endoscopy clinic at the RVI. Each patient (n=72) received details about the study 
and had the opportunity to read the study information sheet. Once they agreed to take part 
in the study the patient was asked to listen to the researcher talk through the consent form 
and each point was ticked to say that they agreed. The consent form was signed by the 
patient and the person taking consent in which the printed name, signed name and the date 
was provided. A copy of the consent form was stored at the research facility and also the 
patient received a copy along with the study information sheet (Appendix 8.2). The 
following criteria were taking into consideration when recruiting patients (Table 2.1 and 
Figure 2.1).  
      
Inclusion Exclusion 
16 years and above None sputum providers 
Cystic fibrosis patient Under 16 years of age 
Attending appointment at Royal Victoria 
Infirmary; Freeman hospital, James Cook. 
tube fed only 
Sputum producers upon request (accept for 
Ivacaftor patient cohort/ all recruited) 
 
 Table 2.1 Subject inclusion and exclusion criteria 
 
     In an attempt to increase subject numbers an amendment to the ethical approval was 
applied for and granted to recruit CF patients from two other hospitals. CF patients were 
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recruited from a pre-lung transplant assessment clinic at the Freeman Hospital (Newcastle) 
and the monthly outreach chest clinic at James Cook Hospital in Middlesbrough.  
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Sputum producers Non-sputum producers
Recruited - asked to produce 
expectorated saliva
Recruited
N
ew
 m
ed
ic
at
io
n
 i
n
 C
F
 –
Iv
ac
af
to
r 
C
F
T
R
p
o
te
n
ti
at
o
r 
fo
r 
th
e 
G
5
5
1
D
 m
u
ta
ti
o
n
  
Questionnaire:
• DeMeester Reflux questionnaire 
• Reflux Symptom Index
• Hull Airway reflux Questionnaire
Gastric aspiration:
• Pepsin (ELISA)
Inflammation
• Cell differential
Expectorated sputum/saliva sample
• Sweat chloride concentration
• Weight
• BMI 
Pulmonary function:
• Forced expiratory volume in 1 second
• Forced vital capacity
D
at
a 
co
ll
ec
te
d
 f
o
r 
st
at
is
ti
ca
l 
an
al
ys
is
Longitudinal 
follow-up at:
• Baseline
• 6 week
• 6 month
• 12 month
 
Cystic fibrosis patients (16 years +)
Sputum producers Non-sputum producers
ExcludedRecruited
T
h
e 
d
ie
ta
ry
 m
o
d
if
ic
at
io
n
s 
fo
r 
C
F
 –
as
se
ss
m
en
t 
o
f 
re
la
te
d
 p
ro
b
le
m
s 
Questionnaire:
• DeMeester Reflux questionnaire 
• Reflux Symptom Index
• Hull Airway reflux Questionnaire
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BMI category:
• BMI kg/m2
• Under-weight/ Ideal-weight/ Over-weight/ Obese
 
14 
 
Figure 2.1 Summary of patient recruitment and experimental strategy for each result 
chapter. The summary illustrates the title of each chapter and the data collected for the 
analysis. 
2.4 Patient attendance 
     A total of 72 patients fulfilled all the study requirements and were enrolled onto the 
study. Attempts were made to increase the study number over the recruitment period; a 
further 24 were approached but were unable to produce a sputum sample. Two of these 
patients provided all the study requirements and failed to produce sputum after many 
attempts so they were excluded from the study.  
2.5 Sputum collection 
     Expectorated sputum sample were requested from each patient (accept for the 
assessment of Ivacaftor treatment as expectorated saliva was used to replace sputum for 
the non-producers). The patient was provided with a sputum pot and was given time to 
produce a sample in the consulting room that they were directed to by the nurse upon 
arrival to the RVI, within the contamination regulations of the chest clinic. The patients 
were asked whether they would prefer privacy for this activity and everyone was requested 
to leave the room if required. The expectorated sample was then stored on ice in a secure 
sample collection box until processing within 2 hours of collection in a class 2 cabinet in 
the laboratory. Recruitment usually took place during the hours of 14.00 to 17.00. These 
appointment times were made available for the CF patients to ensure that the consulting 
rooms were cleaned and prepared for each patient depending on the bacteria infection 
within their airways to avoid cross contamination. The cross contamination rules for the 
outpatient clinic times set by the respiratory unit in the RVI aimed to set a clinic date 
depending on colonization of Pseudomonas aeruginosa and Staphylococcus aureus. 
2.6 Sputum processing 
     In a ventilated class 2 cabinet the sputum plugs were separated from the surrounding 
saliva, The plugs were transferred to a pre-weighed centrifuge tube and the sputum weight 
determined. Dulbeccos phosphate buffered saline (DPBS) was added to the sputum (8x 
initial sputum weight) and allowed to disperse in a centrifuge tube rocking on ice for 15 
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minutes. The sample was centrifuged at 2500rpm for 10 minutes at 4°C, the supernatant 
was removed and further centrifuged at 2500rpm for 10 minutes and the resulting 
supernatant was aliquotted in preparation for further analysis. The aliquots were labelled 
and stored at -70°C. 
The sputum pellet consisting of mucus and cells were further processed to determine total 
cell counts using a hemocytometer and to then analyse cell differentials (macrophages, 
neutrophils, eosinophils, lymphocytes and squamous cells). A 0.2% preparation of 
sputolysin (Dithiothreitol (DTT) in deionised water (DH2O)) was used to break down the 
sulphide bonds within the sputum sample. Sputolysin was added (x4 initial sputum weight) 
to the pellet and allowed to disperse in a centrifuge tube rocking on ice for 10 minutes. 
PBS was added to the dispersed pellet (4x initial sputum weight). The dispersed pellet 
solution was filtered through a 48µm nylon gauze into a centrifuge tube and centrifuged at 
2000rpm for 10 minutes at 4°C. After centrifugation the supernatant with DTT was not 
used for any experimental analysis due to DTT interference. The DTT supernatant was 
discarded. The pellet was re-suspended in PBS and a 1:1 mix of 20µl trypan blue and cell 
suspension was modulated for cell count analysis. The cells were counted using an 
improved Neubauer haemocytometer. The remaining cells were washed with Dulbeccos 
phosphate buffered saline (D-PBS) and centrifuged at 800rpm for 10 minutes at 4°C. The 
supernatant was discarded and D-PBS was added to the pellet to adjust the cell 
concentration to about 0.5x 10
6 
cells per ml. Twelve cytospins were prepared using 80µl 
of the cell suspension and spun at 450 rpm for 6 minutes in a cytospin centrifuge. The 
cytospins were air dried for 2 minutes and stored for staining. 
2.7 Cell Staining 
2.7.1 Geimsa 2 (Romanovsky) Stain 
     The stock solution of Geimsa consisted of Azure B thiocyanate dissolved in Dimethyl 
sulfoxide (DMSO) (1.25%) slowly added to Eosin Y dissolved in Methanol (0.16%) and 
stored at 18ºC. The working dilute solution of Geimsa consisted of stock solution diluted 
1:1000 with PBS (pH 7.4) containing 0.05% tween (PBST). One cytospin per patient was 
fixed in 100% acetone for 10 minutes at room temperature and allowed to air dry. The 
slides were stained with the working dilution of Geimsa for 10 minutes. They were 
dispersed and rinsed in dH2O for 1 minute. Once air dried the slides were mounted with a 
glass cover slip with the addition of DPX (Distrene-80, Plasticizer, Xylene). The principle 
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of the Geimsa stain is to stain the nucleus of all types of inflammatory cells.  A differential 
count of the cell types was performed. The percentage of neutrophils, macrophages, 
eosinophils, lymphocyte and squamous as well as the total number of cells per ml of 
solution were determined. 
2.7.2 Oil Red O 
     The principle of the Oil Red O stain is to specifically stain the lipid contained in the 
cells because this has been proposed as a useful reflux diagnostic tool (Hopkins et al., 
2010; Hayes et al., 2013). The stock solution consisted of Oil Red O dissolved in 
isopropanol (0.5%) and stored at 18ºC. The working solution consisted of stock Oil Red O 
solution (30ml) diluted in dH20 (20ml) and allowed to stand for 10 minutes. The solution 
was then filtered and covered with parafilm. 1 cytospin per patient was fixed in 100% 
formalin for 10 minutes at room temperature, and then rinsed in dH2O and again in 
isopropanol. The slides were stained with freshly prepared working solution Oil Red O for 
15 minutes and then were rinsed in isopropanol for 10 seconds and again in dH2O. The 
slides were counterstained with Harris Haematoxylin for 1 minute to stain the nucleus of 
each cell. They were rinsed in dH2O until the stain appears blue in colour. The slides were 
mounted with a glass cover slip with the addition of aqueous mountant (Glycerin Jelly: 
Gelatin 10g, dH20 60ml, Glycerol 70ml, Phenol 0.25g). The slides were ready for counting 
and each cell was analysed for lipid laden macrophage content straight after staining. The 
Oil Red O stain is clearly visible for 24 hours and cannot be stored for later analysis. The 
lipid laden macrophage index was used to score each patient’s lipid laden macrophage 
content.  
The lipid index is the sum of the intensity staining scores for 100 consecutive 
macrophages based on a semi quantitative scale of 0 (no staining) to 4 (maximum 
staining). Thus, the possible range is 0 - 400. Under a microscope each macrophage is 
given a score of 0 to 4 depending on the visible red droplets within the cytoplasm and the 
nucleus. The table below illustrates each score. Once 100 macrophages have been scored 
the total score can be calculated for each patient (Table 2.2). 
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Score Example Details 
0 
 
0: absence of staining 
 
1 
 
1: one or a few lipid 
droplets 
 
2 
 
2: many distinct droplets 
 
3 
 
3: many droplets with 
visible nucleus 
 
4 
 
4: many droplets 
completely covering the 
cytoplasm and 
obscuring the nucleus 
Table 2.2 The Lipid Laden Macrophage Index scoring system 
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2.8 Questionnaire 
2.8.1 Identification of GOR symptoms 
     All patients were evaluated by the validated DeMeester reflux questionnaire (Appendix 
8.3.1) to assess the occurrence of typical GOR symptoms (heartburn, regurgitation and 
dysphagia). Each symptom was given a score of 0 to 3 (0: no symptoms; 1: occasional 
episodes, 2: reason for medical visit, 3: interference with daily activities) and each score 
was totalled to give an overall score with a maximum score possible of 9. If a patient score 
was <1 they were classed as none symptomatic for GOR and if they had a total score >2 
they were classed as GOR symptomatic (DeMeester et al., 1980; DeMeester et al., 1981). 
The questionnaire was validated using 393 patients with suspected oesophageal disease 
that underwent interview with the author of the questionnaire to complete the DeMeester 
reflux questionnaire. The patients underwent 24 hour pH oesophageal monitoring to 
determine abnormal reflux episodes. They underwent a fiberoptic esophagoscopy to 
determine the presence of endoscopic eosophagitis. They also underwent a biopsy of the 
oesophageal mucosa to determine the presence of inflammatory infiltrate within the 
mucosa to consider evidence of esophagitis. This was deemed abnormal if the total reflux 
score sum was above the upper limit of a healthy volunteer cohort determined previously 
in 15 healthy volunteers of an age range similar to that of the GOR patients (Johnson and 
DeMeester, 1974). The 24 hour pH test score correlated with the recorded typical 
symptoms of heartburn, regurgitation and dysphagia. 73% patients with an abnormal 24 
hour acid reflux test and 64% of patients with esophagitis experienced typical reflux 
symptoms. There were only 3% of patients with esophagitis and a negative 24 hour pH 
test that did not experience classical reflux symptoms. In addition 90% of patients with 
typical symptoms of reflux and esophagitis had a positive 24 hour pH test result 
highlighting the validity of the DeMeester reflux questionnaire to determine GOR. 
2.8.2 Identification of EOR symptoms 
     The Reflux Symptom Index (RSI) questionnaire (Appendix 8.3.2) was used to assess 
EOR/atypical GOR symptoms. The questionnaire was first used to assess 
laryngopharyngeal reflux but has been validated to assess EOR in many studies. The 
questionnaire consists of a series of questions about characteristics of EOR including the 
following: hoarseness, clearing of the throat, postnasal drip, difficulty swallowing, 
coughing, breathing difficulties, golbus and GOR symptoms. The questionnaire required 
an answer from 0 to 5 where 0 is no problem at all to 5 being a severe problem. The scores 
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were totalled and the patient classed as EOR symptomatic if they received a score of 13 
and above (a score <12 was classed as none EOR symptomatic) (Belafsky et al., 2002). 
The questionnaire was validated using 25 patients with  laryngopharyngeal reflux and 25 
age-matched and gender-matched healthy controls with no symptoms or evidence of 
laryngopharyngeal reflux. The patients completed the RSI score before and after the 
administration of proton pump inhibitors, the median score pretreatment was 21 and the 
median score post-treatment was 13. The median score for the healthy volunteers was 13 
and therefore this was used as the normal range of symptoms, any score above that was 
deemed abnormal. 
     The questionnaires above have been used as validated questionnaires in studies 
assessing GOR and EOR in a cohort of patients receiving anti-reflux surgery (Robertson et 
al., 2012) and EOR symptoms of patients with sleep apnea causes by GOR 
(Laohasiriwong et al., 2013). 
 
2.8.3 Airway reflux cough 
     The Hull Airway Reflux Questionnaire (HARQ) (Appendix 8.3.3) was used to assess 
cough related EOR. This validated questionnaire assessed symptoms similar to the RSI 
with additional cough questions and asked if the patient experienced a metallic taste in the 
mouth. The questionnaire required the patient to score the symptom severity from 0 (no 
symptoms) to 5 which is a severe problem. The scores were totalled and the patients 
classed as cough related EOR symptomatic if they received a score of 13 and above (a 
score <12 was classed as none cough EOR symptomatic) (Morice et al., 2011). There 
were 185 patients experiencing chronic cough for 8 weeks or more that had an objectively 
proven diagnosis of significant acid gastro-oesophageal reflux on 24-h pH assessment. 
There were 70 healthy controls included in the validity of the HARQ questionnaire. The 
scores of the questionnaire were compared to identify a marked difference between 
healthy controls and chronic cough patient HARQ scores with little overlap. The analysis 
of direct estimation using the lower limit of normal to be 0, a 95% reference interval was 
calculated to give  a 95% reference range of 0-13, with the distribution giving a mean 
score of 4.3 with the standard deviation to be 12.7. The upper limit of the HARQ normal 
score was therefore 13 and any score above that was deemed abnormal. There were 10 
chronic cough patients with a score below 13 which is 6% of the patient population giving 
the HARQ sensitivity for detecting cough hypersensitivity of 94.1% and specificity 95%.  
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2.9 Pepsin identification and quantification using indirect ELISA 
     The immunoassay reported herein is an indirect enzyme-linked immunosorbent assay 
(ELISA) developed in-house from the laboratory of Jeffrey Pearson (Stovold et al., 2007). 
The protocol was optimised for the analysis of sputum supernatant by increasing antibody 
concentrations and introducing shaking at 500-700 rpm during incubation steps. Maxisorp 
NUNC-immuno 96-well plate were used for the pepsin ELISA.  
 Standard and sample coating 
The standard of pepsin from porcine gastric mucosa (sigma) was diluted in PBS ranging 
from 0 to 100 ng/ml, 100µl was coated onto each well. The sputum processing resulted in 
a 1 in 8 (wt/vol) dilution and no further dilutions were necessary. In duplicate 100µl of 
each diluted sputum sample was coated onto the well. A negative control (in duplicate) 
was added for both the standard and samples, the sample in the negative control was 
treated in every step excluding the primary antibody and incubating in antibody diluent 
instead. The plate was covered with pre-cut transparent microplate sealers and incubated 
for 12-16 hours at room temperature with shaking at 700rpm. 
 Blocking 
After the 12-16 hour incubation the residue was discarded and the plate was dried 
thoroughly. The wells were blocked with 300µl of 1% bovine albumin (BSA) for 2 hours 
at room temperature with shaking at 500rpm to block unspecific antibody binding sites.   
 Primary antibody 
The blocking buffer was discarded and the wells were dried by blotting thoroughly. 100µl 
of primary anti-pepsin antibody (anti-pepsin, Biodesign, Saco, MN, USA) was added to 
duplicate wells at a dilution of 1:100 in 0.1% BSA/PBS solution. 100µl of 0.1% bovine 
albumin BSA solution was added to negative wells serving as a background well. The 
plate was incubated with shaking at 700rpm at room temperature for 2 hours.  
 Secondary antibody 
The solution was discarded and wells washed twice with 300µl 0.05% Tween20 in PBS, 
and twice with PBS, then thoroughly dried by blotting. 100µl of the secondary antibody 
(horseradish peroxidise (HRP)-conjugated anti-sheep/goat, Sigma, UK) was added to each 
well (positive and negative) diluted 1:1000 in 0.1% BSA and incubated with shaking at 
700rpm at room temperature for 1.5-2 hours. 
 Development 
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After incubation the solution was discarded and the wash step was repeated with a 
thorough blot to dry. The addition of 100µl of substrate solution (2,2’Azino-bis 3 
ethylbenzothiazoline 6 sulfonic acid (ABTS) from Sigma) was added to each well and 
developed for 20 minutes at room temperature. The reaction was stopped by the addition 
of 50µl 1% sodium dodecyl sulphate (SDS) in DH2O. 
 Analysis 
The colour development in each well of the plate was analysed on the plate reader Infinite 
200Pro at 405nm. The data was captured using the Tecan i-control software (1.10.4.0 
serial number 1301007217). Figure 2.2 describes the principle of the indirect ELISA. 
 
Figure 2.2 Schematic of the indirect pepsin ELISA. The pepsin antigen is added to the 
well and immobilised by direct absorption to the bottom of the plate. The primary 
unlabelled antibody binds to the pepsin antigen which is further detected by the secondary 
antibody which is conjugated with horse-radish peroxidise (HRP). ABTS is added as a 
substrate which reacts with HRP to produce a green colour which is proportional to the 
amount of pepsin in the well and this colour is measured at 405nm. 
2.10 Bile salt identification and quantification using tandem mass spectrometry 
     Twenty-four sputum supernatant samples were analysed for total bile acids by tandem 
mass spectrometry in Sheffield, UK. Bile salts were analysed by identifying taurine and 
glycine conjugates of cholate and deoxycholate and their isomers. These account for 95% 
of the total bile acids because the minor sulphated components are not measured using this 
method (Pearson and Parikh, 2011). The bile acids were calculated by adding the 
PEPSINPEPSINPEPSIN
Secondary antibody
Primary antibody
Substrate
Conjugated HRP
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individual bile salt values. They were measured by using a Waters Acquity TQ Detector 
tandem mass spectrometer with direct flow injection able to measure a lower detection 
limit of 0.01µmol/L. The samples were pre-extracted using 500mg SPE cartridge (Supelco 
LC-18) and then washed with 10ml methanol, followed by washing with 10ml distilled 
H2O. The sample and standard were loaded in amounts of 400µl of sample/standard in 
10ml distilled H2O with 0.15 nmol of d4-taurocholic acid. The column was washed with 
10ml of distilled H2O and 2 ml hexane. The addition of 20 ml ethanol was used to elute 
the bile salts and then they were reduced to dry matter by the process of rotary evaporation. 
The dry extract from each sample was reconstituted in 1ml of acetonitrile prior to 
centrifugation at 13000 rpm for 5 minutes. The supernatant of each sample was injected 
into the mass spectrometer. The analysis of the samples was carried out by electrospray 
ionisation in negative ion mode using mass spectrometry (collision gas argon) in multiple 
reaction mode for conjugated bile acids. 
2.11 Interleukin 8 (IL-8) identification and quantification using capture ELISA 
     To measure human Interleukin 8 (IL-8) a DuoSet ELISA kit was purchased from R&D 
systems (catalogue number: DY208). This kit provides a sandwich ELISA with a 
sensitivity to detect 31pg/ml and measures up to 2000pg/ml. The assay was carried out as 
detailed in the kit protocol with provided materials and is described below. 
 Coating with capture antibody 
100µl mouse anti-human IL-8 diluted to 4µg/ml in PBS was added to each well on a 96 
well microplate and sealed with an adhesive plate cover. The plate was incubated for 16 
hours at 18
o
C.  
 Wash step 
The contents of the plate were discarded and each well washed with wash buffer three 
times. The plate was dried by inversion and by patting the plate with force on paper towels. 
 Blocking step 
100µl of 1% BSA was added to each well and incubated at 18
o
C for 1 hour. 
 Standards and samples 
After washing as in step 2, 100µl of sputum supernatant was added in duplicate to 
assigned wells. 100µl of recombinant human IL-8 (0-2000pg/ml in a 7 point 2-fold serial 
dilution) was added to 8 wells in duplicate. The plate was sealed and incubated for 2 hours 
at 18
o
C. 
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 Detection antibody 
After washing as in step 2, 100µl of biotinylated goat anti-human IL-8 diluted to 20ng/ml 
in reagent diluent (0.1% BSA, 0.05% tween 20 in Tris-buffered saline (0 mM Trizma Base, 
150 mM NaCl) at pH 7.2 – 7.4 and filtered through 0.2 µm filter paper) was added to each 
well. The plate was sealed and incubated at 18
o
C for 2 hours. 
 Development 
After washing, 100µl of streptavidin HRP at a dilution of 1:200 in reagent diluent was 
added to each well and incubated for 20 minutes out of direct light at 18
o
C. The contents 
were discarded and washed and 100µl of TMB (1:1 H2O2 and tetramethylbenzidine) was 
added to each well then incubated for a further 20 minutes out of direct sunlight at 18
o
C. 
The addition of 50ul stop solution (2N H2 SO4) was required for each well and the plate 
was placed on the plate shaker for 1 minute at 100rpm.  
 Analysis 
The optical density (OD) of the contents of each well was immediately determined using a 
microplate reader set at 450nm and corrected at 570nm (OD@570nm-OD@450nm) to 
correct for optical imperfections. 
 Determination of IL-8 in sample from standard 
The average OD value was derived for the standard and sample wells, the zero IL-8 
standard OD value was subtracted from each mean value. GraphPad (version 5) was used 
to create a standard curve with a 4 parameter logistic curve fit. The sample values were 
interpolated from the standard curve. 
 
2.12 Interleukin 6 (IL-6) identification and quantification using capture ELISA 
     To measure natural human Interleukin 6 (IL-6) a DuoSet ELISA kit was purchased 
from R&D systems (catalogue number: DY206). This kit provides a sandwich ELISA 
with a sensitivity to detect 9pg/ml and measures up to 600pg/ml. The assay was carried 
out as detailed in the kit protocol with provided materials as is described below. 
 
 Coating with capture antibody 
100µl mouse anti-human IL-6 diluted to 2µg/ml in PBS was added to each well on a 96 
well microplate and sealed with an adhesive plate cover. The plate was incubated for 16 
hours at 18
o
C.  
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 Wash step 
The contents of the plate were discarded and each well washed with wash buffer three 
times. The plate was dried by inversion and patting the plate with force on paper towels. 
 Blocking step 
100µl of 1% BSA was added to each well and incubated at 18
o
C for 1 hour. 
 Standards and samples 
After washing as in step 2, 100ul of sputum supernatant was added in duplicates to 
assigned wells. 100µl of recombinant human IL-6 (0-600pg/ml in a 7 point 2-fold serial 
dilution) was added to 8 wells in duplicate. The plate was sealed and incubated for 2 hours 
at 18
o
C. 
 Detection antibody 
After washing as in step 2, 100µl of biotinylated goat anti-human IL-6 diluted to 50ng/ml 
in reagent diluent (1% BSA at pH 7.2 – 7.4) was added to each well. The plate was sealed 
and incubated at 18
o
C for 2 hours. 
 Development 
After washing, 100µl of streptavidin HRP at a dilution of 1:200 in reagent diluent was 
added to each well and incubated for 20 minutes out of direct light at 18
o
C. The contents 
were discarded and washed and 100µl of TMB was added to each well then incubated for 
a further 20 minutes out of direct sunlight at 18
o
C. The addition of 50µl stop solution (2N 
H2 SO4) was required for each well and the plate was placed on the plate shaker for 1 
minute at 100rpm. 
 Analysis 
The optical density of the contents of each well was immediately determined using a 
microplate reader set at 450nm and corrected at 570nm (OD@570nm-OD@450nm) to 
correct for optical imperfections. 
 Determination of IL-6 in sample from standard 
The average OD value was derived for the standard and sample wells, the zero IL-6 
standard OD value was subtracted from each mean value. GraphPad (version 5) was used 
to create a standard curve with a 4 parameter logistic curve fit. The sample values were 
interpolated from the standard curve. 
 
The figure 2.3 describes the principle of a sandwich ELISA used from R&D systems 
specific for IL-8 and IL-6. 
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Figure 2.3 Schematic of the sandwich IL-8 and IL-6 ELISA 
The capture antibody was coated onto the surface of the plate and absorbed through 
overnight incubation and any remainder is washed away. The standard (IL-8/IL-6) and 
samples bind to the antigen specific immobilised capture antibody followed by the 
biotinylated detection antibody. The streptavidin horseradish peroxidase binds to the 
detection antibody which binds to the tetramethylbenzidine (TMB) substrate solution to 
result in a blue colour development in proportion to the amount of IL-8/IL-6 analyte 
present. The colour development is then stopped after 20 minutes by adding stop solution 
and the yellow colouration is absorbed at 450nm. 
2.13 Pulmonary function 
     Forced expiratory volume in 1 second (FEV1) and Forced vital capacity (FVC) were 
recorded at routine appointments by clinically trained staff. The predicted values for these 
measurements were corrected according to age, gender and height reference ranges using 
European standards ECCS (Laszlo et al., 2006). The results were gathered and provided 
for the study by Mr Alan Anderson (CF Nurse Specialised) under the authority of Dr 
Stephen Bourke (Respiratory Consultant, RVI).  
2.14 Genotype 
     The patients CFTR genotype was collected by Mr Alan Anderson from the patient’s 
record file. Patients were classed as severe if they were homozygous for deltaF508 
genotype and less severe if they were heterozygous for deltaF508 genotype.  
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2.15 G551D treatment with Ivacaftor 
     In February 2013 twelve patients receiving Ivacaftor medication were asked to consent 
to the following research study. Each patient gave informed consent to be interviewed, the 
interview included questions regarding demographics, 24 hour dietary recall and 
completing three reflux questionnaires (DeMeester Reflux questionnaire, Reflux Symptom 
Index questionnaire (RSI), Hull Airway Reflux Questionnaire (HARQ)). Patients were 
also asked to provide a biological sample for the purpose of a research project evaluating 
the effects of Ivacaftor medication to benefit others in the future. The patients were asked 
to provide expectorated sputum but if they could not produce this they were asked to 
produce expectorated saliva. The patients were informed that interviews and sample 
collection would take place on four occasions, before medication; 6 weeks after first 
taking medication; 6 month after first taking medication and 12 months after first taking 
medication. The sputum and saliva samples were processed as described above and the 
samples were analysed for pepsin as described above.  
2.16 Statistical analysis 
   GraphPad Prism version 5 (GraphPad Software Inc, La Jolla, California, USA) was used 
to perform statistical tests on the data collected. Non-parametric tests were used and there 
were no assumption of specific distribution of data sets. MiniTab (version 16) was used to 
analyse data for the Pearson correlation. The data was regarded as statistically significant 
if the P value was equal to or less than 0.05 and the P values were stated for each 
significant result.   
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 Chapter 3.0 
Gastro-oesophageal reflux and the contribution to airway disease management in the 
cystic fibrosis population 
3.1 Introduction 
3.1.1 The definition of Gastro Oesophageal Reflux (GOR) Disease (D) 
        Gastro-oesophageal reflux (GOR) is characterised by the retrograde movement of 
gastric contents up the oesophagus (Armstrong and Sifrim, 2010; Chen et al., 2010). The 
reflux of gastric contents into the oesophagus is a normal physiological event; Zerbib, et 
al., (2005) found that oesophageal investigations over a 24 hour period of 72 healthy 
adults presented reflux events that were a combination of acid (<4pH), weakly acidic (pH 
4-6), liquid and gas. These data illustrate that the reflux of gastric contents is a frequent 
physiological event that occurs in the healthy population. If oesophageal reflux occurs at 
abnormal frequency (at least once a week) and often related to extended clearance time, it 
is termed Gastro-oesophageal reflux disease (GORD). The Montreal consensus group 
defined GORD as a condition, which develops when the reflux of stomach contents causes 
troublesome symptoms and/or complications (Vakil et al., 2010). The term GORD 
characterises multiple complications with varying levels of injury to the oesophagus. The 
term covers a wide spectrum of symptoms, complications and features of tissue damage. 
There are three main classical symptoms of GORD: The first being heartburn, it is the 
description for a burning sensation of the substernal chest area. Number two, the 
regurgitation of stomach contents is experienced and these may reach the pharynx, larynx 
and oral cavity leading to an acidic taste in the mouth. The third classical symptom is 
regurgitation, this may be provoked by bending over or on position of strain in severe 
cases (Klauser et al., 1990; Chen et al., 2010). Dysphagia is the feeling of food sticking to 
the retrosternal area and difficulties swallowing the food which related to the reflux related 
oesophageal spasm and disordered peristalsis (Gillen and McColl, 2011). 
        The definition of GORD covers a spectrum of complications causing macroscopic 
tissue damage to the oesophagus which can be identified under inspection of upper 
gastrointestinal endoscopy such as oesophageal mucosal damage, oesophagitis and 
oesophageal erosions (Moayyedi and Talley, 2006; Gillen and McColl, 2011).  
     GORD complications are caused by mucosal damage and may be identified during 
endoscopy, these are peptic stricture, Barrett’s oesophagus (secondary to inflammation) 
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and, in severe cases, are adenocarcinoma of the oesophagus (Meining and Classen, 2000; 
Kulig et al., 2004). These complications of GORD have been reported to be a burden to 
health on a global scale and impairs the quality of life of those who experience it (Dent et 
al., 2005; Armstrong and Sifrim, 2010).  
     An epidemiological analysis of 12 studies described the prevalence of GORD in the 
general population defined as at least weekly heartburn and/or acid regurgitation to be 
approximately 10–20% in the western world and 5% in Asia (Dent et al., 2005). The 
incidence in Britain was determined to be 4.5 per 1000 person years (95% confidence 
interval (CI) 4.4–4.7) (Ruigómez et al.,2004). However, the data collected for the 
prevalence and incidence of GORD was collected over 10 years ago.  
3.1.2 The definition of Extra Oesophageal Reflux (EOR) 
       Since the 1960’s GOR has been associated with extra oesophageal reflux (EOR). The 
term EOR refers to the symptoms that reflux of gastrointestinal contents have on the upper 
gastrointestinal tract (Jaspersen et al., 2006). These are namely the pharynx, larynx, nasal 
cavity (Vakil, et al., 2010). The refluxate has been associated with tooth decay (Moazzez,  
et al., 2004) , Otitis media (Tasker, et al.,2002) and identified in the airways (Stovold, et 
al., 2007; Blondeau, et al., 2008). Symptoms include chronic cough and asthma that have 
been associated with pulmonary complication (Kennedy, et al., 1962). Other symptoms 
include hoarseness of the voice, clearing of the throat, post nasal drip, golbus, epigastric 
burning, and nausea (Armstrong, 2005; Klauser et al., 1990; Jaspersen et al., 2006; 
Ruigomez, et al., 2008). 
3.1.3 Anatomy and physiology  
       The oesophagus is a long muscular tube connecting the pharynx to the stomach. Food 
and liquid travels down the oesophagus via peristaltic muscle movements of the 
oesophagus which takes the bolus into the stomach. The lower oesophageal sphincter is a 
circular muscle layer at the distal oesophagus with 90% basal pressure and functions as an 
anti-reflux barrier (along with the crural diaphragm) to prevent the retrograde movement 
of the stomach contents (Figure 3.i). On swallows or belches the muscle of the lower 
oesophageal sphincter normally relaxes to allow food pass into the stomach or intragastric 
air to pass out. The relaxations that are not induced by swallowing or eructation are termed 
transient lower oesophageal sphincter relaxations.  (Boeckxstaens, et al., 2005; Waugh et 
al., 2006). The anti-reflux mechanism of the lower oesophageal sphincter may fail leading 
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to GOR of the stomach contents and exposing the oesophagus to gastric acid and other 
damaging contents of refluxate (Sifrim and Holloway, 2001; Farré, et al., 2013). 
        The lining of the oesophagus is squamous epithelium consisting of three layers, the 
mucosa, the submucosa and the circular muscle layer (Figure 3.b). There are two mucus 
gel layers on the inside of the stomach in a continuous two part surface layer to protect the 
stomach against gastric secretions including pepsin and acid. The two independent gel 
mucus layers in the oesophagus each serve a different protective purpose. The first firm 
adherent mucus layer protects the underlying epithelial cells against pepsin and acid as 
they would otherwise be destroyed. These epithelial cells secrete bicarbonate into this gel 
layer to neutralise the acid to give an environment of around pH 7 at the surface. The 
overlaying mucus gel layer forms a viscous liquid when mixed with consumed food to 
reduce the shear forces between the food and the mucosal cells (Pearson and Brownlee, 
2005). The gastric mucus layer stops at the gastroesophageal junction thus the oesophagus 
requires a different protective mechanism against acid and pepsin. The mucus within the 
oesophageal musosa is present in small quantities and it is secreted by the salivary glands. 
The oesophagus may be able to produce a small amount of watery bicarbonate secretion 
and it secretes carbonic anhydrase, and heat shock protein expression. but does not have 
mucus or goblet cells present like the mucus in the stomach. The mucus can only 
withstand acidic environment for a short period of time thus serves little protection against 
reflux of the stomach contents (Figure 3.a and b). Saliva in the oesophagus may provide 
some protection. The oesophageal surface layer can shed a layer of dead cells which can 
protect the viable cells from acid exposure (Dixon et al., 2001; Johnston et al., 2003;  
Pearson and Brownlee, 2005; Pearson and Parikh, 2010). There is also no protection 
against gastric aspiration of such gastric components to the airway epithelia. 
 
 
 
 
 
 
 
 
30 
 
 
Figure 3.a The schematic of the anatomy of the digestive system and airways. The 
illustration describes the components of the digestive and respiratory system. The 
illustration was purchased from canstockphotos and information modified from Anatomy 
and Physiology in Disease, Chapter 12, The digestive system  (Boeckxstaens, 2005) 
(Waugh et al., 2006). 
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Figure 3.b schematic of the structure of the oesophagus and the stomach. The oesophagus 
is a long muscular tube with a squamous epithelium consisting of three layers; outer 
circular muscular wall, submucosa and mucosa. Food passes down the oesophagus and 
into the stomach. The lower oesophageal sphincter is a circular muscle layer at the distal 
oesophagus and functions as an anti-reflux barrier to prevent the retrograde movement of 
stomach contents. On swallows or belches the muscle relaxes to allow food to pass into 
the stomach or intragastric air to pass. The illustration was purchased from canstockphoto 
and information modified from Anatomy and Physiology in Disease, Chapter 12, The 
digestive system  (Boeckxstaens, 2005; Waugh et al., 2006).  
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3.1.4 Damaging components of refluxate 
     Refluxate contains aggressive agents such as acid, pepsin and bile salts (Pearson and 
Parikh, 2010). The reflux of the stomach and small intestinal duodenum contents are 
damaging to the oesophagus. The stomach’s function is to liquefy consumed food and it 
does this with the aid of acid, pepsin and strong rhythmic muscle contractions (Pearson 
and Brownlee, 2005).  The cells in the mucosa of the stomach produce gastric secretions; 
they are arranged in structures called gastric pits made up of several gastric glands. The 
chief (peptic) cells synthesise, store and secrete the inactive enzyme precursor pepsinogen, 
and the parietal cells secrete hydrochloric acid (HCL) to activate pepsinogen into its active 
form of pepsin. Once the inactive enzyme pepsinogen is activated into pepsin by HCL in 
the stomach it becomes a stable molecule and active up to a pH of 6.0. The major secretion 
of the surface epithelial cells is mucus. Mucus forms a continuous two part surface layer to 
protect the stomach against gastric secretions including pepsin and acid. (Pearson and 
Brownlee, 2005).    
      Pepsin(s) by definition are acidic proteases and there are eight different pepsin 
isoforms that have been identified to date. These different pepsins have maximal activities 
against proteins such as haemoglobin which vary between pH 1.9 and 3.6 (Kageyama et 
al., 2002). Pepsin 3 encompasses 70.3 (± 2.6) % of the total pepsins in refluxate, it has an 
optimum pH of 2.4 to 2.8 against haemoglobin. Interestingly it retains <10% activity 
against purified protein at pH 4.0 and 5% - 10% at pH 5, and holds a measurable activity 
at pH 6 (Pearson & Parikh, 2011). It has been shown that the epithelium of the oesophagus 
and larynx are essentially resistant to damage at pH 4.0, but are damaged when pepsin is 
present. This illustrates that in laryngopharyngeal reflux (LPR) pH 4.0 or above refluxate 
would only be damaging if it contained pepsin (Bulmer et al., 2010). Acid with a pH 
below 4 can remain without causing damage in the stomach but would cause damage to 
the oesophagus (Johnston et al., 2003). 
      The reflux of duodenal fluid secretions of bile and pancreatic enzymes into the 
stomach is termed duodenogastric reflux (Figure 3.b). The muscle of the pyloric sphincter 
may relax to release duodenal fluid into the stomach. Bile has an alkaline pH of 8. Bile 
salts are synthesised in the liver and function to emulsify lipids and cholesterol in the 
small intestine to be absorbed in the intestinal wall promoting cholesterol elimination. The 
process enables fat soluble vitamins, A, D, E, and K to be readily absorbed in the 
intestines (Waugh et al., 2006). Bile acids are conjugated with taurine and glycine amino 
acids within the liver to form bile salts. Primary bile acids are those synthesised in the 
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liver (glycodeoxycholate (G-DHC); glycocholate (G-THC); taurodeoxycholate (T-DHC) 
and taurocholate (T-THC) and they make up about 85% of the total acids. The secondary 
bile acids produced from bacterial action in the intestine is called free lithocholate 
(Hofmann, 1999). Bile acids have been shown to be damaging to the oesophageal mucosa 
of Barrett’s oesophagus patients due to its association with the upregulation of 
cyclooxygenase-2 expression and cell proliferation properties. Exposure to oesophageal 
epithelium  has been shown to result in DNA damage (Jolly et al., 2004). 
3.1.5 Aetiology of GOR 
       GOR occurs due to the failure of physiological protective mechanisms but the 
physiological parameters pertaining to levels of reflux have been poorly characterised. The 
majority of GOR occurs due to impairment of the anti-reflux mechanism whereby the 
resting tone of the lower oesophageal sphincter becomes relaxed allowing the gastric 
contents to be released into the oesophagus (Meining and Classen, 2000; Armstrong, 
2005). An inappropriate transient lower oesophageal sphincter relaxation (TLOSR’s) 
causes most reflux episodes (Dent et al., 1980). This frequently occurs post-prandially that 
are not induced by swallowing (Cucchiara et al., 1991). It has been reported that the 
duration of lower oesophageal sphincter relaxations are longer in GOR patients compared 
to healthy controls (Holloway, et al., 2000). The primary mechanisms described in the 
literature for transient lower oesophageal sphincter relaxation are reduced pressure of the 
lower oesophageal sphincter (Ledson et al., 1998); delayed gastric emptying (Couturier et 
al., 2004) and impaired fundic relaxation. Other reasons have been mentioned to affect 
transient lower oesophageal sphincter relaxations including the diet; obesity; high levels of 
oestrogen during pregnancy; and certain medications (Nandurker et al., 2004; Armstrong, 
2005). Across the general population the severity of GORD encompasses a large spectrum 
and the disease is multifactorial. The reason for differences in disease severity is unknown 
but Armstrong, (2005) has suggested it could be a result of individual differences in 
oesophageal protection. Epithelial bicarbonate secretion in the oesophagus or salivary 
bicarbonate production could be impaired in the patients that suffer with oesophageal 
lesions and an increased protective mechanism could be present in non-erosive reflux 
disease (NERD) patients such as increased bicarbonate secretion (Farré, et al., 2013).  
3.1.6 Diagnosis of GOR 
       The diagnosis of GOR can be made through the assessment of symptoms. 
Questionnaire assessment has been designed to characterise symptoms of both GOR and 
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EOR. The tools are designed to determine whether the patient is experiencing typical 
symptoms and validated questionnaires may be used to define abnormal symptoms. 
     The DeMeester reflux Questionnaire assesses the classical symptoms of GOR with the 
assessment of heartburn, regurgitation and dysphagia in a 3-point questionnaire with a 
severity score of 0 to 3 (Figure 3c). This questionnaire is a widely used tool to assess GOR 
dating from the 1980’s (DeMeester et al., 1981; DeMeester et al., 1980). To assess EOR 
symptoms a questionnaire designed for laryngopharyngeal reflux assessing hoarseness, 
vocal changes and fatigue, excessive throat clearing, globus, post nasal drip, chronic 
cough and heartburn. The Reflux Symptom Index (RSI) was validated in 2002 and 
included 25 patients with laryngopharyngeal reflux and 25 age and gender matched 
controls. The questionnaire has 9 questions that are each scored for severity from 0 to 5, a 
total score of 13 or above suggests abnormal symptoms and deemed positive for 
laryngopharyngeal reflux (Figure 3.d) (Belafsky et al., 2002). Chronic cough has been 
associated with reflux and shares a relationship with symptoms of EOR such as asthma 
like symptoms and post nasal drip (Irwin et al., 1984; Mandal et al., 2013). Chronic cough 
has been reported to be a consequence of the aspiration of reflux contents and causing 
hypersensitivity to the upper airways. (Avidan et al., 2001). Morice and colleagues 
developed a questionnaire to characterise chronic cough due to the hypersensitivity of the 
upper airways caused by GOR. The term airway reflux defines the extra-oesophageal 
symptoms of the airways caused by reflux (hoarseness, chronic coughing, globus, and 
wheezing). The 14 point questionnaire has been validated and is a diagnostic instrument 
for the assessment of cough hypersensitivity caused by airway reflux  (Morice et al., 2011) 
(Figure 3.e). 
      Oesophageal reflux can be confirmed by upper gastrointestinal endoscopy, 
oesophageal manometry and pH metry. These measure different aspects of how the 
oesophagus and stomach function, if the refluxate is liquid or gas, and the pH of the 
refluxate. This invasive procedure allows for the measurement of liquid and gas traveling 
up the oesophagus and can detect the pH of the liquid. Evidence of acid (pH<4) and 
weakly acidic (pH4-6) exposure through 24 hour pH monitoring will verify GORD when 
compared to normal values (Zerbib et al., 2005). Upper gastrointestinal endoscopy is the 
gold standard of determining GOR because the endoscopic evidence of oesophageal 
erosions can be used to document the damage to the mucosa and identify carcinoma. 
However, this procedure is not useful for assessing refluxate traveling beyond the 
oesophagus into the aerodigestive tract or airways. Assessing gastric aspiration with non-
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invasive methods can be achieved by reflux biomarker analysis of sputum supernatant 
(Stovold et al., 2007) and lipid laden macrophage index (LLMI) of sputum cells (Colombo 
et al., 1987; Hopkins et al., 2010). 
       There are non-invasive methods to measure gastric aspiration by the analysis of reflux 
biomarkers such as pepsin and bile acids in the samples collected from the airways or 
pharynx (expectorated sputum, saliva or Bronchoalveolar lavage). For research purposes 
an enzyme-linked immunosorbent assay (ELISA), based on a monoclonal antibody to 
porcine pepsin has been locally developed. It has measured both pepsin and total 
pepsinogens, henceforth referred to as “pepsin” in human Bronchoalveolar lavage and 
sputum samples. This ELISA provides a non-invasive alternative to identify and quantify 
reflux markers (Stovold et al., 2007). Stovold et al. (2007) assessed BAL samples of 57 
subjects using this ELISA to detect pepsin a biomarker of gastric aspiration. The study 
found that significant amounts of pepsin was present in lung transplant patients compared 
to controls (p<0.004). The Peptest
TM
 is a lateral flow device specific for human pepsin 3, 
the pepsin found in the stomach. Pepsin can be detected from saliva and sputum samples 
as low as 25ng/ml (Strugala, et al., 2007). It has been shown to be a useful tool for testing 
reflux in a clinical setting due to the rapid and inexpensive procedure. It was shown that 
the diagnostic utility of the Peptest to measure pepsin in expectorated saliva in patients 
with chronic cough was very useful showing pepsin positive tests in at least one of three 
samples in 64% of chronic cough patients and 36% of healthy volunteers (n=300) with no 
GOR symptoms result in a pepsin positive test (Hayat et al., 2013). Bile acids can be 
measured using methods such as tandem mass spectrometry and diagnostic enzymatic kits 
designed to measure bile salts in serum  (Blondeau et al., 2008; Aseeri et al., 2012; 
Savarino et al., 2013). It has been reported that the preferred method to analyse bile acids 
in the samples of airways is tandem mass spectrometry because the limit of detection was 
0.01 µmol/L which is lower than the sensitivity of the enzymatic kits at 5µmol/L (Parikh, 
et al., 2013). 
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Figure 3.c The DeMeester Reflux Questionnaire to assess gastro-oesophageal reflux (GOR) 
classical symptoms. The questionnaire is a 3 point questionnaire for symptoms of 
heartburn, regurgitation and dysphagia with a maximum score of 9. (DeMeester et al., 
1981; DeMeester et al., 1980). 
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Figure 3.d The Reflux Symptoms Index (RSI) questionnaire to assess laryngopharyngeal 
reflux. The self-administered nine-item reflux symptom index (RSI) for the assessment of 
symptoms in patients with laryngopharyngeal reflux. The scale for each individual item 
ranges from 0 (no problem) to 5 (severe problem), with a maximum total score of 45. A 
score of 13 or above indicates an abnormal RSI score (Belafsky et al., 2002). 
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Figure 3.e The Hull Airway Reflux Questionnaire (HARQ) to assess airway reflux cough 
hypersensitivity. The HARQ is a validated 14 point questionnaire to assess the present of 
cough due to airway reflux.   This is self-administered and has 14 items. Responses to 
each question can vary from 0 to 5 to maximum of 70. A score of 13 or over is abnormal 
and is used to determine airway reflux (Morice, et al., 2011). 
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3.1.7 GOR in the CF population 
     Reflux is common in the CF population both in paediatric and the adult patients. The 
first observation of GOR in CF was identified in 1975 by a French researcher at a time 
when the age of survival was around 10 years of age. The study uncovered the problem of 
GOR that has now become a major concern in the CF community (Feigelson and 
Sauvegrain, 1975). Reported high prevalence of GOR in infant CF patients started a 
research topic of interest at various CF paediatric clinics. Early investigations of GOR in 
CF observed that seven paediatric CF patients experienced abdominal pain, peptic 
oesophagitis, upper GI haemorrhage and oesophageal stricture. This raised the awareness 
of GOR and highlighted the importance of detection and treatment to prevent GOR 
associated morbidity (Scott et al. 1985; Brodzicki et al., 2002). The classical symptoms 
heartburn, regurgitation and vomiting were observed in paediatric CF patients with a 
reported prevalence of 55%. Evidence that GOR contents were reaching the airways was 
illustrated by the association with recurrent pneumonia (Scott et al., 1985; Vinocur et al., 
1985). Interestingly, the association of GOR and poor nutritional status was observed with 
many GOR patients failing to thrive (Vinocur et al., 1985; Malfroot and Dab, 1991). The 
availability of genotype analysis allowed researchers to study the role of CFTR mutations 
and prevalence of GOR. Researchers reported that the CFTR mutation did not affect the 
incidence of GOR (Brodzicki et al., 2002). 
          As CF survival time has increased, studies assessing GOR symptoms in the adult CF 
population (16-50 years) proceeded for the first time in 1998. At this time the prevalence 
of heartburn was reported to be 80% in CF adults, regurgitation and dysphagia was 
experienced in 52% (Ledson et al., 1998). Other studies have reported even higher 
prevalence of classical GOR symptoms at 85% (Blondeau, et al., 2008). The prevalence of 
EOR symptoms has been shown to affect 94% of CF patients (Blondeau, et al., 2008). 
Recently, Sabati, et al., (2010) used validated questionnaires to determine GOR and this 
prospective cross sectional study of CF patients in the USA found that 63% of CF patients 
reported GOR symptoms with 24% experiencing symptoms at least weekly. Interestingly, 
there were 66% symptomatic patients using PPI therapy illustrating that PPI therapy does 
not alleviate classical GOR symptoms for all patients (Sabati et al., 2010). The prevalence 
of GOR in CF has been shown to be up to 85% and EOR 95% in the adult CF population 
and the differences in prevalence may be due to the variety of research tools used to define 
the presence such as questionnaires, pH impedance and manometry, reflux biomarker 
identification and clinical features.   
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3.1.8 The role of GOR in the pathogenesis of CF pulmonary disease 
      Several observations have demonstrated that GOR may be associated with increased 
pulmonary disease. It has been observed that cystic fibrosis patients with GOR have 
poorer lung function than those without abnormal GOR. This was defined by a persistent 
decline in lung function measured by forced expiratory volume in 1 second (FEV1) 
(Navarro et al., 2001; Palm, Salwicki and Rosen, 2012). To support this, Gustafsson and 
colleagues (1991) examined pulmonary function and chest radiographs of twelve CF 
patients to reveal that patients with better respiratory results (n=4) had fewer signs and 
symptoms of oesophageal dysfunction and GOR. Controversial evidence emerged in 1996 
by Escobar and colleagues who found that their research of 10 infants with abnormal 
reflux index was not related to decline in spirometry data. Although the study number was 
low and this data cannot be used to represent the general CF population. Evidence for 
GOR leading to a decrease in pulmonary function was observed in paediatric patients in 
the Netherlands in a longitudinal study comparing GOR in CF (Van der Doef et al., 2009). 
Acid and non-acid GOR may have an effect on lung disease (Blondeau, et al., 2008). The 
acidic contents of the stomach was shown to reach the upper oesophagus and the trachea, 
and could be prevalent in around 35% of CF patients (Ledson, Tran and Wilshaw, 1998; 
Pauwels, et al., 2011). It is reported that gastric aspiration may participate in further 
deterioration of lung function. However, the true potential damage that GOR and 
aspiration may cause is yet to be fully understood. Reflux reaching the proximal 
oesophagus and extra-oesophageal areas have been shown to be implicated in multiple 
respiratory disorders. For the first time it was reported that CF patients experience 
duodeno-gastric reflux of bile acid (n=5) and bilirubin (n=8 p=0.003) in a study comparing 
the contents of gastric juice of CF with healthy volunteers (n=10) (Hallberg, Fandriks and 
Strandvik, 2004). This refluxate has been identified in the airways by pepsin and BA 
detection in sputum, BAL and tracheal washings (Blondeau et al., 2010). Reflux 
biomarkers have been shown to be a useful method of assessment in the samples collected 
from the airways (sputum, saliva, tracheal washings and BAL). Pepsin and BA have been 
the most widely studied biomarkers with some work on, trypsin, and bilirubin. 
Interestingly, GOR has been associated with Pseudomonas aeruginosa and 
Staphylococcus aureus by a number of studies (Van der Doef et al., 2009; Palm, Salwicki 
and Rosen, 2012). This finding suggests that refluxate leads to poorer lung function which 
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is either a primary cause of gastric content damage to the epithelium or a secondary effect 
of increased pulmonary exacerbations potentially related to GOR. 
       The CF population tend to live longer now, this brings about complications that were 
not previously seen in paediatrics. There have been cases of oesophageal malignancies 
reported in adult CF patients which are attributed to GOR. This highlights the importance 
of clinical care surrounding GOR in CF. Whether the care is to increase quality of life, 
prevent GOR diseases or to prevent gastric aspiration it is important to treat patients and 
research this area. It was documented in 1993 that Barretts oesophagus was observed in 
two CF adolescents with GOR and this had not been previously described and esophagitis 
was prevalent in 7 patients with GOR (Hassal, 1993; Brodzicki, Trawinska-Bartnicka and 
Korzon, 2002)  
 
3.1.9 Mechanisms of GOR in the CF population 
     Understanding the mechanism of GOR in CF may lead to a better understanding of the 
problem. Chronic cough is a common problem for CF patients (Fathi, et al., 2008), Bendig 
(1982) explained that chronic cough in CF may result in GOR by increased abdominal 
pressure and a depressed diaphragm.  This was supported by Blondeau et al., (2008) who 
observed a positive association between oesophageal acid exposure and the cough 
symptom association probability (p=0.03). However, researchers in Hull (Fathi et al., 2009) 
argued that the sequence of GOR and cough can work both ways and speculate that it is 
GOR causing chronic cough in CF. The authors reported that patients with chronic cough 
that was untreatable with conventional cough medicine underwent laparscopic Nissen 
Fundoplication to result in a significant improvement of cough symptoms (p=0.01). 
Interestingly, pulmonary function significantly increased post operatively with a 50% 
reduction of pulmonary exacerbations suggesting GOR leading to gastric aspiration could 
be a contributor to pulmonary disease. 
       In 1991, Cucchiara and colleagues found that GOR in CF could be due to an 
inappropriate relaxation of the lower gastro-oesophageal sphincter. This was supported by 
findings by other researchers that found the LOS pressure lower than 5mmHg was 
significantly correlated with a higher DeMeester score determined by oesophageal 
investigation (mean 81.0, range 47.9-128.8) compared to patients with a normal LOS 
pressure (mean 26.9, range 8.7-56.5) (Ledson, Tran and Wilshaw, 1998).  
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      The mechanisms of increased GOR in the CF population could be multifactorial. 
Pauwels et al., (2011) found multiple defective mechanisms in CF but could not associate 
them with GOR. Delayed gastric emptying was prevalent in 33% of 33 patients but this 
did not correlate to reflux episodes assessed by pH impedance and there were significantly 
lower LOS pressure observed in CF (n=12) when compared to healthy controls 
(n=11)( p=0.04). A later study observed that reflux caused by transient lower oesophageal 
sphincter relaxations was not found to be different in CF compared to healthy controls 
(Pauwels et al., 2012). 
3.1.10 The treatment of GOR in the CF population 
       Drug therapy for general GORD patients include H2 receptor antagonists (H2-RA) and 
proton pump inhibitors (PPI) to lower the volume of the refluxate and increase the pH of 
the refluxate. PPI treatment (lansoprazole and Omeprazole) is primary treatment for GOR. 
Research has stated that PPI therapy is far superior to H2-RAs (Chiba, et al., 2003; van 
Pinxteren, et al., 2003; Armstrong, 2005). However, 5-20% of patients do not respond to 
current therapy, PPI therapy is not effective at 20mg/day for many GOR patients and the 
medication may be effective if increased to 40mg/day (Armstrong, 2005). PPI therapy will 
reduce the volume and time of acid exposure in GOR patients but the acid exposure will 
still tend to be above normal (Gerson, et al., 2005; Gerson, et al., 2004). In America, 50% 
of CF patients are currently treated with PPI medication to reduce the acidity in the 
stomach. This is used for both GOR treatment and to increase efficiency of pancreatic 
enzyme replacement therapy (Smyth, et al., 2014). Despite the benefits of PPI or H2RA 
treatment lowering refluxate pH, the refluxate will still contain pepsin, bacteria and many 
other damaging agents; it will also be weakly acidic (pH 5-7). Therefore, PPI therapy will 
not prevent reflux episodes and refluxate reaching the oesophagus can still cause damage, 
but lessen the symptoms of reflux (Pearson & Parikh, 2011). A previous study found that 
bile acids were present in the saliva samples of 38 CF patients and 11 of these patients 
were on PPI therapy (Blondeu et al., 2008) illustrating that gastric contents reach the 
pharynx regardless of PPI therapy. However, it has been reported that the method of bile 
acid detection used in this study was not sensitive enough to detect the low bile acid levels 
reported (below 5mmol/L) (Parikh, et al., 2013). In addition, it has recently been shown 
that 65% of patients on acid suppression medication reported continued classical GOR 
symptoms (Sabati et al., 2010). 
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        Surgical management of GOR has been shown to slow down the decline in 
pulmonary function, increase weight and reduce exacerbations (Sheikh, et al., 2013). If 
patients do not respond to medicated treatment they can be considered for Nissen 
Fundoplication. The first published reports of surgery outcomes in CF children at a 
Childrens medical centre in the USA reported 28% discontinued reflux medication post-
surgery and there were no surgical mortalities. Interestingly, surgery significantly 
improved lung function by 8.6% per year (p=0.004) in children with a starting FEV1 
below 60% predicted (Boesch and Acton, 2007). Furthermore, surgical intervention 
(laparoscopic fundoplication) was found to be highly effective in controlling reflux in a 
small selection of CF patients that did not respond to medication (Fathi, et al., 2009). 
Hayes and colleagues reported a reduction in lipid laden macrophages post laparoscopic 
fundoplication suggesting decreases in aspiration of gastric contents (Hayes, et al., 2013). 
     GOR is a recognised problem in the CF community. A recent publication by the 
European Cystic Fibrosis Society highlighted the awareness of GOR prevalence in the CF 
centre and suggest that patients experiencing symptoms should be diagnosed and 
subsequently treated for GOR (Smyth, et al., 2014). 
3.1.11 Inflammation in the CF airways and the association with pulmonary disease   
     A major characteristic of CF disease is the susceptibility to chronic pulmonary 
infection caused by inflammation responding to the bacterial infection. They have a 
negative impact on health reducing the quality of life and survival therefore antibiotic 
treatment is prescribed upon identification of bacterial infection. Progressive pulmonary 
disease is a leading cause of mortality for the CF population (Sagel et al., 2007; Anthony 
et al., 1999). The clinical indicators of a pulmonary infection vary and there are many 
indicators such as chronic cough, sputum production, shortness of breath, chest pain, 
decreased exercise ability and decreased appetite (Smyth et al., 2008). A new symptom, 
change in symptoms or worsening of existing symptoms is termed exacerbations (Bhatt et 
al., 2013).  
      Upon bacterial infection (such as Pseudomonas aeruginosa), the inflammatory system 
responds to the bacterial infection by producing inflammatory mediators at the site of 
infection. (Segal et al., 2007). The epithelium of the airway produce cytokines and 
chemokines to initiate the immune response via Natural Killer cells intracellular signalling. 
Interleukin 8 (IL-8) and Interleukin 6 (IL-6) are proinflammatory cytokines released by 
the airway epithelium cells to mediate inflammatory response. The mediators recruit 
44 
 
neutrophils to attack the infection in order to eliminate it. Neutrophils are phagocytes with 
a function to engulf bacteria to eliminate invading infection from the site. The 
inflammatory response in the CF airway does not function effectively (as described in 
chapter 1) and cannot clear recurrent infections within the airways (Shanks et al., 2010). 
Inflammation develops in the airways excessively in relation to the presence of bacteria 
and continues as the infection cannot be cleared (Bourke and Burns, 2011). This leads to a 
vicious cycle of excessive inflammatory cell/metabolite influx in the CF airway resulting 
in airway damage. Viral infections within the CF lung may potentially damage the 
epithelium (Banner et al., 2009). IL-8 has been shown to be one of the most potent of 
chemoattractants to activate neutrophils. Studies have shown that samples taken from the 
CF lung such as sputum (Bergin, et al., 2013) and BAL (Bonfield et al., 1995) have 
significantly elevated concentrations of IL-8 and IL-6 compared to healthy controls and 
this has a negative correlation with pulmonary function (Colombo, et al., 2011).  
     The measurement of inflammatory mediators in the sputum of CF patients has been 
used to identify disease activity in CF lung disease. Inflammatory response has been 
demonstrated in the CF airway by counts of abundant neutrophils dominating other cells 
in sputum and BAL samples taken from the CF lung. These samples have also been shown 
to contain high levels of inflammatory mediators such as IL-8 and IL-6. The levels of IL-8 
and IL-8 in CF sputum have been reported to be released in excess by the airway 
epithelium and this is thought to be due to the absence of normal function highlighting 
further consequences of CFTR dysfunction in addition to channel gating dysfunction 
(Segel et al., 2007). Respiratory tract epithelium damage caused by defective cytokine 
production is one theory to the enhanced inflammatory response in the airway but not 
other sites of CF epithelium. Starosta et al., (2007) found that Interleukin-8 (IL-8) 
concentrations and numbers of neutrophils were correlated to the number of proximal 
reflux events measured by 24h eosophageal pH measurements. McNally et al., (2011) 
supported this finding and produced data to illustrate a higher IL-8 concentration in CF 
patients with raised pepsin levels in BAL samples suggesting increased lung inflammation 
due to gastric aspiration. Neutrophil elastase is a marker of airway inflammation and can 
be quantified in the CF lung. Evidence suggests that bile acids contained in the lung 
significantly associated with neutrophil elastase (p=0.05) (Pauwels et al., 2012). 
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3.1.12 Aims and objectives of the following chapter 
      Due to a wide range of prevalence of GOR reported in the CF population the following 
study aimed to investigate the prevalence of GOR and EOR in CF adults at the out-patient 
clinic, Newcastle upon Tyne allowing for the assessment of a range of CF disease severity 
and easy patient access. During my study the characteristics of GOR and EOR were 
assessed using validated questionnaires specific for GOR and laryngopharyngeal reflux 
termed herein as EOR. Gastric aspiration was determined by the analysis of reflux 
biomarkers present (pepsin and bile acids) in expectorated sputum samples collected 
during out-patient clinic appointments. The lipid laden macrophage index was determined 
by staining the cells of sputum samples. This has been used as a reflux diagnostic tool 
assessing the lipid contained in macrophages of sputum cells.  
     The association between GOR and pulmonary function was assessed to investigate the 
relationship between reflux in the CF population and pulmonary function based on 
GOR/EOR symptoms and gastric aspiration. The spirometry measurements (FEV1 and 
FVC) were calculated according to the percentage predicted based on the ERS guidelines. 
     The inflammation within the airways was explored by methods of expectorated sputum 
from within the airway. The relationship between gastric aspiration and pulmonary 
inflammation was explored. 
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3.2 Results 
3.2.1 Study population and sampling 
 
The Ethical approval for this study was granted by the County Durham & Tees Valley 2 
Research Ethics Committee (REC NO: 10/H0908/8). There were 72 adult CF patients 
(range 16-60 years, median 21) recruited onto the study from their routine clinical 
appointments at the RVI, Newcastle Upon Tyne between 2011 and 2014. There were 39 
males and 33 females with a median weight of 57.8kg (range 34.1-87.0) and median BMI 
of 21.5 (range 14.1-30.9). (See figure 3.1, 3.2, 3.3, 3.4 and 3.5 and see appendix 8.7 for 
individual patient data). 
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Figure 3.1 Patient age (n=72, range 16-60, median 21 years)  
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Figure 3.2 The age of male (n=39) and female (n=33) patients (male range 16-44, median 
24 years; female range 17-60, median 25) 
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Figure 3.3 Patient weight (kg) (n=72; range 34.1 -87.0 kg, median 58.7 kg) 
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Figure 3.4 Patient Body Mass Index (BMI kg/m
2
) (n=72; range 14.1-30.9, median 21.5) 
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Figure 3.5 The prevalence of delta F508 in the 61 patients recorded was n=22 
homozygous and n=39 heterozygous.  
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3.2.2 The investigation into the prevalence of reflux symptoms in the CF population. 
 
     The symptoms of reflux were assessed by questionnaire. GOR symptoms were 
determined by the DeMeester Reflux Questionnaire (n=72), EOR symptoms were 
determined by the Reflux Symptom Index (RSI) (n=72) and the assessment of airway 
reflux cough was determined by the Hull Airway Reflux Cough Questionnaire (HARQ), 
This was introduced at a later stage in the study following feedback from presentation of 
my work at a national meeting and so had a lower number of results (n=22). Of the 72 
patients recruited the median DeMeester score was 1 (range 0-9, normal = 1 or below).  30 
patients (42%) scored >2 presenting GOR symptoms (median 2, range 2-7) (Figure 3.6). 
The median RSI score was 16 (n=72, range 0-43) and more than half of patients 45 (63%) 
were EOR symptomatic, with an RSI score >13 (median 19, range 13-43) (Figure 3.7). 
Reflux associated cough was determined by the Hull Airway Reflux Questionnaire 
(HARQ). The HARQ questionnaire was introduced in January 2013 therefore n= 22 
patients completed the HARQ from the total patients recruited (n=72). The median score 
of the 22 patients who completed the HARQ questionnaire was 15 and there were 11 
patients (50%) symptomatic of airway reflux cough (median 31, range 15-44) (Figure 3.8). 
The questionnaire data illustated that 42% of the patients that were recruited experienced 
GOR symptoms, 63% experienced EOR symptoms and 50% of 22 patients experienced 
airway reflux cough. This level of symtomatic burden was present despite the fact that  46 
patients were treated with proton pump inhibitors (PPI) and 3 treated with Histamine2 
Receptor Antagonists (H2RA) for acid reflux. There were 20 patients that were not taking 
any medication to treat acid reflux. Of the 30 patients that experienced GOR symptoms 63% 
(n=19) were on PPI medication. There were 69% (n=31) of patients on PPI medication 
who experienced EOR symptoms. Of the 3 patients taking H2RA’s there were 2 patients 
who experienced GOR symptoms and EOR symptoms. Similarly there were 7 patients on 
PPI medication that scored an abnormal HARQ score (n=11) (Figure 3.9). 
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Figure 3.6 Presence of GOR symptoms determined by the DeMeester reflux questionnsire 
maximum score 9; normal score <1 represented by the red line. There were 42 patients 
asymptomatic of GOR determined by a DeMeesterscore of 1 or below (58%) (range 0-1, 
median 1. 30 (42%) patients were GOR symptomatic (range 2-7, median 2) determined by 
a DeMeester score of 2 or above. The graph illustrates individual patient DeMeester scores 
with Mean and SEM. 
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Figure 3.7 Presence of EOR symptoms determined by the Reflux Symptom Index (RSI) 
Questionnsire maximum score 45; normal score <12 represented by the red line. There 
were 27 (37%) patients asymptomatic for EOR determined by a RSI score of 12 or below 
(range 0-12, median 8). There were 45 (63%) patients that were EOR symptomatic 
determined by an RSI score of 13 or above (range 13-43, median 19). The graph illustrates 
individual patient RSI scores with Mean and SEM. 
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Figure 3.8 Presence of airway reflux cough (ARC) symptoms determined by the Hull 
Airway Reflux Questionnaire (HARQ) n=22; maximum score 70; normal <12 represented 
by the red line. There were 11 (50%) patients that were asymptomatic of airway reflux 
cough symptoms determined by a HARQ score of 12 or below (range 0-12, median 6). 
There were 11 (50%) patients symptomatic for airway reflux cough determined by a 
HARQ score of 13 and above (range 15-44, median 31). The graph illustrates individual 
patient HARQ scores with Mean and SEM. 
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Figure 3.9 The number of symptomatic patients using PPI and H2RA medication. There 
were 30 patients symptomatic for GOR determined by the DeMeester reflux questionnaire 
(score of 2 or above), of which 19 were on PPI medication and 2 were on H2RA 
medication. 45 patients experienced EOR symptoms determined by the RSI score (score of 
13 or above) of which 31 patients were on PPI medication and 2 were on H2RA 
medication. Of the 22 patients that completed the HARQ questionnaire to assess airway 
reflux 11 were symptomatic and 7 were on PPI medication. 
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3.2.3 The investigation of gastric aspiration in the CF population 
3.2.3i Pepsin as a biomarker for gastric aspiration 
      The initial experiments carried out to identify pepsin in sputum supernatant involved 
optimisation of an in house pepsin indirect ELISA. The optimisation of the blocking 
solution was assessed to prevent nonspecific binding to the plate. It was determined by 
blocking a plate with three pepsin standard curves with a range of 0 to 100ng/ml using 1% 
BSA (R
2
=0.99), 1% milk powder (R
2
=0.72) and 5% milk powder (R
2
=0.71). The standard 
curve which was blocked with 1% BSA was deemed the superior blocking agent 
compared to milk powder therefore it was used in the pepsin ELISA protocol of further 
experiments. The standard curve used to determine pepsin concentration was linear 
between 0 and 100ng/ml. The pepsin ELISA linear standard curve measured an 
absorbance value up to 0.79 optical density units (Figure 3.10).  
      The standard operating procedure for sputum processing required a sputum sample to 
be homogenised in DPBS at 8 times the sputum plug weight (1:8 dilution) (see Chapter 2 
Methods: subheading 2.7). Prior to sample collection and processing the analysis of pepsin 
recovery in sputum supernatant was investigated. To ensure pepsin could be detected from 
a 1:8 sputum supernatant a experimental sputum plug was collected and processed as 
directed. The 1:8 sputum supernatant samples was spiked with known concentrations of 
porcine pepsin in order to recover the known concentration through the pepsin ELISA 
procedure. Pepsin was recovered from the spiked sputum supernatant sample to a lower 
detection limit of 10ng/ml (1ng/100µl). Pepsin was not recovered at 0.0ng 0.3ng, 0.5ng. 
Sputum spiked with 1.0 ng, 1.5 ng 3.0 ng and 5.0 ng of porcine pepsin resulted in full 
recovery. Therefore samples could be collected and processed as directed using the 
standard dilution. 
     Sputum samples were processed according to the standard protocol and therefore were 
diluted 1:8 in DPBS to homogenize the sputum plugs.  The samples were aliquotted, 
labelled and stored at -70°C for later analysis. The question was raised about the correct 
dilution factor of sputum supernatant of CF patients to ensure any pepsin that was to be 
detected fell within the standard curve of 0-100ng/ml of porcine pepsin. Thus, various 
dilution factors of sputum supernatant were assessed (1:8, 1:200, 1:1000) to ensure the 
pepsin detected would fall within the standard curve range of 0-100ng/ml dilution and 
determining the correct dilution factor for future sample analysis. From the same sputum 
supernatant sample the concentration of pepsin recovered from the 1:8 dilution was 
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5ng/100µl (50ng/ml); 1:200 dilution 0ng/100µl; 1:1000 dilution 0ng/100µl. The dilution 
factor of sputum supernatant suitable for the pepsin ELISA to fit onto a standard curve of 
0-100ng/ml was the 1:8. The prepared sputum supernatant samples were used at the 
dilution they were stored at and there were no further dilution necessary.  
       Sputum supernatant samples were analysed for pepsin (n=69) using the indirect 
ELISA and the overall range of pepsin was 0 to 1150ng/ml with the median of 230ng/ml. 
Of the 69 patient samples analysed there were 48 (70%) patient samples with detectable 
levels of pepsin with a median of 330ng/ml ranging from 80 to 1150ng/ml. There were 21 
(30%) patient samples that did not contain pepsin above the lowest level of accurate 
quantification of pepsin at 1ng in 100µl (100ng/ml). Figure 3.10 shows a typical standard 
curve and figure 3.11 displays the individual patient pepsin values measured in sputum 
supernatant samples. 
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Figure 3.10 Porcine pepsin standard curve measured with in-house in-direct ELISA using 
goat monoclonal primary antibody at 1:100 followed by monoclonal secondary to goat 
monoclonal raised in mouse (peroxidase conjugated) at 1:1000 (mean ± SEM, n=3). 
 
 
0.00
0.10
0.20
0.30
0.40
0.50
0.60
0.70
0.80
0.90
1.00
0 2 4 6 8 10
A
b
so
rb
a
n
ce
 (
4
0
5
 n
m
) 
Pepsin (ng/100µl) 
60 
 
 
 
Figure 3.11 The analysis of sputum supernatant pepsin levels (ng/ml) in 69 patients 
measured with in-house ELISA using goat monoclonal primary antibody at 1:100 
followed by monoclonal secondary to goat monoclonal raised in mouse (peroxide 
conjugated) at 1:1000 (mean with SEM). The range of pepsin was 0 to 1150ng/ml, median 
230, mean 280, SEM 35.  
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3.2.3ii Total Bile Acid as a biomarker for gastric aspiration 
 
     Taurine and glycine conjugates of cholate and deoxycholate and their isomers were 
measured using a mass spectrometry Acquity TQ Detector (Waters Corp, Milford, MA). 
The Taurine conjugates make up around 25% of the total bile acids and the glycine 
conjugates make up 75%. Although trace free bile acids are present and these make up to 5% 
of the total bile acids (J. P. Pearson and S. Parikh, 2011). The term Total Bile Acids (TBA) 
herein describes the Taurine and glycine conjugates which equates for 90-100% of TBA. 
The individual bile acids were detected to a sensitivity of 0.01µMol/L and then these 
levels were added together to give the TBA concentration. The concentrations were 
assessed in 24 sputum supernatant patient samples at Sheffield Childrens Hospital, UK. 
The median level of TBA’s was 0.22 µmol/L and ranged from 0.00 to 3.17 (figure 3.12 
and 3.13). Glycine and Taurine conjugates were compared to find that there were no 
median differences between the two conjugates. Median Glycine conjugates were 0.08 
µMol/L (range 0.00-2.24) and Taurine conjugates were 0.08µMol/L (range 0.00-0.96). 
Reported TBA in human serum are reported to be up to 10µmol/L and therefore used as a 
lower detection limit when assessing abnormal levels (Parikh et al., 2013). 
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Figure 3.12 Taurine and glycine conjugates of cholate and deoxycholate and their isomers 
in sputum supernatant samples were measured using an Acquity TQ Detector (Waters 
Corp, Milford, MA). Individual bile acid levels of sputum supernatant (n=24) samples are 
presented measured by mass spectrometry sensitive to 0.01µMol/L and multiplied by 
dilution factor (1:8). Median levels of glycodeoxycholate (G-DHC) were 0.08 (range 0-
1.44), glycocholate (G-THC) 0.08 (range 0-1.60), taurodeoxycholate (T-DHC) 0.00 (range 
0-0.56), (taurocholate (T-THC) 0.04 (range 0-0.88) and free lithocholate 0.39 (range 0-
2.10).  
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Figure 3.13 Sputum supernatant TBA levels measured by mass spectrometry to a 
sensitivity of 0.01µMol/L. Median TBA levels were 0.22 (range 0-3.17, mean 0.47, SEM 
0.16 µMol/L). 
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Figure 3.14 Sputum supernatant Glycine conjugates and Taurine conjugates concentration 
measured by mass spectrometry to a sensitivity of 0.01µMol/L. Median Glycine 
conjugates were 0.08 µMol/L (range 0.00-2.24) and Taurine conjugates were 0.08µMol/L 
(range 0.00-0.96). 
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3.2.3iii The Lipid Laden Macrophage Index Score as a diagnostic tool for gastric 
aspiration 
          The oil red O stain was used to determine lipid laden macrophage index score 
(LLMIS) from sputum samples that were processed and prepared to 0.5x10
6
/ml cells on a 
glass slide and stained with Oil Red O/Sudan Red followed by a counter stain to identify 
the nucleus of cells with Harris Haematoxylin. The cells were differentiated into 
neutrophils, eosinophils, macrophages and lymphocytes by counting a total of 500 cells 
and calculating the percentage of each cell type based on characteristic morphology. The 
LLMI score requires the assessment of 100 consecutive macrophages upon the visible 
identification of red lipid droplets contained within the cell. The cell differential of the 
sputum supernatant samples analysed (n=36) showed that there were a median 0% 
macrophages (range 0 to 0.8%) present and therefore prevented identification of lipid 
laden macrophages (Table 1 and Figure 3.15). 
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Cell type Median % Range % Mean % SEM % 
Neutrophil 100 97 – 100 99 0.09 
Eosinophil 0 0 – 0.8 0 0.03 
Macrophage 0 0- 2 0 0.05 
Lympocyte 0 0-1 0 0.05 
 
Table 3.1 The cell differential of expectorated sputum of CF patients. Sputum samples 
were processed to provide a cell cytospin of 500,000 cells per ml on a glass slide. Each 
cell sample was stained to identify the cell differential count. The Giemsa stain identified 
that in 36 patient samples analysed the median neurophil counts were 100% (97.2-100); 
median eosinophil counts were 0% (0.4-0.8); median macrophage counts were 0% (0-2); 
median lymphocytes counts were 0% (0-1.2) 
 
 a)  b) 
Figure 3.15 A representative image of the Oil Red O stained sputum supernatant samples 
illustrating the presence of neutrophil nuclei and no red droplets visible. (a and b represent 
two different patients with no macrophages present, thus a lipid laden macrophage score 
of 0) 
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3.2.4 The relationship between aspiration of gastric juice and symptoms of GOR/EOR 
 
     The DeMeester questionnaire score was used to determine the presence of GOR 
symptoms in 72 patients. The patients were grouped into those that were symptomatic of 
GOR scoring 2 or above on the questionnaire (GOR) and those that were asymptomatic 
(no GOR) of GOR scoring 1 or below. The pepsin concentration detected in each group 
was assessed using a non-parametric two-tailed Mann-Whitney U test to show that there 
were no statistical differences of pepsin concentration detected in sputum samples and the 
presence of GOR symptoms (p=0.11) although patients asymptomatic of GOR had higher 
concentrations compared to symptomatic patients. The median level of pepsin detected in 
the GOR symptomatic group was 140ng/ml (n=30, range 0-800 ng/ml) and median levels 
in the asymptomatic group were 270ng/ml (n=39, range 0-1150 ng/ml) (Figure 3.16).   
The RSI questionnaire score was used to determine the presence of EOR symptoms in the 
aero digestive tract in 72 patients. The patients were grouped into those that were 
symptomatic of EOR scoring 13 or above on the questionnaire (EOR) and those that were 
asymptomatic of EOR scoring 12 or below. The pepsin concentrations detected in each 
group was assessed using a non-parametric two-tailed Mann-Whitney U statistical test to 
show that there were no statistical differences of pepsin levels detected in sputum samples 
and the presence of EOR symptoms (p=0.23). The median level of pepsin detected in the 
EOR symptomatic group was 180 ng/ml (n=47, range 0-1020 ng/ml) and median levels in 
the asymptomatic group were higher at a median concentration of 290 ng/ml (n=22, range 
0-1150 ng/ml) (Figure 3.17).  Of the 24 patient sputum samples that were analysed for 
BA’s there were 16 patients that were symptomatic for GOR symptoms with median TBA 
concentration of 0.3 µmol/L (range 0.0 to 3.2) and there were 8 patients that were 
asymptomatic of GOR symptoms with a median TBA level of 0.2 µmol/L (range 0.0 to 
2.0). There were 20 patients that were symptomatic of EOR symptoms with median TBA 
levels of 0.2 µmol/L (range 0.0 to 3.2) and 4 patients that were asymptomatic of EOR 
symptoms with a median of 0.2µmol/L (range 0.2-1.2). There were no statistical 
difference between TBA levels and symptoms of EOR (P=0.56). or GOR (p=0.07) but the 
concentrations were higher in the symptomatic group (Figure 3.18 and 3.19). 
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Figure 3.16 Sputum supernatant pepsin levels in symptomatic GOR patients (n=30) 
defined by DeMeester Score >2 (range 0-800ng/ml, median 140, mean 210, SEM 43 ) and 
asymptomatic GOR patients (n=39) defined by DeMeester score <1 (range 0-1150ng/ml, 
median 270, mean 330, SEM 51). There was no statistical difference between pepsin 
levels and the symptoms of GOR (P=0.11) assessed by Mann Whitney U Test and 
Gaussian approximation.  
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Figure 3.17 Sputum supernatant pepsin levels in symptomatic EOR patients (n=47) 
defined by RSI Score >13 (range 0-1020ng/ml, median 180, mean 280, SEM 41) and 
asymptomatic EOR patients (n=22) defined by RSI score <12 (range 0-1150ng/ml, median 
290, mean 340, SEM 60). There was no statistical difference between pepsin levels and 
the symptoms of EOR (P=0.23) assessed by Mann Whitney U Test and Gaussian 
approximation.  
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Figure 3.18 Sputum supernatant TBA levels in symptomatic GOR patients (n=16) defined 
by DeMeester Score >2 (range 0.0-3.2 µmol/L, median 0.3, mean 0.6, SEM 0.2) and 
asymptomatic GOR patients (n=8) defined by DeMeester score <1 (range 0.0-2.0 µmol/L, 
median 0.2, mean 0.2, SEM 0.0). There was no statistical difference between pepsin levels 
and the symptoms of GOR (P=0.07) assessed by Mann Whitney U Test and Gaussian 
approximation. 
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Figure 3.19 Sputum supernatant TBA levels in symptomatic EOR patients (n=20) defined 
by RSI Score >13 (range 0.0-3.2 µmol/L, median 0.2, mean 0.5, SEM 0.2) and 
asymptomatic GOR patients (n=4) defined by DeMeester score <1 (range 0.2-1.2 µmol/L, 
median 0.2, mean 0.4, SEM 0.2). There was no statistical difference between pepsin levels 
and the symptoms of GOR (P=0.56) assessed by Mann Whitney U Test and Gaussian 
approximation. 
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3.2.5 The investigation into the association between reflux and CF pulmonary function 
 
     Pulmonary function was routinely assessed during the clinical appointment and the 
results of pulmonary function (L) were expressed relative to predicted values. Predicted 
values were calculated based on gender, height and age and observed values calculated as 
a percentage of the predicted value. Of the 61 patient pulmonary function scores collected 
the median FEV1% was 47% (range 12-110%) of the predicted value and the median FVC% 
predicted was 66% (range 11-119%) (Figure 3.21 and 3.22). These values were consistent 
with airway obstruction. To assess whether the presence of gastric aspiration into the 
airways was associated with a decrease in pulmonary function, the patients were grouped 
into pepsin positive and pepsin negative sub groups and the pulmonary function scores of 
each group were compared with a non-parametric two tailed statistical test. There was no 
statistical difference between the median pulmonary function scores and presence of 
gastric aspiration in the airways determined by the presence of pepsin (p=0.44) but the 
trend of increased pulmonary function with decreased pepsin concentrations is illustrated 
in Figure 3.23.  The relationship between TBA levels measured in 22 patients and 
pulmonary function was assessed to show that there was no correlation (TBA and FEV1% 
P=0.675; TBA and FVC% P=0.696). There were 2 patient sputum supernatant samples 
containing high levels of TBA, as shown on figure 3.24 and 3.25, patient A sample 
contained 3.16µmol/L with a low FEV1% of 30% and a low FVC% of 34%. Patient B as 
shown on figure 3.24 and 3.25 sputum supernatant sample contained 2.42µmol/L TBA 
and had a high pulmonary function of FEV1% 80 and FVC% 93. The two patients 
illustrate that duodenal GOR demonstrated by high levels of TBA in sputum supernatant 
was inconclusive regarding the relationship between GOR and decreased pulmonary 
function.  
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Figure 3.21 The pulmonary function of CF patients measured by FEV1 and FVC 
percentage predicted. n=61 patients presented in the percentage of predicted pulmonary 
function. The median FEV1% predicted was 47% (range 12-110%, SEM 2.9) and the 
median FVC% predicted was 66% (range 11-119%, SEM 3.0). 
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Figure 3.22 The FEV1 and FVC ratio (L) of CF patients n=61. The range of FEV1/FVC 
ration was between 0.35 and 1.0 with the median 0.67, (mean 0.66; SEM 0.02). 
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Figure 3.23 Pulmonary function test results (% predicted) of patients that experience 
gastric aspiration measured by pepsin ELISA (n=38) (FEV1% range 12-92%, median 43, 
mean 49, SEM 4; FVC% range 11-100, median 61, mean 65, SEM 4) and those that did 
not experience gastric aspiration (n=20) (FEV1% range 25-110, median 50, mean 54, SEM 
5; FVC% range 34-119, median 70, mean 70, SEM 6). There was no statistical difference 
in pulmonary function in patients with gastric aspiration (FEV1% P=0.46) (FVC% P= 0.44) 
analysed by Mann Whitney U test with Gaussian approximation. 
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Figure 3.24 Sputum supernatant samples TBA levels compared to FEV1% (n=22) on a XY 
scatter graph. The Pearson correlation test was used to analyse the statistical relationship 
between levels of TBA in sputum supernatant samples and the FEV1% score of patients. 
There was no statistically difference between levels of TBA and FEV1% (P=0.675; 
Pearson correlation of TBA and FEV1% = -0.092). 
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Figure 3.25 Sputum supernatant samples TBA levels compared to FVC% (n=22) on a XY 
scatter graph. The Pearson correlation test was used to analyse the statistical relationship 
between levels of TBA in sputum supernatant samples and the FVC% score of patients. 
There was no statistically difference between levels of TBA and FVC% (P=0.696; Pearson 
correlation of TBA and FVC%% = -0.086). 
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3.2.6 Neutrophilic inflammation and increased cytokines in sputum from cystic fibrosis 
population 
 
     The processing of sputum samples was carried out as directed by standard operating 
procedures of the cytology laboratory at the William Leech centre, Freeman Hospital. The 
viscous sputum plugs were selected from expectorate sample to reduce squamous cell 
contamination from saliva contained in the expectorated sputum sample. The 
contamination of squamous cells was required to be below 20% to ensure the sample was 
a valid representation of the airway and so inflammatory cell counting was quicker, easier, 
and reproducible (Efthimiadis et al., 2002). There were 36 expectorated sputum samples 
processed and a cell differential was performed under a light microscope at X400. 500 
inflammatory cells were counted and the percentage of cell types was calculated. There 
was a median of 100% neutrophils (range 97.2 to 100, mean 99.8, SEM 0.09) contained in 
the CF sputum samples (P= 0.0001). There was a median of 0.6% eosinophils (range 0.4 
to 0.8, mean 0.6, SEM 0.12), a median of 1.3% macrophages (range 1 to 2, mean 0.4, 
SEM 0.30), and a median of 0.6% lymphocytes (range 0.2 to 1.2, mean 0.4, SEM 0.14) 
present in expectorated CF sputum. 
     The resulting supernatant of 64 sputum samples was analysed for IL-8 levels using the 
R&D systems IL-8 capture ELISA for recombinant and human IL-8. The disregard of 
saliva of expectorated sputum samples results in the analyte in sputum supernatant to be 
unaffected or diluted by the confounding influence of saliva. The analyte concentration 
was corrected for by the dilution factor (Efthimiadis et al., 2002). The kit measured IL-8 
concentrations between 32 pg/ml to 2000 pg/ml. Figure 3.26 shows a shows a typical 
standard curve of the IL-8 with an R
2
 value of 0.99. The overall range of IL-8 was 1 to 
35ng/ml with the median of 9ng/ml. Of the 64 patient samples analysed all the patient 
samples contained detectable levels of IL-8. Figure 3.27 displays the individual patient IL-
8 values measured in sputum supernatant samples. 
     The resulting supernatant of 62 processed sputum samples was analysed for IL-6 
concentrations using the R&D systems IL-6 capture ELISA for recombinant and human 
IL-6. The kit measured IL-6 to a level between 10 pg/ml and 600 pg/ml. The sputum 
supernatant was used at an x8 dilution introduced during the sputum processing procedure 
and no further dilution was required for the IL-6 analysis. Figure 3.28 shows a typical 
standard curve of the IL-6 standard with a R
2
 value of 0.99. The overall range of IL-6 was 
0 to 700pg/ml with the median of 0ng/ml. Of the 62 patient samples analysed there were 
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16 patient samples with detectable levels of IL-6 with a median of 100pg/ml ranging from 
30 to 700pg/ml. There were 46 patient samples that did not contain IL-6 above the lowest 
level of accurate quantification of IL-6 at 10pg/ml. Figure 3.29 displays the individual 
patient IL-6 values measured in sputum supernatant samples.  
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Figure 3.26 IL-8 standard curve measured with R&D systems kit for capture ELISA using 
mouse anti-human IL-8 capture antibody at 4µg/ml followed by biotinylated goat anti-
human IL-8 at 20ng/ml (mean ± SD). The detection range of the ELISA was 32pg/ml to 
2000pg/ml. The four parameter regression curve fit gave a R
2
 value of 0.99.  
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Figure 3.27 The analysis of sputum supernatant IL-8 concentration (ng/ml) in 64 CF 
patients measured with the R&D Systems IL-8 kit for capture ELISA using mouse anti-
human IL-8 capture antibody at 4µg/ml followed by biotinylated goat anti-human IL-8 at 
20ng/ml. The IL-8 concentration ranged from 1 to 35 ng/ml, with a median of 9ng/ml; a 
mean of 10ng/ml, and SEM 1ng/ml. 
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Figure 3.28 IL-6 standard curve measured with R&D systems kit for capture ELISA using 
mouse anti-human IL-6 capture antibody at 2µg/ml followed by biotinylated goat anti-
human IL-6 at 50ng/ml (mean ± SD). The detection limit of the ELISA was 10pg/ml to 
600pg/ml. Variable slope of four parameters gave an, R
2
 value of 0.99. 
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Figure 3.29 The analysis of sputum supernatant IL-6 concentration (pg/ml) in 62 CF 
patients measured with the R&D Systems IL-6 kit for capture ELISA using mouse anti-
human IL-6 capture antibody at 2µg/ml followed by biotinylated goat anti-human IL-6 at 
50ng/ml. The IL-6 concentration ranged from 0 to 700pg/ml, with a median of 0pg/ml; a 
mean of 43pg/ml, and SEM 10pg/ml. 
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3.2.7 Correlation between cytokine production and the CFTR mutation in the CF 
population 
 
     The concentrations of IL-8 and IL-6 cytokine production in the airways of CF patients 
were assessed in patients homozygous and heterozygous for delta F508. The median levels 
do not differ significantly (IL-8 homozygous median was 5ng/ml and heterozygous 
median 10ng/ml; P=0.46; IL-6 homozygous median was 0pg/ml and heterozygous median 
0pg/ml; P=0.16) but the range of IL-8 and IL-6 are higher in the heterozygous group of 
patients (IL-8 range 1 to 30ng/ml; IL-6 0 to 700pg/ml) than the homozygous range (IL-8 
range 2 to 23ng/ml; IL-6 range 0 to 166pg/ml) as illustrated in figure 3.30 and 3.31. 
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Figure 3.30 IL-8 concentrations of patients depending on genotype. Homozygous IL8 
median levels were 5ng/ml ranging from 2 to 20ng/ml (n=18, n=4 missing data, mean 8.6, 
SEM 1.45) and heterozygous IL-8 median levels were 10ng/ml ranging from 1 to 35 ng/ml 
(n=36, n=3 missing data, mean 11, SEM 1.31). Nonparametric Two tailed T-test (Mann-
Whitney test with Gaussian approximation) show no significant difference between the IL-
8 levels of patient who are homozygous or heterozygous for delta F 508 (P=0.46). 
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Figure 3.31 IL-6 concentrations of patients depending on genotype Homozygous IL-6 
median levels were 0pg/ml ranging from 0 to 166pg/ml (n=17, n=5 missing data, mean 17, 
SEM 10.6) and heterozygous IL-6 median levels were 0pg/ml ranging from 0 to 704pg/ml 
(n=35, n=4 missing data, mean 68, SEM 23.7). Nonparametric Two tailed T-test (Mann-
Whitney test with Gaussian approximation) show no significant difference between the IL-
6 levels of patient who are homozygous or heterozygous for delta F 508 (P=0.16). 
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3.2.8 Correlation between cytokine production and GOR/EOR symptoms in the CF 
population 
 
     The DeMeester questionnaire score was used to determine patients symptomatic of 
GOR. The patients were grouped into those that were symptomatic of GOR scoring 2 or 
above on the questionnaire (GOR) and those that were asymptomatic (no GOR) of GOR 
scoring 1 or below. The IL-8 levels detected in each group was compared using a non-
parametric two-tailed statistical test which showed that there were no statistical differences 
of IL-8 levels detected in sputum samples and the presence of GOR symptoms (p=0.38). 
The median level of IL-8 detected in the GOR symptomatic group was 10ng/ml (n=29, 
range 1-30ng/ml) and median levels in the asymptomatic group were 8ng/ml (n=35, range 
1-35ng/ml) (Figure 3.32).  The same analysis was used to identify a relationship of IL-6 
levels and GOR. There was no statistical difference of IL-6 levels and GOR symptoms 
(P=0.12).  The median IL-6 levels in the GOR symptomatic group were 0pg/ml (n=29, 
range 0-270pg/ml) and the asymptomatic group median IL-6 scores were 0pg/ml (n=33, 
range 0-700pg/ml) as shown in figure 3.33.  
      The RSI questionnaire score was used to determine the presence of EOR symptoms in 
the aero digestive tract and used to identify EOR symptomatic patients. The patients were 
grouped into those that were symptomatic of EOR scoring 13 and above on the 
questionnaire (EOR) and those that were asymptomatic (no EOR) of EOR scoring 12 or 
below. The IL-8 levels detected in each group was compared using a non-parametric two-
tailed statistical test to show that there were no statistical differences of IL-8 levels 
detected in sputum samples and the presence of EOR symptoms (p=0.72). The median 
level of IL-8 detected in the EOR symptomatic group was 8ng/ml (n=43, range 1-35ng/ml) 
and median levels in the asymptomatic group were 9ng/ml (n=21, range 2-30ng/ml) 
(Figure 3.34).  The same analysis was used to identify a relationship of IL-6 levels and 
EOR. There was no statistical difference of IL-6 levels and EOR symptoms (P=0.63).  The 
median IL-6 levels in the EOR symptomatic group were 0pg/ml (n=41, range 0-290pg/ml) 
and the asymptomatic group median IL-6 scores were 0pg/ml (n=21, range 0-700pg/ml as 
shown in Figure 3.35. 
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Figure 3.32 Sputum supernatant IL-8 levels as measured by R&D Systems capture ELISA 
in GOR symptomatic patients defined as having a DeMeester score 2 or above (n=29, 
range 1-30ng/ml, median 10, mean 11, SEM 1.3) and asymptomatic patients defined as 
having a DeMeester score of 1 or less (n=35, range 2-35ng/ml, median 8, mean 10, SEM 
1.2). There was no statistical difference of IL-8 levels between symptomatic and 
asymptomatic GOR patients (P=0.38) analysed by Mann Whitney U test with Gaussian 
approximation. 
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Figure 3.33 Sputum supernatant IL-6 levels as measured by R&D Systems capture ELISA 
in GOR symptomatic patients defined as having a DeMeester score 2 or above (n=29, 
range 0-266pg/ml, median 0, mean 18, SEM 10) and asymptomatic GOR patients defined 
as having a DeMeester score of 1 or less (n=33, range 0-704pg/ml, median 0, mean 66, 
SEM 24). There was no statistical difference of IL-6 levels between symptomatic and 
asymptomatic GOR patients (P=0.12) analysed by Mann Whitney U test with Gaussian 
approximation. 
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Figure 3.34 Sputum supernatant IL-8 levels as measured by R&D Systems capture ELISA 
in EOR symptomatic patients defined as having a RSI score 13 or above (n=43, range 1-
35ng/ml, median 8, mean 10, SEM 1) and asymptomatic EOR patients defined as having a 
RSI score 12 or below (n=21, range 2-30ng/ml, median 9, mean 11, SEM 2). There was no 
statistical difference of IL-8 levels between symptomatic and asymptomatic EOR patients 
(P=0.72) analysed by Mann Whitney U test with Gaussian approximation. 
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Figure 3.35 Sputum supernatant IL-6 levels as measured by R&D Systems capture ELISA 
in EOR symptomatic patients defined as having a RSI score 13 or above (n=41, range 0-
290pg/ml, median 0, mean 31, SEM 11) and asymptomatic EOR patients defined as 
having a RSI score 12 or below (n=21, range 0-704pg/ml, median 0, mean 68, SEM 36). 
There was no statistical difference of IL-6 levels between symptomatic and asymptomatic 
EOR patients (P=0.63) analysed by Mann Whitney U test with Gaussian approximation. 
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3.2.9 Cytokine production and gastric aspiration in the CF population 
     Gastric aspiration was investigated by identifying pepsin and total bile acids (TBA) 
levels in sputum supernatant samples. Firstly, the investigation into the relationship 
between gastric aspiration determined by the presence of pepsin and its effects on cytokine 
levels in the airways was assessed. The patients were grouped into those that had 
measurable amounts of pepsin levels (above 1ng/100µl) in sputum supernatant and those 
that did not have measurable pepsin levels identified above the lower detection limit of 
1ng/100µl assayed on the in-house indirect pepsin ELISA. The levels of IL-8 and IL-6 in 
each group were compared to identify any effects of gastric aspiration on the production of 
these cytokines. The median level of IL-8 detected in the pepsin positive group was 
8ng/ml (n=46, range 2-36ng/ml) and median level in the group that did not have pepsin 
detected was 10ng/ml (n=18, range 1-28ng/ml) (Figure 3.36).  There was no statistical 
difference between levels of IL-8 in the sputum samples from the sputa of CF patients and 
the presence of gastric aspiration confirmed by pepsin identification (P=0.33). The 
relationship between levels of IL-6 and gastric aspiration detected by pepsin identification 
was not statistically significant (P=0.70). The median IL-6 levels in each group was 
0pg/ml (pepsin positive n=44, range 0-290; pepsin undetectable n=18, range 0.700) but 
interestingly one patient that did not have pepsin present in the sputum supernatant had a 
very high level of 700pg/ml IL-6 (Figure 3.37). 
     The relationship between the levels of TBA detected in the sputum supernatant of CF 
patients and the production of IL-8 and IL-6 cytokines was explored. Of the 24 patient 
sputum samples that were analysed for TBA’s there were 22 patient samples analysed for 
IL-8 and IL-6 due to 2 patient samples being too small for multiple analysis. A scatter 
graph was produced of TBA levels along the y axis and IL-8 (Figure 3.38) and IL-6 
(Figure 3.39) levels on the x axis because TBA’s were present in all patient samples and 
therefore the patients could not be divided into groups of gastric aspiration present or 
absence  on TBA detection. A linear regression fit illustrated the relationship of increasing 
TBA levels with increasing cytokine levels. There were no statistical relationship between 
TBA levels in the sputum supernatant of patients and cytokine production of IL-8 (P=1.00) 
and IL-6 (P=0.487). Interestingly, two patients with the highest TBA levels of 3.17 and 
0.80µmol/L had no IL-6 detected within the sputa in the airway collected by expectorated 
sputum sample (median TBA result of patients with no detectable IL-6 was 0.23µmol/L; 
range 0.09 to 3.17) compared to 7 patients with IL-6 production that had low levels of 
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TBA below 0.27µmol/L (median 0.19µmol/L; range 0.00 to 1.27) illustrated in Figure 
3.39. 
 
 
 
         
Figure 3.36 Sputum supernatant samples IL-8 levels in patients that have gastric aspiration 
measured by pepsin ELISA (n=46, range 2-35ng/ml, median 8, mean 10, SEM 1) and 
those that did not have gastric aspiration (n=18, range 1-28, median 11, mean 12, SEM 2). 
There was no statistical difference of IL-8 levels and gastric aspiration (P=0.33) analysed 
by Mann Whitney U test with Gaussian approximation. 
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Figure 3.37 Sputum supernatant samples IL-6 levels in patients that have gastric aspiration 
measured by pepsin ELISA (n=44, range 0-290, median 0, mean 32, SEM 11) and those 
that did not have gastric aspiration (n=18, range 0-700, median 0, mean 70, SEM 40). 
There was no statistical difference of IL-6 levels and gastric aspiration (P=0.70) analysed 
by Mann Whitney U test with Gaussian approximation. 
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Figure 3.38 Sputum supernatant samples IL-8 levels compared to TBA levels (n=22) on a 
XY scatter graph. The Pearson correlation test was used to analyse the statistical 
relationship between levels of IL-8 and TBA in sputum supernatant samples. There was no 
statistical difference between the two analytes either positive or negative (R
2
=0.0%, n=22, 
P=1.00; Pearson correlation of TBA and IL-8 = -0.000). 
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Figure 3.39 Sputum supernatant samples IL-6 levels compared to TBA levels (n=22) on a 
XY scatter graph. The Pearson correlation statistical test was used to analyse the statistical 
relationship between levels of IL-6 and TBA in sputum supernatant samples. There was no 
statistical difference between the two analytes either positive or negative in sputum 
supernatant samples (R
2
=2.6%, n=22; P-Value = 0.487; Pearson correlation of TBA and 
IL-6 = -0.161). 
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3.2.10 Cytokine levels and pulmonary function in the CF population 
 
     The levels of cytokine production (IL-8 and IL-6) in the airways was assessed by 
capture ELISA (R&D systems). The production of cytokines (levels of IL-8 and IL-6) and 
their association with pulmonary function was evaluated by plotting the data points of 
each cytokine on the Y axis and plotting the pulmonary function (FEV1 and FVC % 
predicted) along the X axis of a scatterplot. A linear regression curve was fitted to identify 
the relationship of increasing cytokines and pulmonary function. The production of IL-8 
levels (FEV1% n=60, P=0.811, R
2
 0.1%; FVC% n=60, P=0.493, R
2
0.9%) and IL-6 (FEV1% 
n=60, P=0.265, R
2 
2.5%; FVC% n=60, P=0.126, R
2 
4.6%) were not statistically related to 
pulmonary function. 
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Figure 3.40 The presented data illustrates the XY scatterplot of patient IL-8 levels on the y 
axis and patient FEV1% (A) (n=60; R
2
 0.1%) and FVC% (B) (n=60; R
2
 0.9%) predicted 
scores along the X axis. The Pearson correlation statistical test was used to analyse the 
relationship between levels of IL-8 and pulmonary function (FEV1% R
2
=0.1%,P=0.811; 
FVC% R
2
=0.9%,P=0.493). 
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Figure 3.41 The presented data illustrates the XY scatterplot of patient IL-6 levels on the y 
axis and patient FEV1% (A) (n=60; R
2
 2.5%) and FVC% (B) (n=60; R
2
 4.6%) predicted 
scores along the X axis. The Pearson correlation statistical test was used to analyse the 
relationship between levels of IL-6 and pulmonary function (FEV1% R
2
=2.5%, P=0.265; 
FVC% R
2
=4.6%, P=0.126). 
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3.3 Discussion 
 
3.3.1 The symptoms of GOR and EOR in the study population 
      It is a normal occurrence for the healthy population to experience oesophageal reflux 
episodes. These episodes entering the oesophagus are a mixture of liquid and gas leaving 
the stomach, pH and impedance illustrated that these can be non-acidic, acidic or weakly 
acidic (Sifrim, et al., 2001; Zerbib, et al., 2005). The common belch, termed eructation is 
the escape of air released from the oesophagus into the pharynx. Air swallowed into the 
stomach during eating is intragastric air and subsequently re-enters the oesophagus by the 
transient lower oesophageal sphincter relaxation to prevent this air entering the pylorus 
and intestines. It has been demonstrated that these can occur 25 to 30 times per day in the 
normal population (Bredenoord, et al., 2013). However, these normal physiological events 
may become of increased frequency (Mittal et al., 1995), more acidic (Sifrim, et al., 2001), 
of larger volume and of increased oesophageal exposure time (Dent et al., 1980; Weusten 
et al., 1995). These abnormal reflux episodes result in a multitude of potential 
complications affecting the oesophagus, pharynx, nasal cavity and the airways termed 
GORD. It also results in injury to the epithelium of the oesophagus causing erosions, 
inflammation, and in severe cases carcinoma. It is reported that the prevalence of GORD 
in the general population is 10–20% in the Western world and 5% in Asia. GORD is 
demonstrated to decrease the quality of life and also lead to mortality (Dent et al., 2005; 
Armstrong, et al., 2010).  
      The prevalence figures from the general population highlight the high degree of GOR 
prevalence in the CF population at 63-80% and EOR prevalence even higher at 94% 
(Ledson et al., 1998). The following study aimed to assess the prevalence and 
characteristics of reflux in 72 patients recruited from the RVI, Newcastle upon Tyne. The 
present study found that the prevalence of classical GOR symptoms (heartburn, 
regurgitation and dysphagia) was 42% which is twice that found in the general population, 
however it was lower than the CF prevalence data reported in the literature. An early study 
describing the prevalence of classical GOR symptoms at 80% did not mention if the 
patients were taking acid suppression medication to alleviate symptoms (Ledson et al., 
1998) which is one reason the present data differ. One recent study in 2010, reported the 
prevalence of 63% and over half of those were on PPI medication (Sabati et al., 2010). 
The prevalence in our current is similar to this and we report that of the n=30 GOR 
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symptomatic patients 70% were on PPI or H2RA. We also note that EOR symptoms were 
reported in 63% of the whole study population and specifically airway reflux cough 
present in 50% of the 22 patients who completed the HARQ questionnaire. Of the 45 
patients that were EOR symptomatic 73% were on acid suppression medication. And over 
half the patients with airway reflux demonstrated by the HARQ were on PPI. This 
illustrates that PPI medication does not alleviate upper airways symptoms in many of the 
CF patients.   
      Many studies have explored oesophageal reflux in the CF population using pH metry 
and intraluminal impedance. It has been reported that 85% (28/33) CF patients presented 
GOR that was mostly acidic (Blondeau et al., 2008a). In a small number of 11 patients 
with classical GOR symtoms, Ledson and colleagues (1998) demonstrated with impedance 
studies that 8 had GOR. Interestingly, ambulatory tracheal investigation demonstrated that 
4 patients experienced tracheal acidification accompanied by GOR episodes. The 
oesophageal studies used small numbers but these were appropriate to confirm reflux 
episodes and explore the pH and the distance it reaches up the oesophagus. 
     The advantage of the questionnaire tool within this study was high patient compliance, 
as evidenced by the collection of GOR and EOR symptoms in all the patients recruited. 
The questionnaires are validated tools and they are inexpensive, easy to use and produce 
100% patient data collection. Sabati et al., (2010) recruited 201 patients and assessed 
GOR with two validated questionnaires. Whereas, invasive pH and oesophageal 
impedance studies have a much smaller study number due to the invasive nature of the 
research tool. For example Blondeau et al. (2008) recruited 33 CF patients to explore 
GOR and Ledson et al.,  (1998) recruited 11 CF patients. However, these research tools do 
not allow for the investigation of gastric aspiration. 
3.3.2 Evidence of pepsin and bile acid aspiration in the CF population 
      It has been demonstrated that gastric contents may reach the proximal oesophagus, the 
trachea via saliva from the pharynx and the bronchioles identified via sputa from the larger 
airways. The production of sputum on the outside of airway epithelium is a common 
characteristic in CF, the patients are encouraged to expectorate the sputum via 
physiotherapy methods to clear the airways. Therefore the collection of sputum to explore 
gastric aspiration was an advantage of the study design. The disease in question has the 
characteristic of sputum production and we asked patients to expectorate random sample 
during recruitment in the out-patient clinic allowing for a non-invasive sample. 
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Unfortunately there were a small number of patients that produced small quantities of 
expectorated sputum and consequently resulted in missing data from analysis of the 
analytes pepsin (n=3), IL-8 (n=8) and IL-6 (n=10) due to insufficient sample quantity. 
Nebulised sputum production could have been used however this procedure would have 
required ethical approval amendment which would have delayed the project progression 
due to the procedures invasive nature. A trained nurse would have been required to 
accompany the patient and required to provide nebuliser equipment. The study did not 
include this technique but future studies could use this if the patient has difficulty to 
produce increased quantity of sputum and thus allow for more components in the sputum 
to be analysed with full n number in each. The possibility of increasing pepsin 
concentration due to the procedures ability to induce a GOR even would have caused false 
positive results. 
     There is evidence to support the presence of gastric contents in the airways of the CF 
population. The two analytes pepsin and bile have been widely used as a biomarker of 
aspiration in other airway diseases and are reported in the literature using various samples 
from the airway such as BAL and sputum. Also, saliva samples from the pharynx 
(Blondeau et al., 2010; Grabowski et al., 2011; Davis et al., 2013).  
     Farrell et al.,  (2006) identified pepsin in the BAL fluid of 33 children with GOR who 
were not diagnosed with CF using a pepsin sandwich ELISA to discover that pepsin levels 
were associated with proximal reflux and chronic cough (Farrell et al., 2006). This was 
supported by another study assessing pepsin levels in the BAL of 65 children with 
proximal reflux also observing a positive correlation between proximal reflux and pepsin 
using a Pepsin assay (Starosta et al., 2007). A direct Pepsin ELISA was developed in our 
laboratory here in Newcastle Upon Tyne in 2006. This pepsin ELISA was used as a tool to 
assess gastric aspiration in BAL samples collected from lung allographs and found that 
pepsin was significantly higher in lung transplantation recipients compared to healthy 
controls (Stovold et al., 2007). In 2008, Blondeau and colleagues identified pepsin in the 
BAL fluid of patients receiving lung transplantation. It was observed that 7 CF patients 
included in the study had higher levels of pepsin compared to patients with other 
respiratory diseases such as pulmonary fibrosis, pulmonary hypertension and chronic 
obstructive pulmonary disease (Blondeau et al., 2008b). Other authors have shown that 
pepsin was higher in the BAL of 31 CF patients compared to 7 healthy controls (McNally 
et al., 2011). The sputum of GOR related chronic cough patients was analysed for pepsin 
and compared with the healthy controls. Pepsin was detected in both the samples of 
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chronic cough patients and healthy controls and it was illustrated that there was no 
difference observed. The interesting finding from this study was that pepsin levels were 
higher in the patients that were not using PPI medication suggesting that acidic reflux 
events activate pepsin (Grabowski et al., 2011). Furthermore, the sputum samples were 
induced and it has been demonstrated that induced sputum could cause physiologic GOR 
in a healthy population resulting in increased pepsin levels (Ervine et al., 2009). The 
present study found that approximately 70% of the samples analysed (n=48 of 69) were 
positive for pepsin. The pepsin ELISA was sensitive to 10ng/ml and as our sputum plugs 
were corrected for the 8 times dilution with PBS the final concentration lower than 
80ng/ml were not reported as pepsin positive. The presence of pepsin below the lowest 
levels of sensitivity may derive from plasma pepsinogen. The pepsin ELISA detected a 
range of 80 to 1150ng/ml of pepsin in the 48 patient samples (67%). The present study 
used a primary antibody specific for ‘Pepsin A’ that makes up 86% or all pepsin found in 
gastric juice (Bardhan et al., 2012). It is important that the primary antibody is specific to 
‘pepsin A' and does not bind to gastricsin (known as ‘pepsin C’) due to the observation of 
Bohman et al.,  (2013) who found gastricsin but not ‘Pepsin A’ in the lower airways of 11 
patients undergoing surgery that were not GOR or CF patients. The study suggests that 
assays not specific for ‘pepsin A’ should interpret the results with caution as gastricsin 
could be expressed from pneumocytes of the airways (Bohman et al., 2013). Bulmer and 
colleagues found that pepsin exposure to the porcine laryngeal mucosa damaged the 
respiratory epithelium and membrane bound mucins measured by the release of DNA 
(Bulmer et al., 2010). This finding illustrates the potential damage that could be caused to 
the epithelium of the aero-digestive tract and airways of patients in this study with pepsin 
positive sputum samples. 
      Pauwels et al.,  (2012) identified bile acids in 56% of sputum samples collect from CF 
patients and 13% in healthy volunteers. However, the sputum was nebulised and may not 
be a good comparison to CF expectorated sputum (Ervine et al., 2009) and the number of 
CF patients were much higher (n=41) than the number of healthy controls (n=15) 
(Pauwels, et al., 2012). Blondeau and colleagues (2010) identified bile acid in the saliva of 
23 of a total 65 CF patients and reported that healthy volunteers had no bile acid detected  
(Blondeau et al., 2010). However, saliva originates from the oral cavity and drains back 
into the pharyngeal area thus it is coughed from the pharynx and is not representative of 
the fluid contained in the airway. In addition, the studies reported bile acid levels as low as 
0.2µmol/L and this is below the detection limit of the enzymatic ELISA claimed by the 
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company at 1mmol/L. This finding becomes important when patients are diagnosed and 
treated according to bile acid content of physiological samples. Parikh and colleagues 
explored the methods used for bile acid detection within research and clinical facilities and 
found that the enzymatic methods used in the previous studies mentioned report levels of 
bile acids that are below the detection limits of the kit (Parikh et al., 2013). It was reported 
in 2012 that bile acids were measured in the explanted lungs of CF patients undergoing a 
lung transplant. A sample of the total 30ml airway lavage was measured for taurine and 
glycine conjugates of cholate and isomers and taurine and glycine conjugates of 
deoxycholate and isomers by tandem mass spectrometry. This method allows for sensitive 
lower detection limits of 0.01 µmol/L. The study suggested that future research into the 
reflux of duodeno gastric reflux contents and micro aspiration should use this method 
(Aseeri et al., 2012). Due to reports of the enzymatic method used previously creating an 
uncertainty about the results and given the sensitivity of the tandem mass spectrometry 
method the following study used the latter studies method. The present study detected 
median total bile acids (>80% of total bile acids) to be 0.22 µmol/L and ranging from 0.00 
to 3.17 µmol/L. Our findings are supported by Aseeri et al., (2012) demonstrating TBA 
content of CF BAL samples to be a median of 0.19µmol/L by the tandem mass 
spectrometry method. In addition, Pauwels, and colleagues demonstrated bile acids in CF 
sputum to be a median of 1.5 µmol/L by the enzymatic assay. This data has been 
suggested that CF patients may aspirate duodeno-gastric contents into the airways, 
however the normal values for bile acids in the plasma has been demonstrated to be <10 
µmol/L and therefore used as a lower detection limit in the literature (Pearson and Parikh, 
2011; Parikh, et al., 2013). Due to the low concentrations of TBA (below 10µmol/L) 
detected in 22 CF sputum supernatant samples we could not assume that the patients 
experienced aspiration of duodenal-gastro-oesophageal refluxate. The present study did 
not continue with the analysis of TBA in further samples beyond n=22. The detection of 
pepsin in samples of the airway has been shown to be the best method to explore gastric 
aspiration due to the sensitive and inexpensive methods of analysis available. Previous 
reports regarding bile salts to show that duodenal reflux associated with GOR can be 
questionable depending of the method of analysis and the concentrations reported are not 
above the maximum normal levels found in the serum, thus their origin cannot be certain. 
The measurement of taurine and glycine conjugates of cholate, taurine and glycine 
conjugates of deoxycholate and isomers by tandem mass spectrometry is praised by its 
sensitivity, although it is an expensive procedure.  
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      Hallberg et al.,  (2004) identified duodenogastric reflux of the duodenal contents 
through the pylorus and into the stomach in CF patients with significantly higher levels of 
bilirubin and bile acids identified in gastric perfusate compared to healthy controls 
(Hallberg et al., 2004). Early studies into the effects of bile salts on the rabbit oesophagus 
investigated whether increased concentration of bile salts (up to 5mmol/L) or increased 
exposure time damaged the oesophageal muscoa (Harmon et al., 1981). Kivilaakso and 
colleagues suggest that bile salts and pepsin with the presence of gastric acid are 
components of refluxate that cause the greatest damage to oesophageal musoca 
(Kivilaakso et al., 1980). In human studies, the presence of gastric acid and 
duodenogastric reflux has been shown to be associated with severe oesophagitis in 
children and the presence of isolated gastric acid or gastric reflux is associated with mild 
oesophagitis (Orel and Markovic, 2003). 
      Interestingly, the present study observed GOR and EOR symptoms in those patients 
taking acid suppression medication (PPI and H2RA). It was illustrated that 63% patients 
experiencing GOR symptoms were on acid suppression which illustrates the medication is 
not alleviating the symptoms caused by acidic refluxate. There were 73% of patients using 
acid suppression that were symptomatic of EOR. It has been shown previously that acid 
suppression medication is not useful for EOR symptoms because the refluxate reaching 
the aero-digestive tract and beyond is not acidic, it has been suggested that pepsin and bile 
acids are the damaging contents which are unaffected by acid suppression medication 
(Bardhan et al., 2012). Furthermore, Grabowski et al., (2011) observed bile acids in the 
sputum of chronic cough patients treated with PPI and there were no differences in bile 
acid contents of these patients compared to the untreated group. Pepsin was identified in 
the sputum of 15 chronic cough patients treated with PPI to reduce symptoms, however 
pepsin was higher in the patients that were untreated. The results from this study show 
even higher pepsin concentrations in healthy control subjects so the data should be 
interpreted with caution.      The presence of pepsin was slightly higher in the patients that 
were asymptomatic of GOR and EOR, however there were no statistical differences. 
However, there were two patients with a high TBA content that were symptomatic for 
GOR and EOR. Due to the low number of patients demonstrating this effect the 
assumption cannot be made regarding bile acid effects associated with GOR and EOR 
symptoms. The Bilitec duodenogastric reflux monitoring with oesophageal monitoring 
may be needed to explore this finding further to illustrate the backflow of duodenal 
contents into the stomach followed by proximal reflux events. 
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          The study desired to assess the presence of gastric lipid digested by alveolar 
macrophages by staining the lipid contained within the macrophage with Oil Red O. The 
lipid laded macrophage index (LLMI) score as a tool to assess gastric aspiration requires 
the lipid laden macrophage count of 100 consecutive macrophages present on a 
cytological slide (Wang et al., 2010). The lipid identified within a macrophage is not 
specific to gastric content. They could be dietary lipids that have been aspirated during 
food consumption, furthermore, they could be breakdown products of cellular debris 
within the lung/airways mucus or could even have been absorbed by macrophages in the 
plasma/lymphatic fluid prior to ending up in the airways. The cellular analysis of the 
sputum samples demonstrated that the samples contained a high number of neutrophils 
with a median of 100% neutrophils therefore the lipid laden macrophage analysis was not 
possible. Research is contradictory regarding the fitness of the LLMI in identifying 
aspiration of the gastric contents into the airways. In 1987 it was reported that 85% of 
patients with respiratory tract disorders with GOR presented lipid laden macrophages in 
BAL samples compared to 19% of patients without GOR (Nessbaum et al., 1987). It was 
suggested that the simple sighting of lipid laden macrophages demonstrates a nonspecific 
finding because a LLMI score below 72 out of a possible 400 was observed in children 
with no clinical suspicion of aspiration. The study suggested  quantifying the lipid in the 
macrophage by the LLMI was a good test for recurrent aspiration in light of the median 
LLMI of above 86 was shown in patient with definite aspirators (Colombo and Hallberg, 
1987). Recently, the diagnostic tools was used to assess the effectiveness of Nissen 
funcoplication in CF patients after receiving a lung transplant by comparing LLMI before 
and after surgery and comparing the scores with patients receiving lung transplant that 
refused Nissan fundoplication. The study demonstrated a reduction in LLMI after surgery 
in the patients that underwent a Nissan fundoplication compared to those that did not. This 
suggests that the LLMI score is a useful tool to assess gastric aspiration (Hayes et al., 
2013). Other authors have also confirmed the effectiveness of the LLMI tool in lung 
transplant patients (Hopkins et al., 2010) and patients with GOR symptoms 
(Parameswaran et al., 2000). However, many studies have found that the LLMI is not a 
good marker of gastric aspiration in patients with abnormal reflux index confirmed by dual 
channel 24 hour pH monitoring identifying proximal reflux (Kitz et al., 2012). 
Additionally, the LLMI of sputum samples collected from diagnosed erosive oesophagitis 
patients were not different to the LLMI of healthy volunteers (Köksal et al., 2005). Chang 
et al. also found the LLMI score was not abnormal in patients defined with GORD with 
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the presence of reflux oesophagitis (Chang et al., 2005). The present study could not 
perform the LLMI in the sputum of CF patients, however a BAL sample may have 
provided enough macrophages to assess the usefulness of the aspiration assessment tool.  
3.3.3 The association of gastric aspiration with pulmonary function in the CF 
population 
     Research suggests that gastric aspiration may lead to poor pulmonary function 
(Pauwels et al., 2012) and could be a contributing factor to lung damage in CF (Aseeri et 
al., 2012) (Mousa and Woodley, 2012; Woodley et al., 2014). This association has been 
assumed due to the reduced pulmonary function in CF patients with increased acid GOR 
than those without GOR (Navarro et al., 2001). Blondeau et al. reported that the FEV1% 
predicted was higher in patients with bile acids absent from the sputum of CF patients 
(Blondeau et al., 2008a). Other researchers observed that wheezing was strongly 
associated with a decrease in pulmonary function, a symptom of EOR (Konstan et al., 
2007). However, others did not find any correlation with GOR symptoms and pulmonary 
function measured by FEV1 and FVC (Sabati et al., 2010). The evidence provided may 
provide possible answers but the issue still remains inconclusive.  The present study 
evaluated the association of gastric aspiration with the pulmonary function of CF patients. 
There were no association observed between the gastric aspiration of pepsin or bile acids 
with pulmonary function. Our data could not support the findings observed in the literature, 
this could be due to the difference of methods used to assess the observation. For example, 
Pauwels and colleagues (2012) assessed bile acids in sputum samples using the enzymatic 
assay previously illustrated not to be a sensitive method of assessment. Aseeri et al. 
assessed bile acids using the same method as the present study but analysed BAL samples 
as opposed to sputum. Other authors assessed proximal reflux with oesophageal pH 
impedance monitoring and therefore did not assess the entity of fluid from the airways 
(Mousa and Woodley, 2012; Woodley et al., 2014). 
      Pauwels et al.,  (2012) observed a relationship between the presence of bile acids and 
inflammation within the airway of CF patients. This study assesses the concentration of 
neutrophil elastase, a biomarker of inflammation in the sputum samples of CF patients. 
The study observed higher concentrations of neutrophil elastase in the sputum of CF 
patients with bile acids present compared to those that did not. The limitations of the bile 
acid assay used has been mentioned, however this finding illustrates that inflammation is 
present in the CF lung and further studies are needed regarding the effects of gastric 
108 
 
aspiration and inflammation. Furthermore, high IL-8 concentrations observed in the BAL 
fluid of CF patients have been associated with the presence of pepsin (McNally et al., 
2011). The present study observed high neutrophil content in the sputum of CF patients 
and this was accompanied by high IL-8 in all 72 CF sputum samples, however IL-6 was 
detected in only 16 patients samples. This is supported by finding by Fischer and 
colleagues, (2014) who detected median IL-8 concentration of 50ng/ml in the sputum of 
CF patients and low detected frequencies of IL-6 that were not high enough to report. The 
present study did not observe any association with inflammation in the airways of CF 
patients and the presence of gastric aspiration determined by pepsin. Nor did the results 
show any differences in pulmonary function and the presence of inflammation. 
          A limitation of the current study was the exclusion of CF patients that could not 
provide sputum. In the present study there were 24 potential patients that could have been 
recruited but were unable to provide expectorated sputum. Potential findings regarding the 
difference between GOR and EOR symptoms associated with sputum production was 
unexplored. The purpose of the exclusion was down to one of the major aims of the study 
involving to the analysis of sputum samples for biomarkers of reflux and inflammation. 
We could have included non-sputum producers to gather symptoms data in absence of 
gastric aspiration and inflammation data or included the possibility of BAL fluid 
collection from these patients. However, the BAL sample is taken from one section of the 
bronchiole, and it is not representative of the whole lung. In addition, the protocol of the 
BAL describes the installation of 30-180 ml infiltrated into the bronchiole and then 
recollected for the desired analysis. There is a possibility that concentration of pepsin or 
bile acids diluted in 30-180 ml is present at undetectable concentrations.  Additionally, 
there would be a major difference in methodology to collect fluid from the airways, and 
the results of pepsin ad bile acids from sputum and BAL fluid may not be easily compared. 
The positive aspect that we have observed amongst the patients besides the common 
characteristic of sputum producers, is that there is a wide range of demographics, genotype, 
and pulmonary function. Thus, we can study GOR and EOR in a wide range of CF disease 
severity with varying disease characteristics. The number of CF patients in our study were 
high compared to similar studies, our study recruited 72 CF sputum producers, whereas 
Blondeau et al. (2008) recruited 33 CF patients and Pauwels et al. (2012) 41 CF patients. 
These two studies, like ours, only collected one sample per patient on recruitment. The 
sample was not specified to be provided when the patient was experiencing GOR or EOR 
symptoms and this may result in the varied pepsin levels because the reflux event could be 
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cleared and we do not know how long pepsin will remain within the airway. Due to the 
method of sample processing method the sputum sample was processed within 2 hours of 
collection to perform the cellular analysis. The ideal sputum collection for future studies 
would be collected from each patient on a morning, on symptoms, post prandial and 
before bed. However, a change of sputum protocol would be required so that it was not 
necessary for the samples to reach the lab within 2 hours, therefore the cellular or 
inflammatory biomarker analysis for all 4 samples collected would not be possible.  
3.3.4 Summary of results from chapter 3 
      In summary, the CF population are living longer, with increased life survival rates 
reported to be 40-50 years. This is encouraging, but this also raises the concern of diseases 
observed that may have terminal outcomes other than the existing CF causes of death. The 
consequence of long-term GOR exposure to the oesophagus and aero digestive tract lead 
to unpleasant symptoms, may reduce pulmonary function and lead to fatality. As this 
study has highlighted, there is a high prevalence of GOR and EOR in the adult CF 
population with many patients aspirating gastric contents. The data did not support the 
previous findings in regard of this causing decreased pulmonary function or increasing 
inflammation. The CF airway was shown to contain high numbers of neutrophils and high 
concentrations of IL-8 were present but not associated with gastric aspiration, thus the 
study cannot show any damage caused by gastric aspiration in the CF airway.  
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Chapter 4.0 
New medication in CF – Ivacaftor CFTR potentiator for the G551D 
mutation 
4.1 Introduction 
4.1.1 New medications for Cystic Fibrosis – Ivacaftor for the CFTR G551D mutation 
 
     The first CFTR potentiator agent has been accepted by the North American Food and 
drug association for patients with the G551D mutation available as an oral tablet called 
VX-770; Caledeco or Ivacaftor. The class III G551D mutation requires agents which 
induce channel opening to enable chloride ions to be transported through the CFTR 
present at the cell surface. This type of agent is a CFTR potentiator (Kotha and Clancy, 
2013).  
     As mentioned in chapter 1 there are 6 classes of CFTR mutations. The CFTR G551D 
mutation is a class III none functional gating mutation. Class III mutations occur in 
approximately 4% of CF patients in the U.S,  5% in the U.K and increasing to 11% in the 
Republic of Ireland, the most common mutation in this class is G551D (Flume, et al., 2012; 
Yu, et al., 2012; Kotha and Clancy, 2013; Barry et al., 2014). The CFTR protein is present 
at the cell surface and composed of two nucleotide-binding domains. In a normal manner, 
the opening and closing of the channel pore or channel gating is tightly regulated by 
phosphorlylation, adenosine triphosphate (ATP) binding and hydrolysis. Protein Kinase A 
(PKA) phosphorylates CFTR to allow ATP binding and hydrolysis which in turn opens 
and closes the channel across cell membranes (channel gating) to allow chloride, and 
bicarbonate ions to be transported. In the G551D mutation the mechanisms do not function 
in the normal manner and the channel does not open or close leading to poor flow of 
chloride ions in and out of the cell and resulting in loss of epithelial chloride transportation 
(Van Goor et al., 2013; Yu, at al., 2012). The Ivacaftor molecule acts as a potentiator and 
aims to normalise the CFTR gating channel able the transport of chloride ions.  The 
Ivacaftor molecule was thought to modify one or more of these regulatory events and it 
was described in 2012 by Eckford et al., (2012) in detail. The study reported that the 
Ivacaftor molecule works through an ATP-independent mechanism working in a 
nonconventional manner. It enhances ATPase activity in the G551D mutated CFTR in 
absence of magnesium-ATP.  
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     Unregulated chloride ion transport leads to CF disorders in the exocrine organs. The 
loss of chloride transport leads to elevated sweat chloride concentration and also causes 
other CF complications such as the accumulation of thick, sticky mucus in the bronchi, 
loss of pancreatic function, impaired intestinal absorption and reproductive dysfunction. 
The accumulation of thick sticky mucus in the airways leads to decreased pulmonary 
function, bacterial growth and exacerbations. This leads to an increase in energy demands 
caused by a decrease in appetite, poor fat digestion and increase in energy expenditure 
from breathing difficulties (Orenstein et al., 2000; Simmonds, 2013). Mucus blocks the 
pancreatic ducts minimising the release of pancreatic enzymes and impairing intestinal 
absorption. As a consequence malabsorption and malnutrition occur which is corrected for 
by pancreatic enzyme replacement capsules with every meal to aid digestion and 
absorption. CF complications are multifactorial and result in a multitude of problems 
which reduce quality of life (Van Goor et al., 2013; Yu et al., 2012). Measuring the sweat 
chloride concentrations of CF patents is a widely used tool to diagnose CF as this method 
can be carried out on patients of any age, it is a relatively cheap procedure and sweat 
chloride changes occur early on in disease (Accurso et al., 2014). Normal sweat chloride 
concentrations are <39mmol/L, these concentrations would provide the clinician with the 
knowledge that a patient were at an unlikely risk of CF. Concentrations ranging from 40-
59 mmol/L would put the patient at a possible likelihood of CF and concentrations above 
60mmol/L would suggest the patient was likely to have CF (Cystic Fibrosis Foundation, 
2011).    
4.1.2 Ivacaftor outcome of clinical trials and the CF clinic 
             In 2010, investigational studies over a 28 day period started to take place on the 
oral bioavailable agent designed to potentiate CFTR channels that are positioned at the 
surface of the cell. A double blind, placebo-controlled multicentre, phase two trial was 
carried out to evaluate the safety and adverse effects of Ivacaftor involving 39 adult CF 
patients. The participation requirements set specified that patients were to be diagnosed 
with the CFTR G551D mutation on at least one allele with a FEV1% predicted to be 40% 
or higher and aged 18 years or over. Various doses of Ivacaftor (25, 75 or 150 mg) or 
placebo were received every 12 hours for 28 days. Within subject improvement of CFTR 
ion-channel function was observed with decreases in sweat chloride. At day 28 of 
treatment the median sweat chloride measurements reduced by -59.5mmol/L from baseline 
concentrations (P=0.008) in patients receiving 150 mg (every 12 hours for 28 days). 
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Improvements were observed in within subject pulmonary function scores (FEV1% 
predicted) illustrated by significant increases of 8.7% (P=0.008). Reports were made that 
the drug was safe to use and improvements in CFTR and pulmonary function were evident 
(Accurso, et al., 2010). This study was followed by a randomised, double blind, placebo-
controlled phase three trial to assess efficacy and safety of Ivacaftor this time including 
younger CF patients of >12 years, diagnosed with CF with the G551D mutation on one 
CFTR allele, had an FEV1 of 40-90% of their predictive value and for a longer duration of 
48 weeks. The study reiterated the beneficial effects of 150mg Ivacaftor seen previously. 
Ivacaftor every 12h (n=83) was shown to increase pulmonary function (FEV1% predicted) 
by 10.6% compared to the control group (n=78) at the 24 week follow-up. Decreases were 
observed in sweat chloride concentration by -48.1mmol/L compared to controls at 48 
weeks follow-up. The treated patients gained an average of 2.7kg more weight than the 
control group at 48 weeks follow-up. The frequency of pulmonary exacerbations were 
reduced by 55% compared to placebo. Although 28 patients in the group receiving 
Ivacaftor experienced a total of 47 exacerbations this was significantly lower than the 44 
placebo patients experiencing 99 exacerbations (P=0.001). The respiratory symptoms 
improved in the Ivacaftor group compared to placebo determined by the Cystic Fibrosis 
Questionnaire Revised (CFQ-R) score reduction (Ramsey et al., 2011).  The beneficial 
results of Ivacaftor were mirrored in a retrospective case control study from n=21 patients 
receiving Ivacaftor in the UK and Ireland. After 3 months of treatment the pulmonary 
function scores, weight and BMI had increased significantly from baseline (Barry et al., 
2014). Interestingly, the study highlighted that Ivacaftor treatment reduced the days of 
intravenous antibiotics received at home and in hospital. Additionally two patients were 
able to reduce oxygen therapy and one patient stopped  nasogastric tube feeding. These 
positive outcomes illustrate the health benefits to the Ivacaftor treated patients. It also 
highlights the clinical efficiency of the expensive treatment by reducing the costs of other 
healthcare costs associated with severe CF pulmonary and gastrointestinal disorders. A 
case study of one patient homozygous for G551D that did not meet the requirements for 
previous study participation was reported at a CF centre in Ireland.  The 19 year old 
patient had a baseline FEV1 of 24% predicted value, lower than the cut off in clinical trials, 
which was reported to increase to 35%  of predicted after 8 weeks of treatment and 
increasing to 40% of predicted at 12 months with an overall increase of 15% of predicted. 
Improvements in sweat chloride concentration resulted in normalised levels at 18mmol/L 
from 92mmol/L at baseline. The study illustrates the potential of Ivacaftor for not only 
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heterozygous but also G551D homozygous patients, and there are 8 persons with this 
genotype in Ireland (Harrison et al., 2013). Observations of Ivacaftor use in 14 severely ill 
CF patients with a FEV1% <40.0% of their predicted score were reported from a CF clinic 
in Germany. Unfortunately over the 13 months follow-up 3 patients died of CF 
complications reported not related to Ivacaftor use, and 2 patients were discontinued due 
to personal reasons. Reported small increases of pulmonary function were observed from 
baseline in this patient group of a mean 5.2% predicted over the 13 month. The increases 
were small compared to previous studies observations and were thought to be due to 
severe lung damage already present leading to a limited improvement via Ivacaftor 
(Hebestreit et al., 2013).  
4.1.3 Aims of the following chapter 
     As the CFTR mutation results in multiple complications in exocrine tissues there is 
now a strong interest in the possible clinical benefits of Ivacaftor that have not yet been 
investigated. CFTR is expressed in the epithelia of the gastrointestinal tract and it has been 
reported that up to 90% of CF patients experience gastro-oesophageal reflux (GOR) 
leading to extra-oesophageal reflux (EOR) problems (Blondeau et al., 2008). The 
following chapter describes the early experience of Ivacaftor use in the NHS Newcastle 
hospitals. This chapter is an evaluation of gastrointestinal effects of Ivacaftor. The main 
aim of the study was to focus particular investigations on the effects on the presence of 
GOR, EOR and gastric aspiration in the G551D CF populations and evaluate any 
beneficial effect of Ivacaftor in reducing these symptoms.      
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4.2 Results 
4.2.1 Patient demographics 
     There were a total of 12 patients recruited onto the study. There were seven males and 
five females with a median age of 23 years ranging from 17 to 38 years (Figure 4.1). Each 
patient was weighed at baseline, 6 weeks after, 6 month after and 12 months after the 
initial medication. The median weight at baseline was 64kg (range; 41-83Kg) increasing 
significantly by 2kg after 6 months (median 66, range; 43-92Kg, P=0.003) and 1.4kg 
(median 65.4 (range 40.7 to 90.2, P=0.07) at 12 months of treatment (no median increase 
after 6 weeks (median 63kg, range; 41-87Kg). Of the 12 patients recruited 7 increased 
weight by a mean of 2.9Kg after 6 weeks of starting Ivacaftor medication (range;0.5-8Kg) 
and these patients increased weight further by a mean of 4.6kg after 6 months compared to 
baseline (range;1.4-12.6Kg) (Table 4.1 and figure 4.2). The other 5 patients did not 
increase the weight 6 weeks after treatment and all but one of these 5 patients increased 
their weight by the 6 month follow-up appointment. BMI was calculated to assess 
nutritional status of each patient at baseline, 6 weeks after, 6 month after and 12 months 
after initial medication. The median BMI at baseline was 22.4 (range; 17.5-30.9) 
increasing by 0.1 at 6 week follow-up (median 22.5, range; 17.4-30.9), increasing 
significantly by 2.4 at 6 month follow-up (median 24.8, range; 18.1-31.1, P=0.004) and 
increasing by 2.2 (P=0.03) at 12 month follow-up when compared to baseline. The BMI of 
7 patients of whom put on weight increased by a mean of 1.25kg/m
2
 after 6 weeks of 
starting Ivacaftor medication (range; 0.1-3.3kg/m
2
) and increasing further by a mean of 
2.0kg/m
2
 after 6 months compared to baseline (range; 0.7-4.3kg/m
2
) (Table 4.2 and figure 
4.3). At the 12 month follow-up the data of 3 patients was not recorded due to absence. Of 
the 12 patients there were 7 patients treated with PPI therapy and 1 with H2RA’s previous 
to starting Ivacaftor to reduce GOR symptoms. The medication continued throughout the 
study with no patients discontinued of PPI or H2RA. 
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Figure 4.1. Patient age of CF patients treated with Ivacaftor (n=12, range 17-38, median 
22.5) years. The graph shows the individual patient age and the median. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Age
116 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.1. Summary of recorded weight (Kg) of each patient treated with Ivacaftor (1-12) 
at baseline, 6 week, 6 month and 12 month follow-up (ND represents no data available). 
The baseline median was 64.0kg (range 41.0 – 83.0); 6 week follow-up median was 
65.4kg (range 40.7 0 81.0); 6 month follow-up median was 66kg (range 43-92) and 12 
month follow-up median was 65.4kg (range 40.7 – 90.2). 
 
 
 
 
 
 
 
 
 
     
Patient 
Weight (Kg) 
 no     sex Baseline 6 weeks 6 month 12 month 
1 M 48.4 50.0 56.1 53.8 
2 M 79.4 87.4 92.0 90.2 
3 F 41.4 41.2 42.8 40.7 
4 F 61.5 62.0 66.8 65.4 
5 F 47.0 49.8 51.3  ND 
6 F 54.0 57.0 60.4 60.6 
7 F 65.8 65.8 64.8 63.9 
8 M 57.8 60.4 59.5  ND 
9 M 77.0 75.4 78.6 78.8 
10 M 73.8 73.8 75.6 75.8 
11 M 67.4 63.8 73.6  ND 
12 M 82.8 84.6 84.4 82.8 
117 
 
 
 
 
Figure 4.2. Individual dot plot of patient weight (kg) treated with Ivacaftor presented on 
the right as a change in weight (kg) recorded 6 weeks after initial treatment (P=0.169, 95% 
CI (-0.40, -2.70)), 6 month after initial treatment (p=0.003, 95% CI (-6.50, -1.76)) and 12 
months n=9 (P=0.05, 95% CI) after treatment from baseline weight displayed on the left 
(no change from baseline = 0). Statistical analysis performed using one sample Wilcoxon 
signed rank test.  
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Table 4.2. Body Mass Index measurements of each patient treated with Ivacaftor recorded 
at baseline, 6 week, 6 month and 12 month follow-up (ND represents no data available). 
The baseline median was 22.4kg/m
2
 (range 17.5 – 30.9); 6 week follow-up median was 
22.5kg/m
2
 (range 17.4 – 30.9); 6 month follow-up median was 24.8kg (range 18.1 – 31.1) 
and 12 month follow-up median was26.2kg/m
2
 (range 17.1 – 30.2). 
 
 
 
 
 
 
 
 
 
 
Patient BMI 
  Baseline 6 weeks 6 month 12 month 
1 21.2 22.2 24.9 23.6 
2 26.8 29.5 31.1 30.2 
3 17.5 17.4 18.1 17.1 
4 22.2 22.5 24.2 24.0 
5 20.9 22.1 22.8  ND 
6 21.3 22.5 23.9 24.0 
7 30.9 30.9 30.4 30.1 
8 19.8 20.7 20.4  ND 
9 26.1 25.5 26.6 27.7 
10 25.3 25.5 26.2 26.2 
11 22.5 21.3 24.6  ND 
12 26.9 27.6 27.6 26.9 
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Figure 4.3. Individual dot plot of patient BMI treated with Ivacaftor presented as a change 
in BMI status recorded 6 weeks after initial treatment (P=0.110, 95% CI (-0.10, -1.60), 6 
month after initial treatment (P=0.004, 95% CI (0.65, 2.75) and 12 month after initial 
treatment (P=0.03 95% CI (-2.4, -0.16) from baseline (no change from baseline = 0). 
Statistical analysis performed using one sample Wilcoxon signed rank test. 
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4.2.2 Clinical assessment of sweat chloride levels to monitor Ivacaftor performance 
     At each clinical appointment the sweat chloride test of each patient was performed by a 
trained clinical biochemist and assessed in the laboratory. The results were shared amongst 
clinicians and researchers involved in the present study. Normal sweat chloride 
concentrations are <39mmol/L, these concentrations would provide the clinician with the 
knowledge that a patient were at an unlikely risk of CF. Concentrations ranging from 40-
59 mmol/L would mean the patient has a possible likelihood of CF and concentrations 
above 60mmol/L would suggest the patient was likely to have CF (Cystic Fibrosis 
Foundation, 2011).  A patients baseline sweat chloride concentration falling below 
60mmol/L or by >30% determines response to treatment.  In cases of a baseline 
<60mmol/L the concentration must fall by 30% (NHS Commissioning Board, 2013). 
      The median sweat chloride concentration was 109 mmol/L (range; 61-131) at baseline 
significantly decreasing (P=0.001) to a median of 51 mmol/L (range 27-94) at 6 week 
follow-up. Two patients sweat chloride concentrations fell below 39mmol/L at 6 weeks 
follow-up meaning that they had normal concentrations. The concentrations remained 
significantly decreased at a median of 45 mmol/L (range; 20-91) with 6 patients resulting 
in normal sweat chloride concentrations <39mmol/L (Table 4.3 and Figure 4.4). 
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Table 4.3. Measurements of sweat chloride (mmol/L) at baseline, 6 weeks and 6 months 
follow-up. The median sweat chloride concentration at baseline was 109 mmol/L (range; 
61-131); a median of 51 mmol/L (range 27-94) at 6 week follow-up and a median of 45 
mmol/L (range; 20-91) at 6 month follow-up. The green font indicates where patients 
sweat chloride concentrations has returned to the normal range of below 39mmol/L. A 
trained professional perfomed the sweat test which involved transdermal administration of 
pilocarpine by iontophoresis to stimulate sweat gland secretion. The resulting sweat is 
collected onto a gauze/filter paper/Macroduct coil and quantified for chloride 
concentration in a laboratory (Farrell et al., 2008). 
 
 
 
 
 
 
 
 
Patient Sweat chloride concentration mmol/L 
  Baseline 6 weeks 6 month 
1 61 30 20 
2 116 62 59 
3 101 40 34 
4 114 42 37 
5 109 60 56 
6 108 59 53 
7 107 66 65 
8 95 27 30 
9 131 94 91 
10 112 50 66 
11 110 47 37 
12 108 52 36 
122 
 
 
 
 
 
Figure 4.4. Individual patient sweat chloride level treated with Ivacaftor (mmol/L) 
measured at baseline, 6 weeks after medication and 6 month after medication. The median 
sweat chloride concentration at baseline was 109 mmol/L (range; 61-131); a median of 51 
mmol/L (range 27-94) at 6 week follow-up and a median of 45 mmol/L (range; 20-91) at 6 
month follow-up. Statistical analysis was performed using the Kruskal-Wallis test and 
Dunn's Multiple Comparison Test. *** statistically significant (P<0.001). 
 
 
 
 
 
 
 
 
 
 
 
 
*** ***
Baseline                       6 week                      6 month
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4.2.3 Clinical assessment of pulmonary function to monitor Ivacaftor performance  
 
     Pulmonary function of each patient was measured by FEV1 and FVC. These were then 
calculated as a percentage of predicted values by a trained nurse at the out-patient clinic, 
RVI, Newcastle according to European Respiratory Society guidelines (Pellegrino et al., 
2005; Laszlo, 2006). The measurements were recorded at baseline and each follow-up 
appointment (6 weeks, 6 months and 12 months post Ivacaftor treatment). The median 
FEV1% predicted was 79% (range; 19-110%) at baseline, increasing to a median of 101% 
(range; 35-132%) at 6 week follow-up, 93% (range; 32-124%) at 6 month follow-up and 
96% (range: 32-114) at 12 month follow-up. All twelve patients increased FEV1% 
predicted after 6 weeks of Ivacaftor treatment. The mean FEV1% predicted significantly 
increased by 15% (range; 9-37%) (P=0.003) after 6 weeks of treatment and remained at 15% 
(range; 4-32) above baseline after 6 month (P=0.004) and 12 months (P=0.06) of treatment. 
The median FVC% predicted was 89% at baseline (range; 35-119) increasing to a median 
of 100% at 6 weeks (range; 60-125), 100% at 6 months (range; 53-124) and 102% at 12 
months (range; 54-116) follow-up appointments. The mean FVC significantly increased 
by 13% (range 2 to 29) after 6 weeks of treatment (P=0.003) and remained at 13% higher 
than baseline %, (range 1 to 28) (P=0.003) after 6 months of treatment. The mean FVC% 
decreased to 5% change at 12 months compared to baseline, range 0 to 27 (P=0.36) (Table 
4.4 and Figure 4.5 and 4.6). 
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pt Baseline 
 
6 weeks 
 
6 months 
 
12 months 
 
  FEV1%
p 
FVC%
p 
FEV1%
p 
FVC%
p 
FEV1%
p 
FVC%
p 
FEV1%
p 
FVC%
p 
1 90 92 101 99 106 103 104 102 
2 110 119 132 125 124 124 96 105 
3 28 47 40 61 32 53 32 54 
4 90 103 100 105 104 108 107 110 
5 87 89 105 118 110 114  -  - 
6 35 78 44 89 44 93 38 64 
7 90 89 102 100 90 90 98 97 
8 19 35 35 60 35 63  -  - 
9 88 99 103 113 109 111 114 116 
10 70 99 75 106 83 106 83 106 
11 64 74 101 95 96 97  -  - 
12 64 78 79 90 84 93 85 95 
 
Table 4.4 FEV1% predicted and FVC % predicted of CF patients treated with Ivacaftor 
recorded at baseline, 6 week, 6 month and 12 months (- no data available). At baseline the 
median FEV1% was 79% (range 19 to 110, mean 70, SEM 8) and the median FVC% was 
89% (range 35 to 119, mean 84, SEM 7). At 6 weeks follow-up the median FEV1% was 
101% (range 35 to 132, mean 85, SEM 9) and FVC% was 100 (range 60 to 125, mean 97, 
SEM 6). At 6 months follow-up the median FEV1% was 93% (range 32 to 124, mean 85, 
SEM 9) and FVC% 100% (range 53 to 124, mean 97, SEM 6). At 12 month follow-up 
(n=9) the median FEV1% was 96% (range 32 to 114, mean 84, SEM 10) and FVC 102% 
(range 54 to 116, mean 94, SEM 7) 
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Figure 4.5 Change in % predicted of forced expiratory volume in 1 second (FEV1 % 
predicted) at 6 weeks (mean 15%, range 9 to 37) (P=0.003, 95% CI (10.50, 19.00), 6 
month from baseline (mean 15%, range 4 to 32) (P=0.004, 95% CI (10.00, 20.5) and 12 
month from base (mean 10%, range -1 to 27) (P=0.06) (0= no change from baseline). 
Statistical analysis performed using one sample Wilcoxon signed rank test. 
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Figure 4.6 Change in % predicted of forced vital capacity (FVC % predicted) at 6 weeks 
(mean 13%, range 2 to 29) (P=0.003, 95% CI (8.0, 18.00), 6 month (mean 13%, range 1 to 
28) (P=0.003, 95% CI (6.5, 18.5) and 12 month (mean 5, range 0 to 27) (P=0.36) follow-
up from baseline (0= no change from baseline). Statistical analysis performed using one 
sample Wilcoxon signed rank test.  
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4.2.4 Gastro-oesophageal reflux in the G551D CF population; effects of Ivacaftor 
     GOR was present in three patients (median score 1, range; 0-5) at baseline as 
determined by the DeMeester reflux questionnaire and was defined by having a 
DeMeester score <2, this decreased to one GOR symptomatic patient (median score 0, 
range; 0-5) at the 6 week follow-up and to two GOR symptomatic patients (median score 0, 
range; 0-5) at the 6 month follow-up. Of the 12 patients studied there were 6 patients that 
experienced a fall in GOR symptoms after 6 weeks of Ivacaftor treatment and this was 
mirrored at 6 month follow-up when compared to baseline scores. There were 8 patients 
interviewed at the 12 month follow-up and with 1 patient presenting GOR symptoms.  
There was a trend for a significant change in DeMeester score 6 weeks after initial 
treatment (P=0.06) (Table 4.5 and figure 4.7). EOR was present in six of nine patients at 
baseline determined by the RSI questionnaire (RSI score >13) and decreasing to two 
patients after 6 weeks of Ivacaftor treatment. There were three EOR symptomatic patients 
determined at the 6 month follow-up. There is a significant reduction in RSI scores post 
medication with all but one patient showing a continuous reduction in RSI score during 
follow-up (P=0.008) (Table 5.6 and Figure 4.8). The Hull airways reflux questionnaire 
(HARQ) is another tool designed to assess EOR. Using this questionnaire there were 5 of 
the 6 patients mentioned above presenting EOR symptoms at baseline showing that both 
tools detected EOR in 5 symptomatic patients. The number of symptomatic patients 
decreased during Ivacaftor treatment (n=2 at 6 weeks follow-up and n=3 at 6 and 12 
month follow-up). There was a significant decrease of EOR determined by the HARQ 
score at 6 weeks post treatment (p=0.031) (Table 4.7 and Figure 4.9). 
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DeMeester reflux Score 
(GOR determined by score >1 max 7) 
 patient baseline 6 week 6 month 12 month 
1 1 0 1 1  
2 1 1 0 1 
3 1 0 0  ND 
4 0 0 0 0 
5 1 1 0  0 
6 2 0 2  1 
7 5 5 5 6 
8 2 1 0  ND 
9 0 0 0 0 
10 1 0 0  0 
11 0 1 1  ND 
12 1 0 0  ND 
 
Table 4.5. DeMeester score of patients treated with Ivacaftor at baseline 6 week, 6 month 
and 12 month (The numbers highlighted in red represent patients presenting GOR 
symptoms scoring >2; ND represents no data available).  Median DeMeester score at 
baseline was 1, ranging from 0 to 5 and there were 3 patients with a DeMeester score 
over >1 to determine GOR symptoms.  Median DeMeester score at 6 weeks follow-up was 
0, ranging from 0 to 5 and there was 1 patient with a DeMeester score over >1 to 
determine GOR symptoms. Median DeMeester score at 6 month follow-up was 0, ranging 
from 0 to 5 and there were 2 patients with a DeMeester score over >1 to determine GOR 
symptoms. There were 8 patients that attended appointments at the 12 month follow-up 
and median scores were 0 (range 0-6) with one patient presenting GOR symptoms.  
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Figure 4.7. Change in DeMeester reflux score of patients treated with Ivacaftor at 6 weeks 
(P=0.059), 6 months (P=0.091) and 12 months (P=0.62) from baseline (0= no change from 
baseline). Statistical analysis performed using one sample Wilcoxon signed rank test and 
the decrease in DeMeester score was significantly reduced 6 weeks after medication 
(P=0.059). 
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Reflux Symptom Index Score 
(EOR determined by score >13 max 45) 
RSI baseline 6 week 6 
month 
12 
month 
1 14 0 1 2 
2 2 3 3 11 
3 23 10 16 ND 
4 11 9 6 2 
5 17 12 3 15 
6 29 23 16 16 
7 12 14 16 14 
8 15 11 7 ND 
9 3 2 2 0 
10 4 1 2 0 
11 15 5 5 ND 
12 8 3 1 ND 
Table 4.6. Reflux Symptom Index (RSI) score (maximum score 45) of patients treated 
with Ivacaftor at baseline 6 week, 6 month and 12 month (The numbers highlighted in red 
represent patients presenting EOR symptoms scoring RSI >13; ND represents no data 
available).  Median RSI score at baseline was 13, ranging from 2 to 29 and there were 6 
patients with a RSI score over >13 to determine EOR symptoms.  Median RSI score at 6 
weeks follow-up was 7, ranging from 0 to 23 and there was 2 patients with a RSI score 
over >13 to determine EOR symptoms. Median RSI score at 6 month follow-up was 4, 
ranging from 1 to 16 and there were 3 patients with a RSI score over >13 to determine 
EOR symptoms. There were 8 patients that attended appointments at the 12 month follow-
up and median scores were 7 (range 0-16) with 3 patient presenting EOR symptoms.  
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Figure 4.8. Change in Reflux Symptom Index score (maximum score 45) of patients 
treated with Ivacaftor at 6 weeks (P=0.008, 95% CI (10.5, 2.00)), 6 month (P=0.010, 95% 
CI (10.00, 2.00)) and 12 month (P=0.16) from baseline (0= no change from baseline). 
Statistical analysis performed using one sample Wilcoxon signed rank test (mean ± SEM). 
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Hull Airways Reflux Questionnaire score 
(EOR determined by score >13 max 70) 
HARQ Baseline 6 week 6 
month 
12 
month 
1 12 5 5 2 
2 3 2 3 10 
3 31 11 16 ND 
4 7 6 4 2 
5 19 16 17 13 
6 33 27 24 16 
7 12 15 18 16 
8 15 11 12 ND 
9 3 1 1 0 
10 4 8 2 1 
11 27 8 7 ND 
12 8 3 1 ND 
Table 4.7. Hull Airway Reflux Questionnaire (HARQ) score (maximum score 70) at of 
patients treated with Ivacaftor baseline 6 week, 6 month and 12 month (The numbers 
highlighted in red represent patients presenting EOR symptoms scoring HARQ >13; ND 
represents no data available).   The individual patient HARQ measured at baseline are 
shown with a median score of 12 (n=12, range 3-33, mean 14.5, SEM 3.1) and 5 patients 
presented EOR symptoms. The median score at the 6 weeks follow up was 8 (n=12, range 
1-27, mean 9.4, SEM 2.1) with 3 patients presenting EOR symptoms, 6 month after 
medication the median score was 6 with 4 patients presenting EOR symptoms (n=12, 
range 1-24, mean 9.2, SEM 2.3) and 12 month after medication the median score was 6 
with 3 patients presenting EOR symptoms (n=8, range 0-16, median 6, mean 7.5, SEM 
2.5). 
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Figure 4.9. Change in Hull Airways Reflux score (maximum score 70) of patients treated 
with Ivacaftor at 6 weeks (P=0.031, 95% CI (10.50, 1.00)), 6 month (P=0.018, 95% CI 
(10.00, 1.50)) and 12 (P=0.17, 95% CI (-2.17, 10.42) month from baseline (0= no change 
from baseline). Statistical analysis performed using paired t-test (CI=95%). 
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4.2.5 The association of extra-oesophageal reflux symptoms with pulmonary function 
 
     The pulmonary function of EOR symptomatic and none-symptomatic patients (RSI and 
HARQ score; EOR symptomatic patients scored >13 and none EOR symptomatic scored 
<12) was evaluated.  The mean FEV1 % predicted of EOR symptomatic patients 
determined by the RSI score was 54% at baseline (range; 19-90) and significantly higher 
at 85% for the non-symptomatic group (range; 64-110) (P=0.037). FEV1 % of predicted 
was higher in the patients that did not experience EOR symptoms compared to those of 
symptomatic patients. The 6 week follow-up showed that the mean FEV1% predicted of 
patients not symptomatic for EOR was 73% (range; 44-102%) which was higher than the 
EOR symptomatic patients post medication (mean 55%, range; 32-90%) and were similar 
during the rest of the study period. The mean FEV1% predicted of EOR symptomatic 
patients determined by the HARQ score were 47% (range; 19-87%) at baseline whereas 
none-symptomatic patients had a significantly higher mean FEV1% predicted of 86% 
(range; 64-110%) (P=0.02). FEV1 % predicted was higher in the none-symptomatic group 
mean 85% (range; 35-132), 6 month mean 92% (range; 35-124) compared to the EOR 
symptomatic group (6 week mean 84% (range; 44-105), 6 month mean 69 (range 32-110) 
after treatment. At the 12 month follow-up there were 8 patients interviewed and who 
provided a score, 2 of whom were EOR symptomatic and had FEV1% scores of 38 and 
98%. There were 6 non-symptomatic patients with a median FEV1% of 103 (range 83-
114). The data was not statistically analysed because of the low number of patients in the 
EOR symptomatic group. (Figures 4.10 and 4.11). 
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Figure 4.10. Forced expiratory volume in 1 second % predicted in reflux symptomatic 
patients (red) treated with Ivacaftor and none symptomatic (blue) CF patients determined 
by the RSI score in a longitudinal follow-up before medication (P=0.037), 6 weeks after 
initial medication, 6 month after initial medication (P=0.10) and 12 month after initial 
medication. Statistical analysis performed using Mann-Whitney Test (CI=95%) for groups 
with 3 or more data points (baseline and 6 month). 
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Figure 4.11. Forced expiratory volume in 1 second % predicted in reflux symptomatic 
patients (red) and none symptomatic (blue) CF patients determined by the HARQ score in 
a longitudinal follow-up before medication (symptomatic median 47%, range 19-87; none-
symptomatic median 86%, range 64-110) (P=0.02), 6 weeks after initial medication 
(symptomatic median 84%, range 44-105; none-symptomatic median 85%, range 35-132) 
(P=0.58), 6 month after initial medication (symptomatic median 69%, range 32-110; none-
symptomatic median 92, range 35-124) (P=0.46) and 12 month (symptomatic median 68, 
range 36-133; none symptomatic median 89, range 35-139) after initial medication. 
Statistical analysis performed using Mann-Whitney Test (CI=95%) for groups with 3 or 
more data points (baseline and 6 month). 
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4.2.6 The collection and analysis of sputum samples and expectorated saliva 
 
      Each patient was asked to produce an expectorated sputum sample at baseline and each 
follow-up; if sputum could not be produced the patient was advised to produce 
expectorated saliva. There were 8 sputum samples and 2 saliva samples collected at 
baseline from 12 patients with 2 patients unable to provide samples. The number of 
patients who produced Sputa reduced post treatment, there were 5 sputum samples and 3 
saliva samples collected at 6 weeks follow-up; 5 sputum and 6 saliva samples collected at 
6 months follow up and 3 saliva samples collected at 12 month follow-up but no sputum 
produced (Table 4.8). The samples were analysed for pepsin identification and quantity 
using the in-house pepsin ELISA. At baseline the median pepsin levels was 481ng/ml 
(range 110 to 1150), at 6 weeks the median was 400ng/ml (range 0 to 820), at 6 month the 
median was 230 (range 0 to 1502). There was no pepsin detected in the 2 saliva samples 
collected at the 12 month follow-up. There was no statistical difference of pepsin levels at 
baseline compared to post medication (baseline median 480ng/ml; range 110-710, 6 week 
median 400ng/ml; range 0 – 820, 6 month median 230ng/ml; range 0 – 610 and 12 month 
follow-up only two saliva samples analysed with no pepsin present. (P=0.33) (Table 4.9 
and Figure 4.12). A cell differential confirmed that the sputum samples analysed at 
baseline were 100% neutrophilic. In contrast there were two sputum samples at the 6 week 
follow-up containing 0.4 and 32% macrophages and 2 samples at 6 month follow-up 
containing 6 and 2% macrophages. A lipid laden macrophage score was performed for all 
sputum samples. There was lipid present in two samples contained in the macrophages, the 
LLMI score was not performed due to insufficient number of macrophages. (Tables 4.10 
and 4.11 and Figure 4.13). 
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Sputum and expectorated saliva sample collection 
Patient no baseline 6 weeks 6 months 12 months 
1 sputum sputum saliva saliva 
2 sputum No sample 
produced 
sputum No sample 
produced 
3 sputum sputum sputum ND 
4 sputum No sample 
produced 
sputum saliva 
5 sputum saliva saliva No sample 
produced  
6 No sample 
produced  
No sample 
produced 
saliva No sample 
produced  
7 No sample 
produced 
saliva saliva No sample 
produced 
8 sputum sputum saliva ND 
9 saliva sputum sputum No sample 
produced 
10 saliva saliva saliva saliva 
11 sputum No sample 
produced 
No sample 
produced 
ND 
12 sputum sputum sputum ND 
 
Table 4.8. Sputum and expectorated saliva sample collection from patients treated with 
Ivacaftor at baseline, 6 week, 6 month and 12 month follow-up. There were 8 sputum 
samples and 2 expectorated saliva samples collected at baseline, 5 sputum samples and 3 
expectorated saliva samples collected at 6 week follow-up, 5 sputum samples and 6 
expectorated saliva samples collected at 6 month follow-up and 3 expectorated saliva 
samples collected at 12 month follow-up. (ND represents no data available). 
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Pepsin concentration (ng/ml) measure in  
sputum and expectorated saliva 
Patient no Baseline 6 weeks 6 months 12 months 
1 261 464 0 0 
2 - - 644 - 
3 870 543 704 ND 
4 1151 - 1502 - 
5 238 0 0 - 
6 - - 165 - 
7 - 0 0 - 
8 710 820 230 ND 
9 116 347 405 - 
10 150 352 0 0 
11 481 - - ND 
12 611 696 611 ND 
 
Table 4.9. Pepsin levels measured by in-house indirect pepsin ELISA in sputum and 
expectorated saliva samples at baseline (median 480 ng/ml; range 110-710), 6 week 
(median 400 ng/ml; range 0 – 820), 6 month (median 230 ng/ml; range 0 – 610) and 12 
month follow-up only two saliva samples analysed with no pepsin present (- no sample 
analysed). (ND represents no data available). 
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Figure 4.12. The analysis of sputum supernatant and expectorated saliva pepsin levels 
(ng/ml) in patients treated with Ivacaftor at baseline (n=9), 6 weeks (n=8), 6 month (n=11) 
and 12 month (n=2) follow-up measured with in-house ELISA using goat monoclonal 
primary antibody at 1:100 followed by monoclonal secondary to goat monoclonal raised in 
mouse (peroxide conjugated) at 1:1000 (mean with SEM). The range of pepsin at baseline 
was 116 to 1151ng/ml, median 481, mean 510, SEM 118. The range of pepsin at 6 weeks 
was 0 to 820ng/ml, median 408, mean 402, SEM 105. The range of pepsin at 6 months 
was 0 to 1502ng/ml, median 230, mean 387, SEM 139. There was no pepsin detected in 
the 2 saliva samples collected at 12 month follow-up. No statistical difference between 
groups (P=0.33) using the Kruskal-Wallis statistical test. 
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Cell differential of sputum sample (Giemsa stain) 
Su
b 
no 
Macrophages 
% 
Neurophils 
% 
Lymphocytes 
% 
Eosinophils 
% 
Squamous 
% 
 BL 6W 6M BL 6W 6M BL 6W 6M BL 6W 6M BL 6W 6M 
1 0 0 ….. 100 100 ….. 0 0 ….. 0 0 0 0 0 ….. 
2 …... ….. 0 ….. ….. 100 ….. ….. 0 ….. ….. 0 430 ….. 100 
3 0 0 2 100 100 98 0 0 0 0 0 0 0 0 20 
4 0 ….. 0 100 ….. 100 0 ….. 0 0 ….. 0 5 ….. 60 
5 0 ….. ….. 100 ….. ….. 0 ….. ….. 0 ….. ….. 1 ….. ….. 
6 …. …... ….. ….. ….. ….. ….. ….. ….. ….. ….. ….. ….. ….. ….. 
7    0 …... ….. 100 ….. ….. 0 ….. ….. 0 ….. ….. 2 ….. ….. 
8 0 0 ….. 100 100 ….. 0 0 ….. 0 0 ….. 5 0 ….. 
9 ….. 0.4 6 ….. 99.6 94 ….. 0 ….. ….. 0 ….. ….. 2 0 
10 ….. ….. ….. ….. ….. ….. ….. ….. ….. ….. ….. ….. ….. ….. ….. 
11 ….. ….. ….. ….. ….. ….. ….. ….. ….. ….. ….. ….. ….. ….. ….. 
12 0 32.4 0 100 67.6 100 0 0 0 0 0 0 0 25 0.1 
 
Table 4.10. Cell differential of cytological slide preparation of sputum sample (n=12) from 
patients treated with Ivacaftor stained with Giemsa.  10/12 (83%) samples contain 100% 
neutrophils. Two samples contain macrophages, sample number 9 at 6 weeks follow-up 
contained 0.4% and sample number 12 contained 32% at 6 week follow-up. 
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Lipid laden Macrophage Score (Oil red O 
staining of cell preparation) 
    Patient number Oil Red O 
 BL 6W 6M 
1 0 0 ….. 
2 0 ….. 0 
3 0 0 0 
4 0 ….. 0 
5 0 ….. ….. 
6 ….. ….. ….. 
7 0 ….. ….. 
8 0 0 ….. 
9 ….. 0 0 (ORO) 
10 ….. …. ….. 
11 0 …. ….. 
12 0 0(ORO) 0 
 
Table 4.11. Lipid laden macrophage score for each cytological slide of patients treated 
with Ivacaftor was performed by staining with Oil Red O (Sudan red). The LLMI was not 
performed due to insufficient macrophage total (100 needed to perform the score). Two 
samples contained lipid laden macrophages; patient 9 at 6 month and patient 12 at 6 week 
follow-up represented as ORO.  
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Photography of Lipid laden macrophage 
Patient  Follow-up  Lipid laden macrophage 
9 6 month  
 
12 6 week 
  
 
Figure 4.13 The photography of a Lipid laden macrophage under light microscopy (×40) 
from patient treated with Ivacaftor 9 at 6 month follow-up and patient 12 at 6 week 
follow-up. 
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4.3 Discussion 
 
     The CFTR potentiator Ivacaftor was made available by the FDA for CF patients with 
the G551D CFTR mutation on January 31
st
 2012 (Polenakovik and Sanville, 2013). This 
potentiator aims to normalise the gating channel of the CFTR to able the transport of 
chloride ions. This can be tested by measuring sweat chloride levels as a way of measuring 
activity of the drug, and testing compliance with the drug (De Boeck et al., 2013; Accurso 
et al., 2014). The present study observed the longitudinal effects of the G551D CFTR 
mutated recipients prescribed with Ivacaftor medication attending routine clinical 
appointments at the Newcastle upon Tyne RVI chest clinic. The following study presents 
the recorded measurements taken at baseline, and during the 6 week, 6 month and 12 
month follow-up appointments of patients receiving Ivacaftor treatment (150mg/12h). The 
outcome measurements to assess the effects of Ivacaftor were measurement of sweat 
chloride concentrations, weight gain or loss, and pulmonary function (FEV1% FVC% 
predicted). 
     In the G551D mutation the CFTR protein is present at the cell surface but the channel 
does not open or close in a normal manner leading to poor flow of chloride ions in and out 
of the cell and resulting in loss of epithelial chloride conductance (Yu, at al., 2012). CF 
patients with this mutation have in abnormal sweat chloride levels and this is used as a 
gold standard biomarker to diagnose CF disease (normal concentration levels <39mmol/L; 
possible chance of CF 40-59mmol/L; likely chance of CF >60mmol/L) (Cystic Fibrosis 
Foundation, 2011). Continuation of Ivacaftor treatment requires a sweat chloride fall 
below 60mmol/L or 30% lower than baseline concentrations (NHSCommissioningBoard, 
2013). Sweat chloride concentrations were measured at baseline and then repeated at 6 
weeks and 6 month follow-up. The present study found that the use of Ivacaftor in the 
Newcastle Upon Tyne G551D CF cohort significantly decreased sweat chloride levels 
(P=0.001) at 6 weeks follow-up at a median of -58mmol/L and this reduction remained at 
6 months follow-up with a median of -64mmol/L from baseline concentrations. The sweat 
chloride concentrations measured above 60mmol/L at baseline illustrating existing CFTR 
abnormalities and continuation requirements were met by all patients. Interestingly, at 6 
weeks follow-up 7 patients observed a fall in sweat chloride below 60mmol/L and 2 
patients observed a fall below 39mmol/L meaning normal concentrations were met. The 3 
remaining patients observed a fall of more than 30% of their baseline sweat chloride 
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concentrations. At the 6 month follow-up a further fall in sweat chloride was observed 
with 6 patients now having normalised concentrations. These results indicate that the 
administration of prescribed Ivacaftor (150mg/12h), a CFTR potentiator, results in 
increased chloride flux. This is supported by Ramsey et al., (2011) who found that treated 
patients reduced sweat chloride by -48mmol/L at 48weeks from baseline when compared 
to controls. Accurso et al., (2010) reported a sweat chloride reduction of -59.5mmol/L 
when assesses 4 weeks after the start of treatment (P=0.008). However, Barry et al., (2013) 
questions the sweat chloride measurement as a marker of clinical response. Accordingly, it 
was observed that in 4 patients treated with Ivacaftor the improvement in pulmonary 
function and BMI were significant after 1 month, but at 8 weeks follow-up the sweat 
chloride concentrations did not fall below 60mmol/L or by 30% from baseline and these 
patients failed to meet continuation criteria. The sweat chloride tests were repeated in all 4 
patients to observe 2 patients had now met the continuation criteria. One patient admitted 
to missing one dose of Ivacaftor treatment. The two patients that did not observe the 
required sweat chloride reductions were discontinued from Ivacaftor despite an increase of 
15 and 17% FEV1% predicted from baseline. Barry et al., (2013) questioned the 
sensitivity of the sweat chloride test as a measure of clinical response. Additionally the 
data highlight the importance of commitment to medication to observe consistent reduced 
sweat chloride concentrations. 
     CFTR proteins are expressed in the gastrointestinal tract leading to an excess of thick 
and sticky mucus blocking the pancreatic ducts. This minimises the release of pancreatic 
enzymes which impairs intestinal absorption resulting in malabsorption and malnutrition 
(Van Goor et al., 2013; Yu et al., 2012). Factors contributing to poor weight gain 
complications are multifactorial and result in a multitude of problems which reduce 
quality of life (Thomas and Bishop, 2007; Bourke and Burns, 2011). Ivacaftor may affect 
gastrointestinal epithelia which may increase nutrient absorption resulting in a possible 
improved pancreatic enzyme release thus increasing weight. The present study found that 
the median weight of all patients did not increase at 6 weeks from baseline supporting the 
issue that CF weight gain is multifactorial and could be affected by increased caloric needs 
due to exacerbations, diabetes and anorexia. However, seven of the 12 patients increased 
weight by an average of 2.9kg at the 6 weeks follow-up appointment. The success of 
weight gain was not associated with severity of lung disease. The overall median weight 
measured at 6 months significantly increased by 2kg from baseline (P=0.003) and further 
increasing to 4.6kg at 12 months from baseline. Our data is supported by recent literature 
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by Barry et al., (2013) who reported a small increase of 0.6kg/m
2
 observed over a 1 month 
follow-up period. It was observed that in a study of Ivacaftor patients with a FEV1% of 
predicted of above 40% gained an average of 3.1kg after 48weeks of treatment (Ramsey et 
al., 2011). Patients with a FEV1% predicted below 40% were reported to gain an average 
of 2.1kg over a 12 month period (Hebestreit et al., 2013).   
       Unregulated chloride ion transport leads to CF disorders in the exocrine organs. The 
accumulation of thick sticky mucus in the airways leads to decreased pulmonary function, 
bacterial growth and exacerbations resulting in increased energy demands (Thomas and 
Bishop, 2007; Bourke and Burns, 2011). The literature has shown that the effects of 
normalised CFTR channel gating by the use of Ivacaftor has led to significant increases in 
pulmonary function (Accurso et al., 2010; Ramsey et al., 2011). The present study 
mirrored findings that were found in clinical trials and showed that Ivacaftor led to a 
significant increase of median pulmonary function measurements determined by FEV1 and 
FVC % predicted (<P=0.004). At baseline the median FEV1% was 79% of the predicted 
value based on age, sex and height in accordance with the ERS guidelines (Laszlo, 2006). 
The median pulmonary function (FEV1% predicted) measurements increased the most at 
the 6 week follow-up representing a relative 21% increase from the baseline 
measurements and remained consistent up to 12 month follow-up. Three of the patients 
had a FEV1% predicted below 40% which was the cut off for participation in the previous 
clinical trials. These patients responded to treatment and increases in pulmonary function 
were observed resulting in a FEV1% predicted over 40% for two patients at 6 weeks 
follow-up. This was supported by findings from the clinical trial published in 2011 by 
Ramsey et al., (2011) who reported an average increase of 17.2% in FEV1% at 6 month 
from baseline. In addition Accurso et al., (2010) reported an increase of 8.7% at 4 weeks 
from baseline (P=0.008). Barry et al., (2013) observed an increase in FEV1% predicted 
after 1 month of Ivacaftor treatment from a median of 64.3% to 73.4% (Barry et al., 2014). 
Spirometry has been used as a gold standard to measure declining pulmonary function in 
CF but the measurement has now been regarded inadequate enough to detect early signs of 
progressive lung disease because FEV1% is reduced slowly and any falls in measurements 
mean that the lungs have begun the decline caused by infections and inflammatory 
responses that are difficult to reverse. To date no other measurement of pulmonary 
function has taken over FEV1 measurements but the Lung Clearance Index holds prospect 
of fulfilling criteria of early detection and sensitivity of lung function decline. It consists 
of multiple breath washouts to measure ventilation homogeneity (Davies et al., 2008). 
147 
 
Interestingly, Davies et al., (2013) compared lung clearance index in a phase 2 multicentre 
placebo controlled, double-blind 2x2 crossover study. Ivacaftor, 150mg x2 daily led to 
significantly improved lung clearance compared to placebo. It was also added that lung 
clearance methods was a sensitive method to detect a response to Ivacaftor (Davies et al., 
2013). The measurement may not be as highly regarded but the wide use of FEV1% 
predicted allows studies to compare results and in our case response to treatment. The 
clinical trials into the efficiency of Ivacaftor used the spirometry measurements and thus 
this allows our study to compare findings. The lung clearance index informs us about 
abnormalities in the small airways and it is suggested that increased lung clearance index 
scores suggest airway narrowing caused by inflammation or sputum plugs (Davies et al., 
2008). The present study observed that less sputum was produced post Ivacaftor treatment. 
There were 8 patients who were able to expectorate sputum on recruitment at baseline and 
this decreased to 5 patients during 6 week and 6 month follow-up. Interestingly, at the 12 
month follow-up there was no sputum expectorated by 8 patients that attended 
appointments and 4 patients failed to attend their arranged appointments leading us to 
believe they were feeling well and healthy thus not requiring hospital appointments. On a 
negative note the study was unable to compare biomarkers of reflux and inflammation 
from all patients during the study. On a positive note, the patients were unable to 
expectorate sputum, in some cases provided saliva indicating the positive effects of 
Ivacaftor on the CFTR epithelium in the airways. The lung clearance index would have 
provided more information about the inflammation and sputum present in the small 
airways but this is a new method and Davies et al., (2008) report only few studies have 
reported lung clearance index scores to date due to complex and expensive technologies 
needed to analyse samples. This method may be used for research purposes but not for 
clinical follow-up. This may be related to findings of Reznikov et al., (2014) who 
investigated the antibacterial properties of Ivacaftor on strains of Streptococcus 
pneumoniae and Staphylococcus aureus which are two common pathogens of the CF 
airway. The antibacterial properties of Ivacaftor were observed by a dose dependant 
reduction in Streptococcus pneumonia determined by bioluminescence. There were only 
mild decreases of Staphylococcus aureus and this was thought to be due to the outer 
membrane of these bacteria to be a barrier to the Ivacaftor molecule. These data suggest 
that Ivacaftor may reduce the bacteria colonization within the CF airways which may 
therefore reduce the inflammatory response. In essence, the reduction of sputa may be 
related to a reduction of the vicious cycle surrounding infection and inflammation in the 
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CF airway by Ivacaftor treatment. A reduction in pulmonary exacerbations is a common 
observation seen in CF patients post Ivacaftor treatment. The phase III trial conducted in 
83 patients observed that 67% of patients were free of pulmonary exacerbations by week 
48 of the trial Ramsey et al., (2011). Further analysis into these observed decreases show 
that less patients reported coughing and sputum production in the treated group compared 
to the placebo group (Flume et al., 2013) . A case report highlighted the significant 
improvement in the health of a severely ill CF patient of the G551D/deltaF508 mutation 
with a FEV1% of 24% of the predicted value following Ivacaftor treatment. The case 
report illustrated that the hospitalised patient improved pulmonary function, discontinued 
from supplementary oxygen and didn’t experience a pulmonary exacerbation in the 7 
month Ivacaftor treatment (Polenakovik and Sanville, 2013).  
       The benefits of Ivacaftor on the epithelia containing CFTR expression have 
highlighted the efficiency of this molecule to restore CFTR function. To date, no reports 
have been made regarding the effects of Ivacaftor on CFTR function in gastrointestinal 
epithelia. GOR is highly prevalent in CF (Ledson et al., 1998; Blondeau et al., 2008; 
Sabati et al., 2010) but the effects of Ivacaftor on GOR and EOR symptoms have not been 
investigated to date. GOR occurs in up to 90% of CF patients resulting in the 
administration of proton pump inhibitors (PPI) (Blondeau et al., 2008). The present study 
aimed particular evaluations on the effect of Ivacaftor on gastro-oesophageal reflux 
symptoms. The aim of the study was to firstly evaluate the effects of Ivacaftor medication 
on the symptoms of GOR and EOR in these patients. Patients were interviewed regarding 
their gastro-oesophageal symptoms using three validated questionnaires (DeMeester 
Reflux Questionnaire; RSI and HARQ); these were then assessed against pulmonary 
function. This study observed that GOR was present in 3 patients at baseline, the patients 
experienced classical GOR symptoms. Following Ivacaftor treatment two of these patients 
reported less GOR symptoms and the DeMeester score reduced below the cut off for GOR 
(<1) at the 6 week follow-up. It was illustrated that GOR symptoms were not highly 
prevalent in the study population due to 9 patients not experiencing symptoms. One 
patient continued to experience GOR symptoms over the 12 month follow-up, it was 
reported that this patient had a hiatus hernia and thus suffered with GOR. At baseline 6 
patients were experiencing EOR symptoms determined by the RSI and HARQ score (>13) 
and following 6 weeks of Ivacaftor treatment the symptoms decreased to a normalised 
score in 5 patients (determined by RSI score <12). This was supported by a second 
questionnaire assessing EOR (HARQ) which illustrated a decrease in EOR symptoms post 
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treatment. Interestingly, pulmonary function is significantly higher in the non-EOR 
symptomatic patient group when compared to the EOR symptomatic group at baseline 
(P=0.037). This finding was observed throughout the study from baseline to 12 months 
suggesting that the decrease in pulmonary function seen in patients experiencing EOR 
Symptoms (determined by RSI and HARQ score) may be due to the complications caused 
by EOR. The numbers of patients positive for EOR symptoms post treatment were low 
(n=2-3) and therefore unable to argue effect of treatment. The treatment of Ivacaftor 
illustrated that EOR symptoms decrease but we were not able to investigate a relationship 
between EOR symptoms and increased pulmonary function due to low numbers. 
Interestingly, Flume et al., (2013) illustrated that there were less coughing reported by 
patients when treated with Ivacaftor compared to those in the control group of a phase III 
trial of Ivacaftor. The presence of reflux biomarkers were assesses in sputum and saliva 
samples provided. There was no relationship observed between gastric aspiration and the 
treatment of Ivacaftor due to sample inconsistency over the follow-up period. The 
biomarkers used as a tool to diagnose gastric aspiration was presence of pepsin in the 
sputum supernatant and presence of lipid laden macrophages in the cells of the airways. It 
was observed that patients experiencing GOR symptoms throughout the study treated with 
PPI therapy and H2RA’s continued to experience symptoms. There were 4 patients EOR 
symptomatic taking PPI and H2RA medication. This suggests that the medication did not 
alleviate classical (GOR) or atypical (EOR) symptoms of reflux by evidence of persisting 
symptoms. Our data has illustrated these findings previously in the CF patients that are not 
treated with Ivacaftor and are these patients are discussed in chapter 3 (Crossfield et al., 
2013).  
      Cytological slide preparations were stained with Oil Red O to identify lipid laden 
macrophages. This stain has been used as a diagnosis tool for microaspiration of stomach 
contents into the airways. Macrophages (n=100) are identified under a microscope and 
each given a score from 0-4 depending on presence of red (lipid) pigmentation. This 
microaspiration tool was not useful to determine possible reflux events in the present 
study population due to macrophages present in only 3 patients determined by the a cell 
differential (Giemsa cell stain). Only one patient sample contained >100 macrophages and 
it was therefore possible to score for lipid laden macrophages. Of the patient sputum 
samples collected the cell differential confirmed that they were abundant in neutrophils 
ranging from 67 to 100 %.  The sputum of CF patients was neutrophilic at baseline and a 
lipid laden macrophage score was unable to be produced. The identification of 
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macrophages within the sputum of 4 samples post medication resulted in an observation of 
lipid laden macrophages. This illustrates that less neutrophil influx into the lungs post 
medication and that gastric aspiration may still be present.       
          In summary, the present study supports the literature published to date and confirms 
that patients receiving Ivacaftor treatment improve CFTR protein function resulting in 
decreased sweat chloride concentrations, increased pulmonary function and weight gain. 
This study presents a novel finding that has not been investigated to date. Ivacaftor 
treatment reduced the symptoms of GOR and EOR which have an effect on pulmonary 
function in the CF population. 
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5.0 Chapter 5 
The dietary modifications for Cystic Fibrosis – assessment of related 
problems 
5.1 Introduction 
5.1.1 Dietary recommendations for the CF patient 
 
      CF is associated with malnutrition and weight loss as a result of the basic defect of the 
disease. In the 1930’s one of the early signs that was observed in babies and infants with 
CF was the failure to gain weight despite eating well accompanied by foul smelling, oily 
stool known as steatorrhoea (Thomson and Harris, 2008). This is due to deficient CFTR 
expression in the cells of the pancreatic ducts, which become blocked with mucus leading 
to insufficient pancreatic enzyme secretion. The diet cannot be efficiently digested in the 
absence of the pancreatic enzymes lipase, amylase, trypsin and chymotrypsin, thus leading 
to fat, carbohydrate and protein malabsorption and as a result the fat is passed in the stool. 
It has been reported that 85-90% of CF patients have pancreatic insufficiency resulting in 
the patient having difficulty gaining weight and malabsorption of fat soluble vitamins 
A,D,E and K (Cohen et al., 2005). The CFTR expression in cells of the airways are also 
affected leading to increased mucus secretion in the airways. The production of sputum 
within the lungs requires nitrogen, when increasing sputum production occurs the patient 
becoming deficient of amino acids. Sputum blocks the airways resulting in symptoms of 
chronic cough and heavy breathing, and in turn increased energy expenditure in the work 
of breathing. Bacteria and fungi populate within the CF airways and the patient suffers 
with chronic lung infections resulting in poor eating habits and decreased appetite 
(Orenstein et al., 2000; Thomson and Harris, 2008).  The past 50 years have seen advances 
in CF clinical nutrition and highlighted the significant importance of nutritional 
intervention within the CF clinic. The first serious discussions of the importance of 
nutritional status in CF was prompted in 1974 by Douglas Crozier who started the CF 
clinic in Toronto. The CF children were advised to have a diet of high saturated fat foods 
including whole milk, butter, eggs and animal fats along with 60 to 100 pancreatic enzyme 
tablets per day. This resulted in a higher survival rate when compared to CF patients at 
other Canadian and the Boston CF clinic, who adhered to the conventional low fat diet to 
reduce steatorrhoea (Crozier, 1974; Hodson et al., 2007). This was supported by 
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observations published in 1978 demonstrating the inverse relationship between 
underweight CF patients and survival (Kraemer et al., 1978). In addition, findings by 
Gaskin et al., (1982) indicated significantly higher FEV1% of predicted and lower 
mortality in patients with patients that were able to absorb fat compared to those with 
steatorrhoea (Gaskin et al., 1982). Furthermore, it was highlighted that patients at the 
Toronto CF clinic maintaining a normal growth rate and nutritional status had longer 
survival rates compared those at the Boston CF clinic that showed deficient nutrition and 
growth (Corey et al., 1988). Later studies assessing nutrition in CF found that long-term 
nutritional support to improve weight-gain led to better nutritional status, better lung 
function and associated increased survival (Jelalian et al., 1998). These significant 
developments in dietetic care generated a European consensus in 2002 on the nutrition 
advice for CF patients to increase fat and calories accompanied by Pancreatic enzyme 
replacement therapy (Sinaasappel et al., 2002). 
     Routine dietetic care and nutritional management have remarkably overcome problems 
of malnutrition in CF. The dietitian monitors growth and nutritional needs. They provide 
dietetic advice, meal planning, suggest food and supplements and adjust pancreatic 
enzyme replacement therapy (PERT). The diet of a CF patient is modified to meet the 
requirements of nutrients needed despite the complications caused by the disease 
manifestations. The main modifications are explained further focusing on energy, fat, 
enzyme replacement, protein and additional supplements.  
     The CF patient requires increased energy in the diet. The requirements vary and depend 
on individual age, gender, nutritional status, pancreatic insufficiency and pulmonary 
function although the guidelines are set at 120-150% of the estimated average requirement 
for energy (White et al., 2004; Hodson et al., 2007). These requirements are met by 
advising the liberal use of high fat food such as high-fat snacks, fried food, full fat 
products, and adding butter, cheese, oil and cream to meals (Hodson et al., 2007; Webster-
Gandy et al., 2012). 
     Pancreatic enzyme replacement therapy (PERT) is a method used to aid in the 
absorption of fat, carbohydrate and protein to prevent malabsorption, malnutrition and 
growth failure as a complication of CF. The United Kingdom Committee of the Safety of 
Medicines advise that CF patients receive a daily upper limit of 10,000 Units of lipase per 
kilogram of body weight (Committee of the Safety of Medicine, 1995). PERT capsules are 
coated with a pH sensitive microsphers designed to be resistant to the acidic conditions of 
the stomach. The capsules are dispersed with chyme at a pH of 5.5 to 6.0, thus available to 
153 
 
metabolise fat in the small intestine. Agents that increase the pH of the stomach 
environment including H2 antagonists and proton pump inhibitors have been shown to 
potentiate (increase effect of PERT) the benefits of PERT (Robinson, Smith and Sly, 1990; 
Heiherman, 1992). 
       Dietary fat is increased to provide higher energy per gram of food (fat has 9 Kcal per 
gram compared to carbohydrate at 4 Kcal per gram). The % energy from fat in a normal 
diet is around 28% and this is increased to a recommended 40% of energy from fat for a 
CF patient. The management is individualised to calculate the ideal weight of the patient 
based on their height and body composition.  PERT is prescribed for pancreatic 
insufficient patients to aid the metabolism of fat. The recommended units are modified to 
each individual patient and dependant on fat intake e.g. two PERT capsules (Creon 
10,000, Solvay) of 10,000 units of lipase, 600 units of protease and 8,000 units of amylase 
with each meal and one with each snack containing fat, protein or starchy carbohydrate. It 
is advised for the capsule to be taken just before or with each meal and snack and avoiding 
mixing it with hot food or drinks to minimise the risk of deactivating the enzymes 
(Webster-Gandy et al., 2006; Thomas and Bishop, 2006). Oral food supplements have 
been recommended for patients that have poor weight gain in the form of juices, ready 
drinks or powder to mix with milk and contain high carbohydrate or fat in a small serving 
(Thomson and Harris, 2008). 
     A diet high in protein is recommended to promote growth and development due to poor 
nutrition intake and nitrogen loss during sputum production. The amino acids are present 
in abundance in sputum, it was reported that CF sputum specimens contained higher 
amino-acid content than non-CF samples. There were various amino acids identified in the 
sputum specimens such as leucine, isoleucine, phenylalanine, tyrosine, alanine, serine and 
methionine or valine or both (Barth et al., 1996). Due to the increased protein uptake 
during sputum production the protein intake is advised to be increased by 20% of the 
reference nutrient intake (Webster-Gandy et al., 2012). In practice, this is achieved 
because the protein intake is likely to be increased if the patient adheres to the advised 
high energy intakes (Hodson et al., 2007) by increasing the amount of food per se. 
     The supplementation of fat soluble vitamins A,D,E and K are recommended for 
pancreatic insufficient patients as deficiency is common due to the inadequate vitamin 
absorption co-absorbed with fat. The risk of vitamin toxicity is also a concern if vitamins 
are absorbed from both the diet and supplements so patients should receive annual vitamin 
serum level measurement to monitor the deficiency/toxicity of A,D,E and K. The vitamin 
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levels should be adjusted to meet the requirements of each patient. The suggested doses of 
fat soluble vitamins A, D, E and K for an adult are 1200-3000µg; 20-50µg; 100-200mg 
and 10mg respectively (Yankaskas et al., 2004; Hodson et al., 2007). 
5.1.2 Prevalence of overweight and obesity in CF 
 
     During the past 50 years researchers, clinicians and dietitians have consistently shown 
that increasing CF patient’s weight to achieve normal growth and avoidance of under-
nutrition brings significant positive impact (Simon et al., 2009; Stephenson et al., 2013). 
Due to these advances in knowledge regarding the importance of nutritional status in CF 
we observe CF patients surviving longer with a median age of death to be 40 - 50 today 
(Simmonds, 2013). It has been reported that those that are born today with the CFTR 
mutations will have normal life expectancy due to future therapies that treat the basic 
defect (O'Sullivan and Freedman, 2009).  
     The positive outcome of increasing BMI status for CF patients over the years has led to 
BMI increasing beyond what is classified by the WHO as an ideal weight (BMI >25.0). 
BMI classifications were redefined by the WHO in 1998 as underweight (kg/m
2
 <18.5); 
ideal weight (kg/m
2
 18.5-24.9); pre-obese/over-weight (kg/m
2
 25.0 – 29.9) and obese 
(kg/m
2
 >30.0). The report defined over-weight and obesity to identify individuals or 
groups at risk of morbidity and mortality who can be prioritised for intervention. The 
report highlighted that a BMI over 25kg/m
2
 increased the risk of co-morbidities (such as 
cardiovascular disease and certain types of cancer) and a BMI over 30kg/m
2
 increased the 
risk to a moderate level (WHO, 1998). An emphasis on characterising the prevalence of 
overweight and especially obesity in CF is becoming increasingly prioritised to assess the 
potential health risks a population with increasing life expectancy.  
     In 1979 the first cases of over-weight male patients with CF were identified in America 
(n=22) (di Sant'Agnese and Davis, 1979). A study reporting overweight/obese BMI from 
1985 to present day in Toronto described significant increases in BMI over a 25 year 
analysis. The over-weight and obese BMI scores increased significantly over 2.5 decades 
(P=0.001). There was a reported 7.0% of adult CF patients with a BMI over 25.0 kg/m
2
 
from records in 1985 to 1989; increasing to 15.8% in 1990 to 1999 and  increasing further 
to 18.4% in the decade 2000 to 2011 (Stephenson et al., 2013). Review of the literature 
published over the past decade has reported increasing percentages of over-weight BMI 
status in CF ranging from 4.3% to 18.4% and obesity ranging from 0.7% to 5.9% 
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(Kastner-Cole et al., 2005; Stack et al., 2007; Munck et al., 2007; Coderre et al., 2012; 
Stephenson et al., 2013; Smith et al, 2014; Panagopoulou et al., 2014; Kochavi, 2014). 
Interestingly, Ireland reported the highest percentage of obesity among children in their 
paediatric CF clinic at 5.9% in 2007 (Stack et al., 2007) followed by 3.8% in an adult CF 
clinic in Toronto  at a similar time (2000-2011) (Stephenson et al., 2013). 
    The characteristics of patients with a BMI over 25.0kg/m
2
 have been reported 
highlighting that there were less homozygous deltaF508 patients and higher numbers of 
pancreatic sufficient patients, with increased pulmonary function when compared to 
under-weight and ideal weight patients ((Munck et al., 2007; Coderre et al., 2012; 
Panagopoulou et al., 2014). Researchers in Canada observed the average BMI increased 
by 3.8% per year over a 25 year period for pancreatic sufficient patients compared to an 
increase of 0.4% per year for pancreatic insufficient patients (P=0.001) (Stephenson et al., 
2013). However, one research team identified 9% of over-weight patients and 1% obese 
patients in a large cohort (n=1118) of adult CF patients homozygous for delta F508 in the 
U.K. The study revealed that increasing FEV1% was positively associated with increasing 
BMI although only significant up to a BMI of 23.0kg/m
2
 (Kastner-Cole et al., 2005).  
     Beneficial effects have been illustrated with increasing BMI of over-weight and obese 
classifications but the literature has failed to provide evidence for potential risks of 
increasing BMI in the ever-aging CF population. It has been described that CF patients are 
living longer now, they may have a normal life expectancy in the future, thus it is a major 
priority to determine the risks presented to them in older age. Kastner-Cole et al., (2005) 
proposed the need for caloric counselling for adult CF patients with a BMI above 
23 kg/m
2
 because they observed only a small benefit of obesity on pulmonary function 
increases (Kastner-Cole et al., 2005). In support of this, Stephenson et al (2013) suggested 
that the traditional high fat and high calorie diet maybe disadvantageous to CF patients 
heterozygous for delta F508 and in particular those pancreatic sufficient in view of small 
increases seen in FEV1% and higher prevalence of BMI >25.0 for these patients 
(Stephenson et al., 2013). Both of the studies witnessed an increase in pulmonary function 
with increasing BMI despite the increase not being significant, and as this is a predictor of 
survival the increase becomes of value to the patient and their family however small the 
increase may be. The authors highlight their concern of over-weight and obesity for the 
future of the CF patients in view of chronic diseases associated with obesity in the general 
population (i.e. heart disease, high blood pressure). However, less co-morbid conditions 
such as diabetes and cirrhosis were observed in a French CF cohort of over-weight and 
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obese CF patients than the under-weight and ideal weight patients. Regrettably, 1.7% of 
patients with a BMI below 24.9kg/m
2
 were on the lung-transplant list and 1% deceased 
(Munck et al., 2007). Furthermore, (Panagopoulou et al., 2014) documented no 
characteristics of metabolic syndrome in the overweight/obese patients with only positive 
findings of the associated of increased pulmonary function relating to a higher BMI.  
     The issue of modified nutritional advice for over-weight and obese patients with CF is 
yet to be resolved. Further study has been recommended to assess the problems that may 
occur with over-weight/obesity in CF as the population’s life expectancy increases 
(Kastner-Cole et al., 2005; Stephenson et al., 2013). So far, however, there has been no 
discussion about the potential negative effects that the traditional high fat/calorie CF diet 
may have on the existing high prevalence of GOR. As the CF life expectancy increases the 
CF over-weight and obese population may also increase. High fat diets and increased BMI 
are predictors of GOR in the general population and thus an important area to explore. 
5.1.3 The association of dietary components with reflux   
     The reported factors which are frequently suggested to lead to the pathogenesis of GOR 
in general include obesity, being overweight and incorrect dietary habits such as a high fat 
diet, and spicy food (Dore et al., 2008). GORD patients receive recommendations from 
their G.P. to adopt lifestyle modifications to lower the frequency and severity of GOR 
symptoms (Nowak et al., 2005) due to the numerous studies providing associations with 
refluxogenic foods. G.P’s recommend GORD patients to avoid alcohol, avoid spicy food, 
maintain a low fat diet and reduce weight. Research suggests specific dietary components 
such as, saturated fats may directly worsen GORD (Dore et al., 2008; Zheng et al., 2007; 
Nebel et al., 1972) but the research to date is contradictory (Friedenburg et al., 2010; Fox 
et al., 2007).  
      Numerous studies report a relationship between high fat diets and GOR (Meyer et al, 
2001; Holloway et al., 1997; Iwakiri et al., 1996).  It was research conducted in 1975 
(Nebal et al, 1975) that first illustrated high fat foods are associated with GOR in the 
general population providing an insight and a starting point into foods causing GOR 
symptoms. Becker et al., (1989) found that high fat foods increased oesophageal acid 
exposure in twenty subjects. Later, it was found that oesophageal pH monitoring 
highlighted high fat foods such as chocolate to be positively associated with GOR 
(Murphy et al., 1988). However, other clinical studies involving oesophageal pH 
monitoring provide inconsistent evidence regarding fatty foods and GOR (Saberi-Firoozi 
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et al., 2007; Fox et al., 2007). Fox et al., (2007) observed that reflux symptoms were 
significantly higher when subjects consumed a high fat diet than low fat (p<0.05), but this 
was not supported by the presence of intra-oesophageal acid exposure to explain the cause 
of increased symptoms. This was supported by the findings of Shaprio et al., (2007) who 
found GORD patients consumed more cholesterol, saturated fatty acids and % of calories 
from fat and were more likely to experience acidic reflux events (Odds Ratio (OR) ¼ 2.8, 
95% Confidence Interval (CI): 1.2–6.5). Furthermore, cholesterol was 3 times as likely to 
trigger a reflux event compared to no consumption of cholesterol (OR 2.8; CI 95% 1.2 – 
6.5).  In addition, in 2005 it was observed that increased amounts of total fat, saturated fat, 
cholesterol, average fat servings and % of energy from dietary fat was prominent in the 
diet of GORD symptom patients when compared to those without symptoms (El Serag et 
al., 2005). Controversially, Saberi-Firoozi et al., (2007) found that fried food was 
inversely associated with GOR symptoms and fast food did not have any association with 
GOR symptoms (Saberi-Firoozi et al., 2007). Importantly, evidence suggests there are no 
risks of low fat diets or monounsaturated fatty acids and polyunsaturated fatty acids with 
episodes or symptoms of GOR (Pehl et al., 1999; Fox et al., 2007; Shapiro et al., 2007). 
There seems to be a large body of data to support the relationship of dietary saturated fat 
with reflux symptoms but inconclusive data to demonstrate the promotion of GOR 
episodes within the gut (Penagini et al., 1998 and Becker et al., 1989; Ruhl and Everhart, 
1999; Pehl et al., 1999; Penagini, 2000; Colombo et al., 2002). Many authors could not 
support the general advice given to patients by their GP’s to lower saturated fat from their 
diet as a therapeutic attempt to decrease GOR (Colombo et al., 2002; Penagini, 2000 and 
Pehl et al., 1999). The volume of food has been questioned in regards to the pressure of 
the lower oesophageal sphincter (LOSP). Dore et al., (2008) were unable to identify a 
relationship between GORD and the reported consumption of large meals (Dore et al., 
2008). 
     Increasing BMI status has been associated with GORD symptoms, significantly in 
obesity ((El-Serag et al., 2005; Hampel et al., 2005; Dore et al., 2008). El-Serag and 
colleagues (2005) illustrated that the number of classical GOR symptoms increase with 
higher BMI status in a dose response manner. Moreover, a high fat diet was associated 
with  GORD, but when the data was adjusted for patient BMI status there was no 
significant association suggesting that BMI could have been the cause of increasing 
GORD symptoms rather than dietary fat (El Serag et al., 2005). In contrast, evidence by 
Shaprio et al., (2007) highlighted that the BMI (BMI mean 27.7 ± 1.0) of GORD patients 
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didn’t illustrate a correlation with GOR symptoms and added that it was the cholesterol, 
saturated fatty acids and % of calories from fat that directly correlated with GORD 
symptoms.  
 
5.1.4 Aim of the following chapter  
     CF patients suffer with up to 90% impaired nutrient absorption, therefore causing 
weight loss and undernutrition which are both associated with a worse clinical outcome 
(Kraemer et al., 1978; Corey et al., 1988; Sharma et al., 2001). CF patients have increased 
nutritional requirements and it is therefore imperative to maintain adequate energy intake. 
Therefore, dietetic advice recommends that fat should not be restricted despite evidence to 
support that this leads to reflux. However, some saturated fat can be replaced by 
monounsaturated and there was no reported association between unsaturated fats and GOR. 
General GORD advice regarding dietary modifications cannot be adopted by CF patients 
as their increased dietary requirements are imperative to survival (Thomas and Bishop, 
2007). Diet has been shown to be associated with GORD in the general population and 
GORD patients but there have been no reports to date of diet affecting GOR in the CF 
population.  
     Due to the inconclusive evidence regarding the unknown risks of over-weight and 
obese CF patients the following chapter looks at BMI status in a UK regional CF 
population. The aim of following chapter was to evaluate the relationship between CFTR 
genotype (homozygous or heterozygous for delta F508) with BMI and pulmonary function 
in CF patients to assess whether patients that are homozygous are at risk of low BMI 
compared to patients heterozygous for delta F508 receiving the same dietary advice.  As 
BMI status has been shown to effect pulmonary function the relationship between 
genotype and pulmonary function (FEV1%, FVC% predicted and FEV1/FVC ratio) was 
investigated:       
Aim 1. To explore a potential association between increasing BMI and pulmonary 
function in CF. 
Aim 2. To investigate a potential association of CFTR mutation 
(homozygous/heterozygous for delta F508) on the BMI status and pulmonary function of 
CF patients. 
Aim 3. To discover a potential association of BMI status with patient symptoms of reflux 
(GOR/EOR) and markers of gastric aspiration. 
159 
 
5.2 Results 
5.2.1 Study design and sampling 
     The following chapter analyses data that was reported in chapter 3. Seventy two 
patients were recruited into the study and their weight and height was measured at 
recruitment during their routine clinical appointment by a trained nurse. The BMI data was 
categorised according to the definition of under-weight (UW): <18.5 kg/m
2
, normal-
weight (NW): 18.5-25.0 kg/m
2
, over-weight (OW): 25.1-30.0 kg/m
2
 and obese 
(OB): >30.1 kg/m
2
 as defined by the World Health Organisation (WHO.).  Lung function 
(FEV1 % predicted; FVC% predicted and FEV1/FVC ratio) and genotype were recorded at 
the time of data collection. To evaluate the relationship between BMI and pulmonary 
function with genotype the Kruskal-Wallis statistical test was used followed by the Mann 
Whitney U test.  
5.2.2 Patient BMI categories  
     There were 15% of patients with a BMI below 18.4 and classed as UW (n=11; range 
14.1 to 18.2; median 17.5). A large proportion of patients achieved a normal BMI (NW) 
between 18.5 and 24.9 at 68% of the study population (n=49; range 18.5 to 24.1; median 
21.2).  There was 15% of patients with a BMI over 25.0 and classified as overweight (OW) 
(n=11; range 25.3 to 29.8; median 26.8) and one patient had a BMI of 30.9 and classified 
as obese (OB). The data were examined to observe any differences in BMI between males 
and females (Figure 5.1). There were no statistical differences between BMI and gender 
(the median BMI for males (n=39) was 21.5; range 15.2 – 27.9 and the median for females 
was 21.0; range 14.1 to 30.9) (P=0.43) of the BMI categories assessed by the Kruskal 
Wallis test with Gaussian Approximation and Dunns multiple comparison tests shown in 
Figure 5.2. 
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Figure 5.1 The BMI categories of CF patients. Of 72 patients; 11 patients underweight 
(range 14.1 to 18.2, median 17.5, mean 16.9 SEM 0.4), 49 patients normal weight (range 
18.5 to 24.1, median 21.2, mean 21.3 SEM 0.2), 11 patients overweight (range 25.3 to 
29.8, median 26.8, mean 27.0 SEM 0.4), 1 patient obese (BMI 30.9). 
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Figure 5.2 The BMI classified groups of CF patients split into gender. Of the underweight 
patients there were 7 males and 4 females; of the normal BMI patients there were 24 males 
and 25 females; of the overweight patients there were 8 males and 3 females; the 1 obese 
patient was female. The median BMI for males (n=39) was 21.5; range 15.2 – 27.9 and the 
median for females was 21.0; range 14.1 to 30.9. There was no statistical differences of 
gender and BMI (P=0.423) assessed by the Kruskal Wallis test, Gaussian Approximation 
and Dunns multiple comparison test. 
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5.2.3 The association of BMI with CF pulmonary function 
    The pulmonary function measured by FEV1%; FVC% predicted and FEV1/FVC ratio 
was measured in 63 patients on the day of recruitment by trained pulmonary function staff 
at the out-patient clinic, RVI, Newcastle according to European Respiratory Society 
guidelines ((Pellegrino et al., 2005; Laszlo et al., 2006). There were 9 patients that did not 
have the tests performed and the data was not provided for the study. FEV1 ranged from 
12 to 110% of percentage of predicted values. Increased BMI scores were associated with 
improved pulmonary function measured by FEV1 % predicted). The median FEV1% in the 
underweight group was 48 (n=11; range 25–56; mean 45.1; SEM 2.9). The median in the 
normal weight group was 41.5% (n=44, range 12 – 92, mean 45.1, SEM 5.0) and the 
median score of the overweight group was 69.0% (n=11, range 54-110, mean 75.0, SEM 
5.7). The one patient in the obese BMI category had a FEV1% predicted score of 90.0%. 
The mean FEV1% of the over-weight patients was significantly higher than the under-
weight group (P=0.02) and normal-weight group (P=0.0003) illustrated in Figure 5.3. The 
FVC% predicted ranged from 11 to 119 % of the predicted values. Of the 63 patient FVC% 
predicted scores collected the median of the underweight patients was 59.0% (n=7, range 
38 – 84; mean 58.7, SEM 6.6); the median normal weight scores were 59.0% (n=44, range 
11 – 100, mean 60.9, SEM 3.2), the median score of the overweight group was 94.0 (n=11, 
range 68-119, mean 94.3, SEM 4.4) and the one patient in the obese BMI category had a 
FVC% predicted score of 89.0%. The mean FVC% of the over-weight patients was 
significantly higher than the under-weight group (P=0.02) and normal-weight group 
(P=0.0004) illustrated in Figure 5.4. The FEV1/FVC ratio of the underweight group was 
0.60 (n=7, range 0.52-0.87, mean 0.64, SEM 0.05); the normal weight group median was 
0.67 (n=44, range 0.35-1.00, mean 0.65, SEM 0.02); and the median of the over-weight 
group was 0.71 (n=11, range 0.48-0.83, mean 0.68, SEM 0.04). The one patient in the 
obese category was 0.88. There was no significant differences between the FEV1/FVC 
ratio of BMI categories (P=0.38) as shown in Figure 5.5. If the FEV1% and FVC% are 
improving then the ratio will not change improvement. 
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Figure 5.3 The FEV1% predicted of each CF patient in BMI classified groups. Of the 63 
FEV1% predicted scores collected the median of the underweight patients was 48.0% (n=7, 
range 25 – 56; mean 41.6, SEM 5.0); median normal weight scores were 41.5% (n=45, 
range 12 – 92, mean 45.1, SEM 2.9) median score of the overweight group was 69.0 
(n=11, range 54-110, mean 75.0, SEM 5.7) and the one patient in the obese BMI category 
had a FEV1% predicted score of 90.0%. The mean FEV1% of the over-weight patients was 
significantly higher than the under-weight group (P=0.02) and normal-weight group 
(P=0.0003). Kruskal-Wallis test and Dunns multiple comparisons test.  
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Figure 5.4 The FVC% predicted of each CF patient in BMI classified groups. Of the 63 
FVC% predicted scores collected the median of the underweight patients was 59.0% (n=7, 
range 38 – 84; mean 58.7, SEM 6.6); median normal weight scores were 59.0% (n=45, 
range 11 – 100, mean 60.9, SEM 3.2) median score of the overweight group was 94.0 
(n=11, range 68-119, mean 94.3, SEM 4.4) and the one patient in the obese BMI category 
had a FVC% predicted score of 89.0%. The mean FVC% of the over-weight patients was 
significantly higher than the under-weight group (P=0.02) and normal-weight group 
(P=0.0004). Kruskal-Wallis test and Dunns multiple comparisons test.  
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Figure 5.5 The FEV1/FVC ratio of CF patients n=64 (9 results not available) categorised 
into BMI groups UW (n=7, median 0.60, range 0.52-0.87, mean 0.64, SEM 0.05); NW 
(n=45, median 0.67, range 0.35-1.00, mean 0.65, SEM 0.02); OW (n=11, median 0.71, 
range 0.48-0.83, mean 0.68, SEM 0.04); OB n=1 0.88. Kruskal-Wallis test with Gaussian 
Approximation Not significantly different; Dunns comparison test (P=0.38). 
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5.2.4 The association of Delta F508 genotype and BMI category 
 
     The relationship between BMI status and the mutation of CFTR was assessed firstly by 
dividing patients into those homozygous for delta F508 and those heterozygous for delta 
F508. A comparison was made between the BMI status in each group by a nonparametric 
Two tailed T-test (Mann-Whitney test with Gaussian approximation). This showed no 
association between CF genotype status and BMI (P=0.30). The median BMI score of the 
homozygote patients was 20.5 (range 15.2 to 27.9; mean 21.6; SEM 0.7) and the median 
BMI of the heterozygotes was 21.8 (range 15.2-30.9; mean 22.2; SEM 0.49) shown in 
Figure 5.6. 
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Figure 5.6 The BMI of patients depending on genotype. Of the 22 patients homozygous 
for Delta F508 the median BMI was 20.5 ranging from 15.2 to 27.9 (mean 21.6, SEM 0.7). 
The median BMI for those patients heterozygous (n=39) was 21.8 (range 15.2-30.9, mean 
22.2, SEM 0.49). Nonparametric Two tailed T-test (Mann-Whitney test with Gaussian 
approximation) showed no significant difference between the BMI of patient who are 
homozygous or heterozygous for delta F508  (P=0.30). 
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5.2.5 The association of Delta F508 genotype and pulmonary function 
 
The genotype data for delta F508 was available for 61 of the total 72 patients recruited 
onto the study. Twenty two of the 61 patients were homozygous for the delta F508 
mutation; the remaining 39 were heterozygous (deltaF508/other). There was no statistical 
difference observed between delta F508 genotype status and pulmonary function when 
determined by FEV1% predicted (P=0.28); FVC% predicted (P=0.18) or FEV1/FVC ratio 
(P=0.20). The patients that were homozygous for delta F508 had a median FEV1% 
predicted of 43%  (range 25-69, mean 44.6, SEM 2.6); median FVC% predicted of 59% 
(range 34-105, mean 61.9, SEM 4.38) and a median FEV1/FVC ratio of 0.6L (range 0.5-
0.8, mean 0.6, SEM 0.02). This did not statistically differ from the pulmonary function of 
the heterozygous delta F508 patients. The median FEV1% predicted was 52% (range 12-
110, mean 54.9, SEM 4.23), the median FVC% predicted was 71.0% (range 11-119, mean 
70.5, SEM 4.04) and the median FEV1/FVC ratio was 0.7 L (range 0.4-1.0, mean 0.7, 
SEM 0.03) in the heterozygotes (Figure 5.7, 5.8 and 5.9). The pulmonary function was 
higher in the heterozygous group but not significantly. 
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Figure 5.7 The FEV1% predicted for patients in homo/heterozygous genotypes. There was 
22 patients FEV1% data available for the homozygous for Delta F508 and 39 heterozygous 
patients with available FEV1 scores. The median FEV1% predicted for those patients 
homozygous for delta F508 was 43% (range 25-69, mean 44.6, SEM 2.6). The median 
FEV1% predicted for those patients heterozygous for delta F508 was 52% (range 12-110, 
mean 54.9, SEM 4.23). Nonparametric Two tailed T-test (Mann-Whitney test with 
Gaussian approximation) show no significant difference between the FEV1% predicted of 
patient who are homozygous or heterozygous for delta F 508 (P=0.28).  
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Figure 5.8 The FVC% predicted for patients in homo/heterozygous genotypes There were 
22 patients homozygous for Delta F508 and there were 39 heterozygous patients with 
available FVC% predicted scores. The median FVC% predicted for those patients 
homozygous for delta F508 was 59% (range 34-105, mean 61.9, SEM 4.38). The median 
FVC% predicted for those patients heterozygous for delta F508 was 71.0% (range 11-119, 
mean 70.5, SEM 4.04). Nonparametric Two tailed T-test (Mann-Whitney test with 
Gaussian approximation) show no significant difference between the FVC% predicted of 
patient who are homozygous or heterozygous for delta F 508 (P=0.18).  
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Figure 5.9 The FEV1/FVC for patients in homo/heterozygous genotypes. There were 22 
patients homozygous for Delta F508 and there were 39 heterozygous patients with 
available FEV1/FVC ratio scores. The median FEV1/FVC ratio for those patients 
homozygous for delta F508 was 0.6 L (range 0.5-0.8, mean 0.6, SEM 0.02). The median 
for those patients heterozygous for delta F508 was 0.7 L (range 0.4-1.0, mean 0.7, SEM 
0.03). Nonparametric Two tailed T-test (Mann-Whitney test with Gaussian approximation) 
show no significant difference between the FEV1/FVC scores of patient who are 
homozygous or heterozygous for delta F 508 (P=0.20).  
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5.2.6 The association of BMI category with the symptoms of reflux (GOR and EOR) 
     The effect of BMI status on the symptoms of reflux was assessed in the 72 patients 
recruited onto the study. The association of BMI with the symptoms of GOR was assessed 
by comparing GOR symptoms determined by the DeMeester reflux questionnaire in each 
BMI category. The symptoms of GOR did not statistically correlate with BMI status when 
assessed by the Kruskal-Wallis test with Gaussian Approximation (P=0.66).  The 
DeMeester scores in each BMI category are shown in Figure 5.10 and the median score 
(±SEM) of the underweight category was 2 (range 0 to 4, mean 2.1, SEM 0.4), the median 
score of the normal weight category was 1 (range 0 to 7, mean 1.4, SEM 0.2), the median 
score of the over-weight category was 1 (range 0 to 5, mean 0.4, SEM 0.4). There was 
only one patient in the obese category and their DeMeester score was 5. 
     The effect of BMI status on the presence of EOR symptoms was determined by 
comparing the RSI questionnaire score of patients in each BMI category. The presence of 
EOR symptoms were higher in the underweight group at a median of 23 (range 9 to 43, 
mean 20, SEM 3.1) compared to the normal weight patients that had a median RSI score 
of 16 (range 0 to 36, mean 16, SEM 1.1) and the overweight patients that had a median 
RSI score of 11 (range 2 to 18, mean 1.9, SEM 0.4). The one patient in the obese category 
had a RSI score of 12. The Kruskal-Wallis test with Gaussian Approximation illustrated 
statistical significance between RSI score to identify EOR symptoms and BMI category 
(P= 0.038). The median scores of the under-weight and normal-weight group are above 
the limit of 13 used to identify EOR, and the median score of the over-weight group is 
below 13 (Figure 5.11). The data was presented in a Scatterplot of BMI status on the y 
axis and RSI score on the x axis. The Pearson correlation showed a statistical correlation 
between low BMI leading to higher EOR symptoms (determined by the RSI) 
(R
2
=0.0638/6.4%, n=72, P-Value = 0.034) (Figure 5.12). 
 
173 
 
 
Figure 5.10 The DeMeester score of patients and association with BMI. The median 
DeMeester score of underweight patients was 2 (range 0 to 4, mean 2.1, SEM 0.4), normal 
weight patients 1 (range 0 to 7, mean 1.4, SEM 0.2) overweight patients 1 (range 0 to 5, 
mean 0.4, SEM 0.4) and the obese patients score was 5. There was no statistical 
significance between DeMeester score to identify GOR symptoms and BMI category (P= 
0.13) Kruskal-Wallis test with Gaussian Approximation. The Pearson correlation showed 
no significance with GOR symptoms determined by DeMeester score and BMI status 
(P=0.66). 
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Figure 5.11 The RSI score of patients and association with BMI. The median RSI score of 
underweight patients was 23 (range 9 to 43, mean 20, SEM 3.1), normal weight patients 
16 (range 0 to 36, mean 16, SEM 1.1) overweight patients 11 (range 2 to 18, mean 1.9, 
SEM 0.4) and the obese patients score was 12. The Kruskal-Wallis test with Gaussian 
Approximation showed statistical significance between RSI score to identify EOR 
symptoms and BMI category (P= 0.038).  
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Figure 5.12 Scatterplot of BMI status plotted on the Y axis and RSI score on the X axis. 
Pearson correlation showed a positive correlation between an increase in BMI and 
decrease in RSI (n=72; R
2
=0.0638/6.4%; P-Value = 0.034). 
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5.2.7 The association of BMI status and the incidence of gastric aspiration 
 
      The detection of pepsin in sputum supernatant samples was performed and analysed as 
described in chapter 3. The concentration of pepsin of each patient is illustrated in Figure 
5.13, grouped by the BMI status category. The median concentration of pepsin was 
highest in the underweight category at a median of 357ng/ml (n=10, range 0 to 782, mean 
319, SEM 74.4). The median level of pepsin in the patients achieving a normal weight 
BMI status was 193ng/ml (n=48, range 0 to 1151, mean 245, SEM 40.2) which was lower 
than the underweight category but with a larger range. The median pepsin levels in the 
over-weight category was 58ng/ml (n=10, range 0 to 611, mean 193, SEM 80.3) and the 
level of pepsin detected in the sputum supernatant of the one obese patient was 128ng/ml. 
Figure 5.13 illustrates the mean (±SEM) pepsin concentrations decrease in each BMI 
category as BMI increases. The Kruskal-Wallis test did not show any statistical 
differences for pepsin level between BMI categories (P=0.47). There is a non significant 
decrease of pepsin levels as the BMI of patients increase which supports the RSI score 
data in Figure 5.11 and 5.12. 
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Figure 5.13 The pepsin concentration of CF patients association with BMI category. The 
median pepsin concentration of underweight patients was 357ng/ml (n=10, range 0 to 782, 
mean 319, SEM 74.4), normal weight patients 193ng/ml (n=48, range 0 to 1151, mean 245, 
SEM 40.2) overweight patients 58ng/ml (n=10, range 0 to 611, mean 193, SEM 80.3) and 
the obese patients pepsin content was 128ng/ml. The Kruskal-Wallis test with Gaussian 
Approximation showed no statistical significance between gastric aspiration using pepsin 
identification as a biomarker and BMI category (n=72). 
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5.3 Discussion 
 
     The present study investigated the prevalence of overweight and obesity within a single 
centre study in the North of England (RVI, Newcastle Upon Tyne, UK) for which 72 CF 
patients were recruited. Twelve (16.7%) patients were reported to be over-weight/obese 
(BMI status >25kg/m
2
 defined by WHO; 1998) (WHO, 1998); of which 11 patients 
(15.3%) were classified as overweight and 1 patient (1.4%) was obese. These findings are 
supported by a number of studies that report the over-weight prevalence to be in a range of 
11% to 13.2% and CF obesity to be 0.5% to 3%, reported in Greece, Israel and Canada 
(Kastner-Cole et al., 2005; Coderre et al., 2012; Kochavi, 2014; Panagopoulou et al., 
2014). Our data agrees with observations from a CF clinic in Toronto recorded in the 
1990’s reporting the average prevalence of BMI >25.0kg/m2 to be 15.8%. Interestingly, 
the clinic reported the prevalent to increase by 6.4% 10 years later in 2011, reporting 18.4% 
to be over-weight and 3.8% to be obese (Stephenson et al., 2013). Additionally, a report of 
BMI data from the adult CF patients on the register in the United Kingdom (U.K) 
observed over-weight prevalence to be 9.5% and obese prevalence at 1% recorded 12 
years ago (Kastner-Cole et al., 2005), our data may suggest that the prevalence of over-
weight BMI status in the U.K has risen by nearly 6% in the past decade. Recently, there 
has been high prevalence of childhood CF obesity reported in Ireland at 5.9% and 
Pennsylvania at 8% determined by BMI for age, sex, height and weight. The cut off limits 
for obesity differed for each study, colleagues in Ireland used the 98
th
 percentile and 
Pennsylvania used the 95
th
 percentile which may explain the higher prevalence (Stack et 
al., 2007; Hanna and Weiner, 2014).   
     Reportedly, CF over-weight and obese BMI status maybe associated with gender. It 
was identified that there was a significantly higher number of males in the over-weight 
and obese categories reported in a Canadian CF population (P=0.001) but they did not 
suggest a mechanism for why this may be. BMI measurement does not take muscle mass 
into consideration and an increase in BMI may be due to high muscle mass rather than fat 
mass. The study did not report body fat % (Stephenson et al., 2013). The present study did 
not find a similar pattern, there was no significant difference observed between gender and 
BMI status (P=0.43) and the one obese patient was a female. This is supported by a recent 
study including 226 CF patients (aged 2-18 years) at a CF clinic in Pennsyvania reporting 
no significant effect of gender on the BMI status of CF patients (Hanna and Weiner, 2014). 
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Furthermore, Coderre et al., (2012) did not find any significant differences for BMI and 
gender. 
     Due to contradictory findings within the literature, the aim of this chapter was to firstly 
explore the potential association between increasing BMI on pulmonary function in CF 
patients with a BMI >25.0kg/m
2
. The present study observed that median scores of the 
pulmonary function in the over-weight group increased significantly compared to the ideal 
weight group and the under-weight group determined by FEV1% and FVC% predicted. 
This data was supported by a number of studies that identified a positive association with 
BMI and pulmonary function even beyond 25.0kg/m
2
 (Munck et al., 2007; Coderre et al., 
2012; Kochavi, 2014; Panagopoulou et al., 2014). Additionally, FEV1% was significantly 
correlated with BMI and percentage of body fat (Panagopoulou et al., 2014) among CF 
patients from a Greek centre. This suggests that it is the weight gain of body fat rather than 
muscle may cause the effect, as could be the case by using BMI data alone. However, 
some researchers have shown that the significant  increase in pulmonary function 
associated with increasing BMI only up to a BMI of 25.0kg/m
2
 (Stephenson et al., 2013) 
and 23.0kg/m
2
 (Kastner-Cole et al., 2005) suggesting that there was no benefit to 
pulmonary function of encouraging over-weight and obese BMI status. Furthermore, it 
was advised that these CF patients may be required to receive caloric counselling and diet 
modification to reduce and maintain their BMI to 23.0kg/m
2
 or 25.0kg/m
2
. It is important 
to mention the data from these studies show increases in FEV1% as BMI increases above 
25.0kg/m
2, 
although not significant and
 
with no other negative effects on health. A recent 
study reported that over-weight and obese BMI status was not significantly associated 
with FEV1% in CF patients aged 2-18 years, although it is reported that small increases are 
observed (Hanna and Weiner, 2014).  
     It has been repeatedly reported that the CF patients with a BMI classified as over-
weight or obese are commonly heterozygous for delta F508 (Kastner-Cole et al., 2005; 
Munck et al., 2007; Stephenson et al., 2013).  These patients are said to have a milder 
genotype and therefore less severe disease outcomes. This may include pancreatic 
sufficiency and therefore do not have difficulty absorbing dietary fat and it is possible that 
if they adhere to the high fat diet advised full absorption will occur and result in increased 
body fat mass. Therefore, our study aimed to explore the potential association of CFTR 
mutation (homozygous/heterozygous for delta F508) on the BMI status and pulmonary 
function of CF patients. In the present study genotype data were available for 61 or the 72 
total patients, there were 22 patients homozygous for delta F508 and 39 were 
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heterozygous. The median BMI score for homozygous patients was 20.5 (range 15.2 – 
27.9) and for the heterozygous patients 21.8 (range 15.2 – 30.9). There was no association 
observed between genotype and the BMI outcome. In addition, we could not identify an 
association between genotype and pulmonary function. The median values for FEV1%, 
FVC% and FEV1/FVC ratio of patients homozygous for delta F508 was lower than the 
median of the heterozygous CF patients but the differences were not significant. It was 
reported by Coderre et al., (2012) that a there was a significant increase in heterozygous 
genotype patients (P=0.001) and less PERT use (P=0.048) in the over-weight/obese BMI 
categories compared to a BMI of the underweight group of patients.  However, the data 
illustrates that there were 62% of overweight/obese patients using PERT and 54% with a 
homozygous genotype. Interestingly, Kastner-Cole et al., (2005) recruited only CF 
patients homozygous for delta F508 and reported a similar prevalence of overweight and 
obese patients at 10% of the population suggesting that genotype alone cannot be the 
cause of increased weight gain or increased pulmonary function.  A study of CF patients 
(n=112) aged 40 years to 71 years were explored by Simmonds et al., (2009) highlighted 
that 30% were homozygous for delta F508 and they had a BMI ranging from 17.4 to 28.7 
(median 20.9) suggesting longevity in the CF population cannot be associated with 
genotype status or BMI status. 
     Review of the literature has highlighted the need for further study into the health 
outcomes of CF patients who are over-weight or obese (Munck et al., 2007; Hanna and 
Weiner, 2014).  Hanna and Weiner (2014) stated that the high fat and high calorie diet has 
been shown to result in adverse consequences for some patients with CF. It was 
highlighted that there are no adult or paediatric guidelines on nutrition for CF patients who 
are overweight or obese. Proposed guidelines for this increasing patient group are needed 
to advise the correct nutritional requirements (Kochavi et al., 2014; Hanna and Weiner, 
2014). Stephenson et al., (2013) advised that these CF patients may be required to receive 
caloric counselling and diet modification to reduce and maintain their BMI to ideal weight 
recommended at 23.0kg/m
2
 (Kastner-Cole et al., 2005) and 25.0kg/m
2
 (Stephenson et al., 
2013). Stephenson et al., (2013) suggested that CF patients with milder CF disease 
including CF patients that are older, pancreatic sufficient and heterozygous for delta F508 
are at risk of obesity and suggested a modified diet may be required (Stephenson et al., 
2013). However, contradictory advice was proposed by Kastner-Cole et al., (2005) who 
suggested calorie restriction was not needed for paediatric CF patients in the over-weight 
and obese BMI groups due to the positive effects on pulmonary function. The present 
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study does not support the requirement for dietary modification due to the significant 
benefits of BMI on pulmonary function which were not associated with genotype.  
     The literature has provided a strong argument for the advantages of over-weight and 
obese BMI (BMI >25.0kg/m
2
) in a wide variety of CF patient studies from around the 
world. It was observed that there was a lower prevalence of CF related diabetes in this 
patient group compared to the under-weight group (Munck et al., 2007; Stephenson et al., 
2013; Panagopoulou et al., 2014). In addition, there were less chronic disease observed in 
patients with increased BMI beyond 25.0kg/m
2
 such as liver disease (Panagopoulou et al., 
2014) and cirrhosis (Munck et al., 2007). As it was repeatedly identified that pulmonary 
function was higher in over-weight and obese patients whether significant or not it is a 
reason to explain why there were no patients on the lung transplant waiting list or 
mortality rates reported by Munck et al., (2007) compared to a reported 77 patients 
waiting for transplant and 45 patients deceased with a BMI <24.9kg/m
2
 in a French CF 
cohort (n=4533).  This data could also be due to the observations found by numerous 
studies describing less Pseudomonas aeruginosa colonisation of the sputum in the airways 
of patients with a BMI >25.0kg/m
2
 ( Munck et al., 2007; Stephenson et al., 2013; 
Panagopoulou et al., 2014). This would be the opposite in the general population. The 
reason that higher BMI serves to be protective for the CF population is yet to be elucidated. 
It could be possible that an increased BMI may lead to better health due to increased 
absorption of nutrients. The cells of the body require fat to function correctly and the high 
fat diet and adequate absorption may lead to a cell environment close to normal.  
     There were negative effects associated with an over-weight and obese BMI status 
within the CF population. Two studies observed increased triglyceride concentration in the 
blood samples of over-weight and obese patients compared to underweight and ideal 
weight patients (Coderre et al., 2012; Stephenson et al., 2013). Blood triglyceride 
concentrations were shown to be significantly increased in the overweight group (mean 
1.17mmol/L (±0.71)) and the obese group (mean 1.74mmol/L (±1.41) compared to the 
underweight (mean 0.89mmol/L (±0.49)) and the ideal weight group (mean 0.94mmol/L 
(±0.47)) (P=0.001). However, the fasting blood lipid profiles were collected from the 
closest recording within 2 years of the most recent clinic visit at which BMI and FEV1% 
were recorded which may lead to a weakness in the methodology if BMI status changed 
since the triglyceride content was measured (Stephenson et al., 2013). The studies also 
reported increased total cholesterol levels from fasting blood samples. Coderre et al., 
(2012) noted that although the levels were significantly higher (P=<0.05) than patients 
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with a BMI <24.9kg/m2 they were in the normal range with the highest median of 
4.2mmol/L (±0.8) in the over-weight group (Coderre et al., 2012). However, Stephenson 
et al., (2013) reported total cholesterol levels above 5.2mmol/L at 9% in the ideal weight 
group, 19% in the over-weight group and 39% in the obese group  (Stephenson et al., 
2013). Interestingly, Coderre et al., (2012) illustrated the same finding with low density 
cholesterol (LDL), significant progressive increases were observed with increasing BMI 
categories whereas high density cholesterol (HDL) was similar in all groups. This is 
interesting because it gives insight into the risks associated with the high fat and calorie 
diet for patients with a BMI above the ideal cut off at 25.0kg/m
2
. LDL cholesterol carries 
more cholesterol with the potential to oxidise into particles that may attach to plaque in the 
arterial wall leading to plaque build-up and thus increasing the chance of atherosclerosis. 
HDL hold positive benefits because they escort cholesterol to the liver for metabolism and 
excretion and hold protective properties against heart disease  by decreasing plaque build-
up in the arteries (Brown, 2013).  
      This knowledge makes it difficult to ignore the relationship observed between the 
increased risk factors for GOR in the over-weight and obese CF population. The reported 
factors which are frequently suggested to lead to the pathogenesis of GORD in the 
literature include obesity, being overweight (El-Serag et al., 2005; Hampel et al., 2005) 
and incorrect dietary habits such as a high fat diet (Iwakiri et al., 1996; Holloway et al., 
1997; Meyer et al., 2001; Dore et al., 2008). Moreover, it was observed in two separate 
studies that CF patients with a BMI above 25.0kg/m
2
 are associated with higher 
cholesterol levels which have been shown to increase the risk of GOR in previous studies. 
Important findings by El Serag et al., (2005) and Shaprio et al., (2007) found positive 
associations between cholesterol from the diet and GORD in the general population. A 
considerable amount of literature has been published highlighting the high prevalence of 
GOR in the CF population (Gustafsson et al.,1991; Navarro et al., 2001; Blondeau et al., 
2008; Pauwels et al., 2013). These findings provide an important opportunity to advance 
the understanding into risks of over-weight and obesity with GOR in the CF population as 
it has not been studied previously. Therefore, the study aimed to explore the potential 
association of BMI status with patient symptoms of reflux (GOR/EOR) and gastric 
aspiration. 
     Our study did not show any significant association with GOR symptoms and BMI 
status across all BMI groups, although the one patient in the obese BMI category scored 5 
(maximum 7) on the DeMeester score and experienced heartburn that was predictable on 
183 
 
the position of straining and reported interference with daily activities. There were higher 
scores seen in the normal (DeMeester score 7) and over-weight groups (DeMeester score 5) 
to illustrate that BMI was not the cause. Interestingly, we showed that EOR symptoms 
were significantly correlated with a low BMI suggesting under-weight BMI carries a 
higher risk of EOR than over-weight and obesity. We illustrated that the symptoms of 
EOR reduced as the BMI status increased. There was a non-significant decrease in RSI 
questionnaire score as the BMI increased, this is supported by a non-significant decrease 
in pepsin levels as the BMI increased. Although GOR and EOR has not been studied in 
relation to the increasing prevalence of over-weight and obesity in CF there has been 
reports of GOR in CF patients with failure to thrive and malnutrition (Malfroot and Dab, 
1991; Dray et al., 2005). Interestingly, Malfroot and Dab (1991) observed that refluxing 
children shared characteristics of recurrent coughing, vomiting, respiratory infections and 
failing to thrive and these were not so common in the group of infants without reflux.  
     The lessons learned from these findings are that the prevalence of over-weight and 
obesity is increasing in the UK CF population. This is associated with significantly 
increased pulmonary function and is not dependant on genotype or gender. Opposite to the 
effects seen in the general population, in fact the presence of EOR symptoms in CF was 
positively associated with low BMI status. In the general population the risks detrimental 
to health are increasingly associated. Such as GORD, other diseases including heart 
disease and cancer and decreased pulmonary function (Friedenberg et al., 2008; Festi et al., 
2009). These are due to changes in the anatomy and physiology of the body, it has been 
reported that central adiposity fat maybe a sign. The overweight and obesity levels in CF 
are not as high as the general population. For example a median BMI of 45kg/m
2
 has been 
reported to be associated with GORD (Dixon et al., 1999) and this is not the level 
observed in CF. Thus, the observed protective aspect of high BMI overweight and obesity 
in CF may be down to the overall health of the patient. It could suggest that they have 
experienced less malnutrition in their lifetime which physically strains the body. Vitamin 
status could play a role, a well-nourished body may see less negative effects on health. It 
has been demonstrated that the membrane lipid composition of the cell has a role to play 
in the phenotype of the CFTR demonstrated in the ilium, pancreas and airway of a CFTR 
mouse. These results illustrate the importance of lipid membrane of cells in CF and lipid 
alterations of fat from the diet may affect the phenotype of the CF patient as seen in the 
results herein. (Freedman et al., 1999). 
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     The limitations of this study begin with small sample size of 72 CF patients compared 
to previous studies reporting prevalence in the UK, France and Canada with a sample size 
from n=651 to n=1489. A larger sample size of the total number of CF patients at the adult 
CF clinic (n=235) would have allowed stronger conclusions to be made. This study was a 
single centre study in the North East of England (RVI, Newcastle Upon Tyne, UK) so 
regional differences of CF patient care, dietary advice and variety of diet may affect the 
results. Secondly, the study used BMI as a tool to assess over-weight and obesity in the 
patient cohort. The BMI was calculated by dividing the weight (kg) by height (m
2
) and 
classified using the BMI scores set by the WHO. This could have been strengthened by 
collecting anthropometric body measurements and bioelectrical impedance data to assess 
body fat mass so that weight increases caused by muscle mass could be accounted for. 
Central adiposity could be explored and compared to the health risks associated with this 
in the general population. The study did not include such measurements into the initial 
ethical application at the beginning of the study. Furthermore, our data set for genotype 
(n=61) and pulmonary function (n=64) was incomplete. The study holds many strengths 
and the most important being the novel findings of a protective effect of over-weight and 
obesity to gastric aspiration and EOR symptoms in the CF population. Further, all the data 
provided was collected at the time of recruitment therefore symptoms and gastric 
aspiration are directly linked to pulmonary function and BMI status.  
     Our data provides a positive overview of over-weight and obesity in the CF population. 
For adults, the CF Foundation recommends maintenance of normal weight-for-height 
because this was associated with better FEV1 and survival (Stallings et al., 2008) but our 
data suggests that the benefit to health increases as the BMI status increases.  
     We suggest that there is a need for further study into the effect of a high fat diet in 
patients with a BMI over 25.0kg/m
2
 as there is a possibility of high triglyceride and 
cholesterol levels that were not measured in our study. The dietary fat consumed in the 
diet may be the focus for further study.  
     To conclude the body weight of the CF population is increasing due to improvements 
in clinical care and today we observe BMI scores reaching OW and OB categories. The 
potential health risks of OW and OB in the CF population are not completely understood 
but appears to be at odds with the non-CF population. The benefits of increased pulmonary 
function scores regardless of gender and genotype were observed. This may be linked to 
less EOR symptoms among this patient group. Further research is needed before a revision 
of dietary advice is proposed to CF patients with a BMI above 25.0kg/m
2
. 
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6.0 General discussion 
 
       The survival rates are increasing for the CF population and many CF patients are 
reaching the age of 40 and 50 years in present times (Thomson and Harris, 2008; Salvatore 
et al., 2012; Simmonds, et al., 2013). The CF community observe age related diseases in 
many patients reaching adulthood, for example CF related diabetes, liver disease and 
GORD (Bourke and Burns, 2011). GOR is the main focus of the present thesis due to the 
high prevalence, the potential for related health problems in adult CF patients and the lack 
of research available. The focus of CF research is changing and it is becoming 
increasingly important to ensure the years gained are of the best quality as possible 
(Simmonds et al., 2009). The prevalence of GOR in the CF population has been a long 
standing problem for a high percentage of patients (Chen et al., 2010; Armstrong, 2005). 
Living with GOR has been demonstrated to decrease the quality of life and in worse cases 
is associated with mortality (Ronkainen et al., 2013; Holt et al., 2013). Aside from the 
GOR symptoms affecting the quality of life, the concerning factor regarding GOR in CF is 
the potential damage it can cause to the airway. GOR may lead to aspiration of the gastric 
contents and it has been demonstrated that it is not acid that is the potent contents but 
pepsin and bile acids (Gustafsson et al.,1991; Navarro et al., 2001; Blondeau et al., 2008; 
Pauwels et al., 2013). Increasing exposure to gastric aspiration has been associated with 
lung damage, decreased pulmonary function and previously observed in lung transplant 
patients (Blondeau et al., 2008; Nally et al., 2011; Aseeri et al, 2012; Pauwels et al., 2012), 
but there is limited data in CF. Other health implications, associated with gastric aspiration 
and relevant in CF include EOR symptoms like coughing, wheezing, shortness of breath 
and persistent clearing of the throat (Dettmar et al., 2011).  
       The present thesis first emphasises the prevalence of classical GOR symptoms in the 
studied CF population to be 42% which is twice that reported in the general population 
(Dent et al., 2005), the prevalence of EOR symptoms were higher affecting 63% of the 
study population. These findings highlight the high number of CF patients that are affected 
by symptoms, therefore outlining the importance of exploring the topic. Secondly, the 
study indicated the high degree of patients that are not responsive to acid suppression 
medication (PPI or H2RA) to treat such symptoms. It was presented that 70% of patients 
with classical GOR symptoms and 73% of patients experiencing EOR symptoms were 
receiving acid suppression medication. i.e. Symptoms persisted despite the use of 
medication. This has also been illustrated in the literature over the previous years and the 
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prevalence remains high despite medication (Zerbib et al., 2013). It is agreed that acid 
suppression medication such as PPI and H2RA relieves the symptoms of heartburn for 
patients but many remain to be non-responsive and continue to experience symptoms 
(Sabati et al., 2010). These patients may be likely to receive anti-reflux surgery (Kahrilas, 
et al., 2013). Medicated acid suppression has not been shown to be useful for EOR 
symptoms. A potential reason for this resides in the fact that it is not the acid in the 
refluxate that is harmful to the aero-digestive tract, nasal cavity and airways but it is the 
potent contents such as pepsin and bile acids causing the epithelial damage (Jolly, et al., 
2004; Bulmer, et al., 2010).  
      Since it has been suggested that the aspiration of gastric contents negatively affects 
pulmonary function (Gustafsson et al.,1991; Navarro et al., 2001; Blondeau et al., 2008; 
Pauwels et al., 2013) the present study investigated reflux biomarkers within the 
expectorated sputum from the CF airway and correlated the results of this with pulmonary 
function test results.  It was observed that the aspiration of gastric pepsin was present in 70% 
of the study population. The concentration of bile acid in the 22 patient samples analysed 
was not above the maximum serum concentration of 10µmol/L. The possible correlations 
between the presence of bile acids and other health outcomes inclusing pulmonary 
function could not be assessed at a median bile salt concentration of 0.22µmol/L as it is 
not known where the origin of these bile acids have resulted from, it could be present in 
the airway due to serum levels or gastric contents (Parikh et al., 2013). Contrary to the 
literature, the present study did not demonstrate a relationship between the presence of 
pepsin or bile acids in sputum from CF airways with pulmonary function. The sputum 
sample contained a high neutrophil content and the IL-8 concentration was high 
illustrating inflammation within the CF airway. There was no association between gastric 
aspiration and inflammation with pulmonary function. The present study did not mirror 
the negative effects of gastric aspiration as seen in the literature and this could be because 
of the different methods used to analyse reflux biomarkers.  
       The CFTR potentiator named as ‘Ivacaftor’ aims to normalise the flow of chloride 
ions through the gating channel of the CFTR in the G551D mutation (Kotha and Clancy, 
2013). The CFTR modulator has been shown to restore the function of the CFTR in 
clinical trials by demonstrating the reduction in sweat chloride concentrations, and in some 
cases the sweat chloride concentrations were normalised (<30.0mmol/L). In CF defective 
CFTR protein is expressed in the epithelium of the gastrointestinal tract leading to thick 
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and sticky mucus blocking the pancreatic ducts which minimises the release of pancreatic 
enzymes. It has been reported that 85-90% of CF patients have pancreatic insufficiency 
resulting in the patient having difficulty gaining weight and malabsorption of fat soluble 
vitamins A,D,E and K (Cohen et al., 2005) which leads to poor weight gain the patient 
becoming malnourished. The Ivacaftor treatment has demonstrated an increase in weight 
demonstrating the CFTR correction reversing the effects of poor weight gain. As the 
CFTR is expressed in the airways the accumulation of mucus results in poor pulmonary 
function, and the effect of malnutrition also decreases pulmonary function (Accurso et al., 
2010; Ramsey et al., 2011; Barry et al., 2014). The present study supported the observed 
findings of the literature in the 12 patients studied with the G551D mutation. The sweat 
chloride concentration significantly decreased after 6 weeks of treatment, with 6 patients 
demonstrating normalised sweat chloride concentrations at the 6 month follow-up. There 
were significant improvements in patient weight after 6 month of treatment and a 
significantly improved pulmonary function after 6 weeks of treatment.  
     As the CFTR mutation results in multiple complications in exocrine tissues there is 
now a strong interest in the possible clinical benefits of Ivacaftor that have not yet been 
investigated. The CFTR proteins are expressed in the gastrointestinal tract and this may 
have a role to play in the high prevalence of GOR. Given the high prevalence of GOR and 
EOR in the CF community this was explored for the first time within the CF population in 
the present study.  Longitudinal observations over a 12 month follow-up period showed 
that the number of patients presenting abnormal GOR, EOR and airway reflux 
questionnaire scores reduced. In addition, the severity of GOR, EOR and airway reflux 
symptoms decreased during the treatment of Ivacaftor. This is a novel and interesting 
finding, not previously shown to my knowledge. The results are limited however could be 
confounded and are in a small number of patients. Confounders could include other factors 
such as patients achieving a healthier weight and increased pulmonary function.   
      It has been reported that the BMI status of the CF population is increasing with the 
highest overweight prevalence to be 18% in Canada and the obese prevalence to be 6% in 
Ireland (Stephenson et al., 2013; Stack et al., 2007). This has not been extensively 
researched however, the present thesis explored the prevalence of overweight and obese 
BMI status within the total study population. In the present study there were 16.7% of 
patients with a BMI above the ideal 25.0kg/m
2
. This was associated with significantly 
increased lung function. The symptoms of EOR were demonstrated to be significantly 
reduced in the over-weight and obese BMI group, this was supported by the decreased 
188 
 
prevalence of gastric aspiration within these groups but the effect was not significant. 
Over-weight and obesity did not show a relationship to F508del/F508del genotype status 
or to gender. It is difficult to reach any firm conclusions as there is a possibility of 
confounding and conflicting variables such as those with obesity may have milder clinical 
disease, or be at an earlier stage in the disease process with less severe lung infections and 
associated catabolic state. 
      It is important to mention that the present study did not provide comparable data 
obtained from a healthy control group. This is a limitation of the study, however, the use 
of validated questionnaires allowed for the analysis of questionnaire scores to be deemed 
abnormal if higher than the validated cut off score previously evaluated in healthy 
individuals. Also, the study of reflux biomarkers and inflammation obtained from the 
collection of sputum was a key part of the study to assess the effect of gastric aspiration 
into the airway. The collection of expectorated sputum collection from healthy volunteers 
would not be possible. To assess declining pulmonary function the spirometry values were 
compared to the spirometric reference equations collected from healthy non-smokers with 
no symptoms of asthma and respiratory problems, this is recommended by the European 
Respiratory Society. The reference equations are compared to the patient spirometry value 
according to gender, sex and height  (Pellegrino et al., 2005), the value from the healthy 
population is set a 100% and the value from the CF patient is calculated as a percentage of 
what a healthy person would achieve of the same anthropometric characteristics. The 
inclusion of a healthy control group in further studies would strengthen the data obtained 
from the questionnaires and the assessment of reflux symptoms with pulmonary function 
would be a possible correlation. Although healthy controls would not provide a sputum 
sample, it would be possible to obtain a BAL sample to obtain data regarding gastric 
aspiration and inflammation within the airway. 
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6.1 Conclusion and future direction 
 
      The study has observed a high prevalence of GOR and EOR symptoms in the CF 
population that is not alleviated by acid suppression medication. The presence of gastric 
aspiration was not correlated to pulmonary function impairment but this cannot be out 
ruled due to the demonstrated a high number of neutrophils in the airway fluid and high 
inflammatory cytokine presence. CFTR modulators were shown to decrease the number of 
symptomatic patients and symptoms severity of reflux for most patients. The increase of 
BMI to over-weight and obese categories was associated with less EOR symptoms and 
gastric aspiration. These findings may be due to better overall health but may suggest that 
EOR symptoms are related with weight and pulmonary function of CF patients.  
     As the results of this study do not support the suggested harmful effects of the gastric 
aspiration collected from one sample of the airway fluid on the airways in terms of 
lowering pulmonary function and increasing inflammation there is room for further 
research. On our first observation taken by analysing one expectorated sputum sample 
during the outpatient appointment there was little opportunity to assume a reflux event 
occurred and therefore may not identify pepsin or bile acids during one sample at one time 
point therefore suggesting a longitudinal study of CF patients with GOR/EOR symptoms 
and using non GOR/EOR CF patients as a comparison group maybe an ideal way to 
observe the effects. Multiple samples throughout the day and one during symptoms would 
eliminate the chances of missing the detection of the reflux biomarkers.  
     For the first time, our study researched the presence of reflux in a novel group of CF 
patients receiving Ivacaftor treatment to correct the CFTR class III mutation. In this 
patient group the effect of correcting the CFTR function brought about the observed health 
benefits including decreased sweat chloride, weight gain and improved pulmonary 
function with the novel finding of reduced symptoms of reflux. The longitudinal study of 
other CFTR correcting treatments including Lumacaftor for the homozygous delta F508 
patients would be beneficial to observe the effects it has on symptoms of reflux.  The 
association of CFTR expression in the gastrointestinal epithelia and in the high prevalence 
of gastric reflux in the CF population can be studied using patients receiving CFTR 
correcting medication.  
     The arising concern of overweight and obesity in the CF population requires further 
study in a larger population. Although the prevalence is increasing the use of single study 
data includes a small number of patients and further multicentre studies are suggested to 
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address the outcome and provide answers to the questions raised during single centre 
studies regarding the benefits over the risks. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
191 
 
7.0 Bibliography 
 
Accurso, F.J., Van Goor, F., Zha, J., Stone, A.J., Dong, Q., Ordonez, C.L., Rowe, S.M., 
Clancy, J.P., Konstan, M.W., Hoch, H.E., Heltshe, S.L., Ramsey, B.W., Campbell, P.W. 
and Ashlock, M.A. (2014) 'Sweat chloride as a biomarker of CFTR activity: Proof of 
concept and ivacaftor clinical trial data', Journal of Cystic Fibrosis, 13(2), pp. 139-147. 
 
Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, Sagel SD, Hornick 
DB, Konstan MW, Donaldson SH, Moss RB, Pilewski JM, Rubenstein RC, Uluer AZ, 
Aitken ML, Freedman SD, Rose LM, Mayer-Hamblett N, Dong Q, Zha J, Stone AJ, Olson 
ER, Ordoñez CL, Campbell PW, Ashlock MA, Ramsey BW. (2010) ‘Effect of VX-770 in 
persons with cystic fibrosis and the G551D-CFTR mutation’ New England Journal of 
Medicine 18;363(21):1991-2003 
 
Anthony, H., Collins, C.E., Davidson, G., Mews, C., Robinson, P., Shepherd, R. and 
Stapleton, D. (1999) 'Pancreatic enzyme replacement therapy in cystic fibrosis: Australian 
guidelines', Journal of Paediatrics and Child Health, 35(2), pp. 125-129. 
 
Armstrong, D. (2005) 'Gastroesophageal reflux disease', Current Opinion in 
Pharmacology, 5(6), pp. 589-595. 
 
Armstrong, D. and Sifrim, D. (2010) 'New Pharmacologic Approaches in 
Gastroesophageal Reflux Disease', Gastroenterology Clinics of North America, 39(3), pp. 
393-418. 
 
Austin, G. L., M. T. Thiny, et al. (2006). "A very low-carbohydrate diet improves 
gastroesophageal reflux and its symptoms." Digestive Diseases and Sciences 51(8): 1307-
1312. 
 
Aseeri, A., Brodlie, M., Lordan, J., Corris, P., Pearson, J., Ward, C. and Manning, N. 
(2012) 'Bile Acids Are Present in the Lower Airways of People with Cystic Fibrosis', 
American Journal of Respiratory and Critical Care Medicine, 185(4), pp. 463-463. 
 
Bardhan, K.D., Strugala, V. and Dettmar, P.W. (2012) 'Reflux Revisited: Advancing the 
Role of Pepsin', International Journal of Otolaryngology, 2012. 
 
Avidan, B., Sonnenberg, A., Schnell, T.G. and Sontag, S.J. (2001) 'Temporal associations 
between coughing or wheezing and acid reflux in asthmatics', Gut, 49(6), pp. 767-772. 
 
Banner, K.H., De Jonge, H., Elborn, S., Growcott, E., Gulbins, E., Konstan, M., Moss, R., 
Poll, C., Randell, S.H., Rossi, A.G., Thomas, L. and Waltz, D. (2009) 'Highlights of a 
workshop to discuss targeting inflammation in cystic fibrosis', Journal of Cystic Fibrosis, 
8(1), pp. 1-8. 
 
Bardhan, K.D., Strugala, V. and Dettmar, P.W. (2012) 'Reflux Revisited: Advancing the 
Role of Pepsin', International Journal of Otolaryngology, 2012. 
 
Barth, A.L. and Pitt, T.L. (1996) 'The high amino-acid content of sputum from cystic 
fibrosis patients promotes growth of auxotrophic Pseudomonas aeruginosa', Journal of 
Medical Microbiology, 45(2), pp. 110-119. 
192 
 
 
Barry, P.J., Plant, B.J., Nair, A., Bicknell, S., Simmonds, N.J., Bell, N.J., Shafi, N.T., 
Daniels, T., Shelmerdine, S., Felton, I., Gunaratnam, C., Jones, A.M. and Horsley, A.R. 
(2014) 'EFfects of ivacaftor in cystic fibrosis patients carrying the g551d mutation with 
severe lung disease', CHEST Journal. 
 
Belafsky, P.C., Postma, G.N. and Koufman, J.A. (2002) 'Validity and Reliability of the 
Reflux Symptom Index (RSI)', Journal of Voice, 16(2), pp. 274-277. 
Boeckxstaens, G.E. (2005) 'The lower oesophageal sphincter', Neurogastroenterology & 
Motility, 17, pp. 13-21. 
 
Becker DJ, Sinclair J, Castell DO, et al. A comparison of high and low fat meals on 
postprandial esophageal acid exposure. Am J Gastroenterol 1989;84:782–6. 
Bell, S.C., De Boeck, K. and Amaral, M.D. (2014) 'New pharmacological approaches for 
cystic fibrosis: Promises, progress, pitfalls', Pharmacology & Therapeutics, (0). 
 
Bendig, D.W., Seilheimer, D.K., Wagner, M.L., Ferry, G.D. and Harrison, G.M. (1982) 
'Complications of gastroesophageal reflux in patients with cystic fibrosis', The Journal of 
Pediatrics, 100(4), pp. 536-540. 
 
Bergin, D.A., Hurley, K., Mehta, A., Cox, S., D, R., O’Neill, S.J., Reeves, E.P. and 
McElvaney, N.G. (2013) 'Airway inflammatory markers in individuals with cystic fibrosis 
and non-cystic fibrosis bronchiectasis', Journal of Inflammation Research, 6, pp. 1-11. 
 
Bhatt, J.M. (2013) 'Treatment of pulmonary exacerbations in cystic fibrosis', European 
Respiratory Review, 22(129), pp. 205-216. 
 
Blondeau, K., Dupont, L.J., Mertens, V., Verleden, G., Malfroot, A., Vandenplas, Y., 
Hauser, B. and Sifrim, D. (2008a) 'Gastro-oesophageal reflux and aspiration of gastric 
contents in adult patients with cystic fibrosis', Gut, 57(8), pp. 1049-1055. 
 
Blondeau, K., Mertens, V., Vanaudenaerde, B.A., Verleden, G.M., Van Raemdonck, D.E., 
Sifrim, D. and Dupont, L.J. (2008b) 'Gastro-oesophageal reflux and gastric aspiration in 
lung transplant patients with or without chronic rejection', European Respiratory Journal, 
31(4), pp. 707-713. 
 
Blondeau, K., Pauwels, A., Dupont, L.J., Mertens, V., Proesmans, M., Orel, R., Brecelj, J., 
Lopez-Alonso, M., Moya, M.J., Malfroot, A., De Wachter, E., Vandenplas, Y., Hauser, B. 
and Sifrim, D. (2010) 'Characteristics of Gastroesophageal Reflux and Potential Risk of 
Gastric Content Aspiration in Children With Cystic Fibrosis.', Journal of Pediatric 
Gastroenterology and Nutrition, Feb;50(2), pp. 116-6. 
 
Boeckxstaens, G.E. (2005) 'The lower oesophageal sphincter', Neurogastroenterology & 
Motility, 17, pp. 13-21. 
 
Boesch, R.P. and Acton, J.D. (2007) 'Outcomes of fundoplication in children with cystic 
fibrosis', Journal of Pediatric Surgery, 42(8), pp. 1341-1344. 
 
193 
 
Bohman, J.K., Kor, D.J., Kashyap, R., Gajic, O., Festic, E., He, Z. and Lee, A.S. (2013) 
'AIrway pepsin levels in otherwise healthy surgical patients receiving general anesthesia 
with endotracheal intubation', Chest, 143(5), pp. 1407-1413. 
 
Bonfield, T.L., Panuska, J.R., Konstan, M.W., Hilliard, K.A., Hilliard, J.B., Ghnaim, H. 
and Berger, M. (1995) 'Inflammatory cytokines in cystic fibrosis lungs', American Journal 
of Respiratory and Critical Care Medicine, 152(6), pp. 2111-2118. 
 
Bulmer, D.M., Ali, M.S., Brownlee, I.A., Dettmar, P.W. and Pearson, J.P. (2010) 
'Laryngeal mucosa: Its susceptibility to damage by acid and pepsin', The Laryngoscope, 
120(4), pp. 777-782. 
 
Boyle, M.P. and De Boeck, K. (2013) 'A new era in the treatment of cystic fibrosis: 
correction of the underlying CFTR defect', The Lancet Respiratory Medicine, 1(2), pp. 
158-163. 
 
Button BM, Roberts S, Kotsimbos TC, et al. Gastroesophageal reflux (symptomatic 
and silent): a potentially significant problem in patients with cystic fibrosis before and 
after lung transplantation. J Heart Lung Transplant 2005;24:1522–9. 
 
Bourke, S.J. and Burns, G.P. (2011) Lecture Notes: Respiratory Medicine. 8th Edition edn. 
United Kingdom: Wiley-Blackwell. 
 
Boyle, M.P., Bell, S.C., Konstan, M.W., McColley, S.A., Rowe, S.M., Rietschel, E., 
Huang, X., Waltz, D., Patel, N.R. and Rodman, D. (2014) 'A CFTR corrector (lumacaftor) 
and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have 
a phe508del CFTR mutation: a phase 2 randomised controlled trial', The Lancet 
Respiratory Medicine, 2(7), pp. 527-538. 
 
Bredenoord, A.J. (2013) 'Management of Belching, Hiccups, and Aerophagia', Clinical 
Gastroenterology and Hepatology, 11(1), pp. 6-12. 
 
Brodzicki J, Trawinska-Bartnicka M, Korzon M. Frequency, consequences and 
pharmacological treatment of gastroesophageal reflux in children with cystic fibrosis. 
Med Sci Monit 2002;8:CR529–37. 
 
Brown, J. (2013) Nutrition Now. Cengage Learning. 
 
Cohen, J.R., Schall, J.I., Ittenbach, R.F., Zemel, B.S. and Stallings, V.A. (2005) 'Fecal 
Elastase: Pancreatic Status Verification and Influence on Nutritional Status in Children 
with Cystic Fibrosis', Journal of Pediatric Gastroenterology and Nutrition, 40(4), pp. 438-
444 10.1097/01.MPG.0000158222.23181.1C. 
 
Chang, A.B., Cox, N.C., Purcell, J., Marchant, J.M., Lewindon, P.J., Cleghorn, G.J., Ee, 
L.C., Withers, G.D., Patrick, M.K. and Faoagali, J. (2005) 'Airway cellularity, lipid laden 
macrophages and microbiology of gastric juice and airways in children with reflux 
oesophagitis', Respiratory Research, 6(1), pp. 1-5. 
 
194 
 
Chen, S.-h., Wang, J.-w. and Li, Y.-m. (2010) 'Is alcohol consumption associated with 
gastroesophageal reflux disease?', Journal of Zhejiang University SCIENCE B, 11(6), pp. 
423-8. 
 
Chiba, N., Thomson, A., Barkun, A., Armstrong, D., van Zanten, S.V., White, R., 
Escobedo, S. and Sinclair, P. (2003) 'The ROME II definition of dyspepsia does not 
exclude patients with gastroesophageal reflux disease (GERD) in primary care', 
Gastroenterology, 124(4, Supplement 1), pp. A223-A224. 
 
NHS Commissioning Board. Clinical Commissioning Policy: Ivacaftor for cystic fibrosis 
(G551D gene)Reference : NHSCB/A01/P/a. 
 
Coderre, L., C. Fadainia, L. Belson, V. Belisle, S. Ziai, G. Maillhot, Y. Berthiaume and R. 
Rabasa-Lhoret (2012). "LDL-cholesterol and insulin are independently associated with 
body mass index in adult cystic fibrosis patients." Journal of Cystic Fibrosis 11(5): 393-
397. 
 
Cohen, J.R., Schall, J.I., Ittenbach, R.F., Zemel, B.S. and Stallings, V.A. (2005) 'Fecal 
Elastase: Pancreatic Status Verification and Influence on Nutritional Status in Children 
with Cystic Fibrosis', Journal of Pediatric Gastroenterology and Nutrition, 40(4), pp. 438-
444 10.1097/01.MPG.0000158222.23181.1C. 
 
Committee on Safety of Medicines., C.o.S.o. (1995) 'Report of the pancreatic enzymes 
working party; London: Committee on Safety of Medicines'. 
 
Colombo, J.L. and Hallberg, T.K. (1987) 'Recurrent aspiration in children: Lipid-laden 
alveolar macrophage quantitation', Pediatric Pulmonology, 3(2), pp. 86-89. 
 
Colombo, P., M. Mangano, et al. (2002). "Effect of calories and fat on postprandial gastro-
oesophageal reflux." Scandinavian Journal of Gastroenterology 37(1): 3-5. 
 
Colombo, C., Faelli, N., Tirelli, T.S., Fortunato, F., Biffi, A., Claut, L., Cariani, L., Daccò, 
V., Prato, R. and Conese, M. (2011) 'Analysis of inflammatory and immune response 
biomarkers in sputum and exhaled breath condensate by a multi-parametric biochip array 
in cystic fibrosis.'. 
 
Couturier O, Bodet-Milin C, Querellou S, et al. Gastric scintigraphy with a liquid–solid 
radiolabelled meal: performances of solid and liquid parameters. Nucl Med Commun 
2004;25:1143–50. 
 
Corey, M., F. J. McLaughlin, M. Williams and H. Levison (1988). "A comparison of 
survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and 
Toronto." Journal of Clinical Epidemiology 41(6): 583-591. 
Crozier, D. N. (1974). "Cystic fibrosis: a not-so-fatal disease." Pediatric Clinic North 
America Nov;21(4): 935-950. 
 
Cucchiara S, Santamaria F, Andreotti MR, Minella R, Ercolini P, Oggero V and G., d.R. 
(1991) 'Mechanisms of gastro-oesophageal reflux in cystic fibrosis.', Archives of Diseases 
in Children, May;66(5), pp. 617-22. 
 
195 
 
Cystic Fibrosis Foundation 2011 
G.L.Crossfield, A. Krishnan, J. Lordan, S. Bourke, A. Anderson, P.W. Dettmar, I.A. 
Brownlee, C. Ward, J.P. Pearson (2013) ‘WS3.1 Gastric aspiration into the CF lung – 
relationship with reflux symptoms and lung function’ [ABSTRACT] Journal of Cystic 
Fibrosis 12,1:S5 
 
Davies, J., Sheridan, H., Bell, N., Cunningham, S., Davis, S.D., Elborn, J.S., Milla, C.E., 
Starner, T.D., Weiner, D.J., Lee, P.-S. and Ratjen, F. (2013) 'Assessment of clinical 
response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-
CFTR mutation and preserved spirometry: a randomised controlled trial', The Lancet 
Respiratory Medicine, 1(8), pp. 630-638. 
 
Davies, J.C., Cunningham, S., Alton, E.W.F.W. and Innes, J.A. (2008) 'Lung clearance 
index in CF: a sensitive marker of lung disease severity', Thorax, 63(2), pp. 96-97. 
 
De Boeck, K., Kent, L., Davies, J., Derichs, N., Amaral, M., Rowe, S.M., Middleton, P., 
De Jonge, H., Bronsveld, I., Wilschanski, M., Melotti, P., Danner-Boucher, I., Boerner, S., 
Fajac, I., Southern, K., De Nooijer, R.A., Bot, A., De Rijke, Y., De Wachter, E., Leal, T.,  
 
Vermeulen, F., Hug, M.J., Rault, G., Nguyen-Khoa, T., Barreto, C., Proesmans, M. and 
Sermet-Gaudelus, I. (2013) 'CFTR biomarkers: Time for promotion to surrogate end-
point?', European Respiratory Journal, 41(1), pp. 203-216. 
 
de Bentzmann, S., Plotkowski, C. and Puchelle, E. (1996) 'Receptors in the Pseudomonas 
Aeruginosa Adherence to Injured and Repairing Airway Epithelium', American Journal of 
Respiratory and Critical Care Medicine, 154(4_pt_2), pp. S155-S162. 
 
Dennersten, U., Lannefors, L., Höglund, P., Hellberg, K., Johansson, H., Lagerkvist, A.-L., 
Ortfelt, M., Sahlberg, M. and Eriksson, L. (2009) 'Lung function in the aging Swedish 
cystic fibrosis population', Respiratory Medicine, 103(7), pp. 1076-1082. 
 
DeMeester, T.R., Lafontaine, E., Joelsson, B.E., Skinner, D.B., Ryan, J.W., OSullivan, 
G.C., Brunsden, B.S. and Johnson, L.F. (1981) 'Relationship of a hiatal hernia to the 
function of the body of the esophagus and the gastresophageal junction.', Journal of 
Thoracic Cardiovascular Surgery, 82, pp. 547–558. 
 
DeMeester, T.R., Wang, C.I., Wernly, J.A., Pellegrini, C.A., Little, A.G., Klementschitsch, 
P., Bermudez, G., Johnson, L., F.  and Skinner, D.B. (1980) 'Technique, indications, and 
clinical use of 24 hour esophageal pH monitoring.', Journal of Thorac Cardiovascular 
Surgery 79, pp. 656–670. 
 
Dent, J., Dodds, W.J., Friedman, R.H., Sekiguchi, T., Hogan, W.J., Arndorfer, R.C. and 
Petrie, D.J. (1980) 'Mechanism of gastroesophageal reflux in recumbent asymptomatic 
human subjects', The Journal of Clinical Investigation, 65(2), pp. 256-267. 
 
Dent, J., El-Serag, H.B., Wallander, M.A. and Johansson, S. (2005) 'Epidemiology of 
gastro-oesophageal reflux disease: a systematic review', Gut, 54(5), pp. 710-717. 
 
196 
 
Dixon, J., Strugala, V., Welfare, M.R., Dettmar, P.W., Allen, A. and Pearson, J.P. (2001) 
'Esophageal mucin: an adherent mucus gel barrier is absent in the normal esophagus but 
present in columnar-lined Barrett's esophagus', Am J Gastroenterol, 96(9), pp. 2575-2583. 
 
Dettmar, P.W., Castell, D.O., Heading, R.C., Ell, S., Fagan, M.J., McGlashan, J.A., 
Morice, A.H. and Watson, M. (2011) 'Review article: reflux and its consequences – the 
laryngeal, pulmonary and oesophageal manifestations', Alimentary Pharmacology & 
Therapeutics, 33, pp. 1-71. 
 
Dodge, J.A., Lewis, P.A., Stanton, M. and Wilsher, J. (2007) 'Cystic fibrosis mortality and 
survival in the UK: 1947-2003', European Respiratory Journal, 29(3), pp. 522-526. 
 
Dore, M. P., E. Maragkoudakis, et al. (2008). "Diet, lifestyle and gender in gastro-
esophageal reflux disease." Digestive Diseases & Sciences 53(8): 2027-2032. 
 
Dixon, J. and O'Brien, P. (1999) 'Gastroesophageal Reflux in Obesity: The Effect of Lap-
Band Placement', Obesity Surgery, 9(6), pp. 527-531. 
 
di Sant'Agnese, P.A. and Davis, P.B. (1979) 'Cystic fibrosis in adults: 75 cases and a 
review of 232 cases in the literature', The American Journal of Medicine, 66(1), pp. 121- 
132. 
 
Dore, M.P., Maragkoudakis, E., Fraley, K., Pedroni, A., Tadeu, V., Realdi, G., Graham, 
D.Y., Delitala, G. and Malaty, H.M. (2008) 'Diet, lifestyle and gender in gastro-
esophageal reflux disease', Digestive Diseases & Sciences, 53(8), pp. 2027-32. 
 
Dray, X., Hubert, D., Munck, A., Moreau, J. and Marteau, P. (2005) 'Manifestations 
digestives de la mucoviscidose de l’adulte', Gastroentérologie Clinique et Biologique, 
29(12), pp. 1279-1285. 
 
Efthimiadis, A.S., Hamid, Q., Kelly, M.M., Linden, M., Louis, R., Pizzichini, M.M.M., 
Pizzichini, E., Ronchi, C., Van Overveld, F. and Djukanović, R. (2002) 'Methods of 
sputum processing for cell counts, immunocytochemistry and in situ hybridisation', 
European Respiratory Journal, 20(37 suppl), pp. 19s-23s. 
 
Eckford, P.D.W., Li, C., Ramjeesingh, M. and Bear, C.E. (2012) 'Cystic Fibrosis 
Transmembrane Conductance Regulator (CFTR) Potentiator VX-770 (Ivacaftor) Opens 
the Defective Channel Gate of Mutant CFTR in a Phosphorylation-dependent but ATP-
independent Manner', Journal of Biological Chemistry, 287(44), pp. 36639-36649. 
 
Eckford, Paul D.W., Ramjeesingh, M., Molinski, S., Pasyk, S., Dekkers, J.F., Li, C., 
Ahmadi, S., Ip, W., Chung, Timothy E., Du, K., Yeger, H., Beekman, J., Gonska, T. and 
Bear, Christine E. (2014) 'VX-809 and Related Corrector Compounds Exhibit Secondary 
Activity Stabilizing Active F508del-CFTR after Its Partial Rescue to the Cell Surface', 
Chemistry & Biology, 21(5), pp. 666-678. 
 
Escobar, C.H., Perdomo, G.M., Gimeno, B.R., Máiz, C.L. and Suárez, C.L. (1996) 
'Gastroesophageal reflux, pulmonary and gastric function in patients with cystic fibrosis. 
Results of a randomized trial', Acta Gastroenterol Latinoam, 26(3), pp. 183-6. 
 
197 
 
Ervine, E., McMaster, C., McCallion, W. and Shields, M.D. (2009) 'Pepsin measured in 
induced sputum—a test for pulmonary aspiration in children?', Journal of Pediatric 
Surgery, 44(10), pp. 1938-1941. 
 
El-Serag, H. B., J. A. Satia, et al. (2005). "Dietary intake and the risk of gastro 
oesophageal reflux disease: a cross sectional study in volunteers." Gut 54(1): 11-17. 
 
Fathi H, Moon T, Donaldson J, Jackson W, Sedman P, Morice AH. Cough in adult cystic 
fibrosis: diagnosis and response to fundoplication. Cough. 2009 Jan 18;5:1. 
 
Farré, R. (2013) 'Pathophysiology of gastro-esophageal reflux disease: a role for mucosa 
integrity?', Neurogastroenterology & Motility, 25(10), pp. 783-799.  
 
Fanen, P., Wohlhuter-Haddad, A. and Hinzpeter, A. (2014) 'Genetics of cystic fibrosis: 
CFTR mutation classifications toward genotype-based CF therapies', The International 
Journal of Biochemistry & Cell Biology, 52(0), pp. 94-102. 
 
Farrell, P.M., Rosenstein, B.J., White, T.B., Accurso, F.J., Castellani, C., Cutting, G.R., 
Durie, P.R., LeGrys, V.A., Massie, J., Parad, R.B., Rock, M.J. and Campbell Iii, P.W. 
(2008) 'Guidelines for Diagnosis of Cystic Fibrosis in Newborns through Older Adults: 
Cystic Fibrosis Foundation Consensus Report', The Journal of Pediatrics, 153(2), pp. S4-
S14. 
 
Farrell, S., McMaster, C., Gibson, D., Shields, M.D. and McCallion, W.A. (2006) 'Pepsin 
in bronchoalveolar lavage fluid: a specific and sensitive method of diagnosing gastro-
oesophageal reflux–related pulmonary aspiration', Journal of Pediatric Surgery, 41(2), pp. 
289-293. 
 
Fischer, N., Hentschel, J., Markert, U.R., Keller, P.M., Pletz, M.W. and Mainz, J.G. (2014) 
'Non-invasive assessment of upper and lower airway infection and inflammation in CF 
patients', Pediatric Pulmonology, pp. n/a-n/a. 
 
Flume, P., Wainwright, C., Tullis, E., Rodriguez, S., Davies, J. and Wagener, J. (2013) '58 
Pulmonary exacerbations in CF patients with the G551D-CFTR mutation treated with 
ivacaftor', Journal of Cystic Fibrosis, 12, Supplement 1(0), p. S63. 
 
Flume P A, Liou T G, Borowitz D S, Li H, Yen K, Ordoñez K L, Geller D E. (2012) 
‘Ivacaftor in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR 
Mutation’ Chest 142, 3: 718-724  
 
Fox, M., C. Barr, et al. (2007). "The Effects of Dietary Fat and Calorie Density on 
Esophageal Acid Exposure and Reflux Symptoms." Clinical Gastroenterology and 
Hepatology 5(4): 439-444.e431. 
 
Friedenberg, F.K., Xanthopoulos, M., Foster, G.D. and Richter, J.E. (2008) 'The 
Association Between Gastroesophageal Reflux Disease and Obesity', Am J Gastroenterol, 
103(8), pp. 2111-2122. 
 
Freedman, S.D., Katz, M.H., Parker, E.M., Laposata, M., Urman, M.Y. and Alvarez, J.G. 
(1999) 'A membrane lipid imbalance plays a role in the phenotypic expression of cystic 
198 
 
fibrosis in cftr−/− mice', Proceedings of the National Academy of Sciences, 96(24), pp. 
13995-14000. 
 
Feigelson, J. and Sauvegrain, J. (1975) 'Letter: Gastro-esophageal reflux in 
mucoviscidosis', Nouv Presse Med., Nov 8; 4 (38), pp. 2729-30. 
 
Gaskin, K., D. Gurwitz, P. Durie, M. Corey, H. Levison and G. Forstner (1982). 
"Improved respiratory prognosis in patients with cystic fibrosis with normal fat 
absorption." The Journal of Pediatrics 100(6): 857-862. 
 
Gillen, D. and McColl, K. (2011) 'Symptoms and signs of upper gastrointestinal disease', 
Medicine, 39(2), pp. 67-71. 
 
Gerson LB, Boparai V, Ullah N, Triadafilopoulos G. Oesophageal and gastric pH profiles 
in patients with gastroesophageal reflux disease and Barrett’s oesophagus treated with 
proton pump inhibitors. Aliment Pharmacol Ther 2004; 20: 637–43. 
 
Gerson, L. B., K. Shetler, et al. (2005). "Control of intra-oesophageal and intra-gastric pH 
with proton pump inhibitors in patients with Barrett's oesophagus." Digestive and Liver 
Disease 37(9): 651-658. 
 
Gibson, L.E. and Cooke, R.E. (1959) 'A TEST FOR CONCENTRATION OF 
ELECTROLYTES IN SWEAT IN CYSTIC FIBROSIS OF THE PANCREAS 
UTILIZING PILOCARPINE BY IONTOPHORESIS', Pediatrics, 23(3), pp. 545-549. 
 
Gustafsson, P.M., Fransson, S.G., Kjellman, N.I. and Tibbling, L. (1991) 'Gastro-
oesophageal reflux and severity of pulmonary disease in cystic fibrosis', Scand J 
Gastroenterol, 26(5), pp. 449 - 56. 
 
Grabowski, M., Kasran, A., Seys, S., Pauwels, A., Medrala, W., Dupont, L., Panaszek, B. 
and Bullens, D. (2011) 'Pepsin and bile acids in induced sputum of chronic cough patients', 
Respiratory Medicine, 105(8), pp. 1257-1261. 
 
Hallberg, K., Fandriks, L. and Strandvik, B. (2004) 'Duodenogastric Bile Reflux Is 
Common in Cystic Fibrosis.', Journal of Pediatric Gastroenterology & Nutrition. , 38(3), 
pp. 312-316. 
 
Hampel, H., Abraham, N.S. and El-Serag, H.B. (2005) 'Meta-Analysis: Obesity and the 
Risk for Gastroesophageal Reflux Disease and Its Complications', Annals of Internal 
Medicine, 143(3), pp. 199-211. 
 
Hassal. E (1993) 'Barrett's esophagus: new definitions and approaches in children.', 
Journal of Paediatric Gastroenterology and Nutrition, 15:, pp. 345–64. 
 
Harmon, J., Johnson, L. and Maydonovitch, C. (1981) 'Effects of acid and bile salts on the 
rabbit esophageal mucosa', Digestive Diseases and Sciences, 26(1), pp. 65-72. 
 
Harrison, M.J., Murphy, D.M. and Plant, B.J. (2013) 'Ivacaftor in a G551D Homozygote 
with Cystic Fibrosis', New England Journal of Medicine, 369(13), pp. 1280-1282. 
 
199 
 
Hayat, J.O., Kang, J.-Y., Dettmar, P.W., Moore, A.T., Hicklin, L.C., Yazaki, E. and Sifrim, 
D. (2012) 'Su1056 Do Patients With Hoarseness and Endoscopic Signs of LPR Have 
Abnormal Esophago-Pharyngeal Reflux? a Study Using Simultaneous Impedance-
Phmetry, Oro-Pharyngeal pH Monitoring (Restech) and Pepsin Measurements in Saliva', 
Gastroenterology, 142(5, Supplement 1), pp. S-411-S-412. 
 
Hayes, D., Kirkby, S., S. McCoy, K., Mansour, H.M., Khosravi, M., Strawbridge, H. and 
Tobias, J.D. (2013) 'Reduction of lipid-laden macrophage index after laparoscopic Nissen 
fundoplication in cystic fibrosis patients after lung transplantation', Clinical 
Transplantation, 27(1), pp. 121-125. 
 
Hanna, R.M. and Weiner, D.J. (2014) 'Overweight and obesity in patients with cystic 
fibrosis: A center-based analysis', Pediatric Pulmonology, pp. n/a-n/a. 
 
Hebestreit, H., Sauer-Heilborn, A., Fischer, R., Käding, M. and Mainz, J.G. (2013) 
'Effects of ivacaftor on severely ill patients with cystic fibrosis carrying a G551D 
mutation', Journal of Cystic Fibrosis, 12(6), pp. 599-603. 
 
Heijerman, H. (1992) 'New modalities in the treatment of exocrine pancreatic 
insufficiency in cystic fibrosis.', Netherlands Journal of Medicine, Oct;41(3-4), pp. 105-9. 
 
Hodson, M., A. Bush and D. Geddes (2007). Cystic Fibrosis, Third Edition, Taylor & 
Francis. 
 
Holloway, R. H. (2000). "Treatment of gastro-oesophageal reflux disease through control 
of transient lower oesophageal sphincter relaxations - feasibility, practicality and 
possibilities." Digestive and Liver Disease 32(3): 183-187. 
 
Holloway RH, Lyrenas E, Ireland A, Dent J. Effect of intraduodenal fat on lower 
oesophageal sphincter function and gastro-oesophageal reflux. Gut 1997; 40: 449-453 
 
Holt, E.W., Yimam, K.K. and Liberman, M.S. (2013) 'Esophageal adenocarcinoma in a 
40-year-old man with cystic fibrosis: coincidence or not?', Ochsner J., Summer;13(2), pp. 
252-5. 
 
Hofmann, A.F. (1999) 'THe continuing importance of bile acids in liver and intestinal 
disease', Archives of Internal Medicine, 159(22), pp. 2647-2658. 
 
Hopkins, P.M., Kermeen, F., Duhig, E., Fletcher, L., Gradwell, J., Whitfield, L., Godinez, 
C., Musk, M., Chambers, D., Gotley, D. and McNeil, K. (2010) 'Oil red O stain of alveolar 
macrophages is an effective screening test for gastroesophageal reflux disease in lung 
transplant recipients', The Journal of Heart and Lung Transplantation, 29(8), pp. 859-864. 
 
Irwin, R.S., Pratter, M.R., Holland, P.S., Corwin, R.W. and Hughes, J.P. (1984) 'POstnasal 
drip causes cough and is associated with reversible upper airway obstruction', Chest, 85(3), 
pp. 346-352. 
 
Iwakiri K, Kobayashi M, Kotoyori M, Yamada H, Sugiura T, Nakagawa Y. Relationship 
between postprandial esophageal acid exposure and meal volume and fat content. Dig Dis 
Sci 1996; 41: 926-930 
200 
 
 
Jaspersen, D., Labenz, J., Willich, S.N., Kulig, M., Nocon, M., Leodolter, A., Lind, T., 
Meyer-Sabellek, W., Vieth, M., Stolte, M. and Malfertheiner, P. (2006) 'Long-term 
clinical course of extra-oesophageal manifestations in patients with gastro-oesophageal 
reflux disease: A prospective follow-up analysis based on the ProGERD study', Digestive 
and Liver Disease, 38(4), pp. 233-238. 
 
Jelalian, E., L. J. Stark, L. Reynolds and R. Seifer (1998). "Nutrition intervention for 
weight gain in cystic fibrosis: A meta analysis." The Journal of Pediatrics 132(3): 486-492. 
Jolly, A.J., Wild, C.P. and Hardie, L.J. (2004) 'Acid and bile salts induce DNA damage in 
human oesophageal cell lines', Mutagenesis, 19(4), pp. 319-324. 
 
Johnston N, Bulmer D, Gill GA, et al. Cell biology of laryngeal epithelial defences in 
health and disease: further studies. Ann Otol Rhinol Laryngol 2003; 112: 481–91. 
Kageyama T. Pepsinogens, progastricsin and prochymosins: structure, function, evolution 
and development. Cell Mol Life Sci 2002; 59: 288–306. 
 
Kahrilas, P.J., Boeckxstaens, G. and Smout, A.J.P.M. (2013) 'Management of the patient 
with incomplete response to PPI therapy', Best Practice & Research Clinical 
Gastroenterology, 27(3), pp. 401-414. 
 
Kastner-Cole, D., C. N. A. Palmer, S. A. Ogston, A. Mehta and S. Mukhopadhyay (2005). 
"Overweight and Obesity in ΔF508 Homozygous Cystic Fibrosis." The Journal of 
Pediatrics 147(3): 402-404. 
 
Kennedy, J.H. (1962) 'Silent gastroesophageal reflux: an important but little known cause 
of pulmonary complications. ', Diseases of the Chest 42, pp. 42–5. 
 
Klauser, A.G., Schindlbeck, N.E. and Müller-Lissner, S.A. (1990) 'Symptoms in gastro-
oesophageal reflux disease', The Lancet, 335(8683), pp. 205-208. 
 
Kitz, R., Boehels, H.J., Rosewich, M. and Rose, M.A. (2012) 'Lipid-Laden Alveolar 
Macrophages and pH Monitoring in Gastroesophageal Reflux-Related Respiratory 
Symptoms', Pulmonary Medicine, 2012. 
 
Kivilaakso, E., Fromm, D. and Silen, W. (1980) 'Effect of bile salts and related 
compounds on isolated esophageal mucosa.', Surgery, mar;87(3), pp. 280-5. 
 
Köksal, D., Özkan, B., Þimþek, C., Köksal, A.Þ., Aðaçkýran, Y. and Þaþmaz, N. (2005) 
'Lipid-Laden Alveolar Macrophage Index in Sputum is Not Useful in the Differential 
Diagnosis of Pulmonary Symptoms Secondary to Gastroesophageal Reflux', Archives of 
Medical Research, 36(5), pp. 485-489. 
 
Konstan, M.W., Morgan, W.J., Butler, S.M., Pasta, D.J., Craib, M.L., Silva, S.J., Stokes, 
D.C., Wohl, M.E.B., Wagener, J.S., Regelmann, W.E. and Johnson, C.A. (2007) 'Risk 
Factors For Rate of Decline in Forced Expiratory Volume in One Second in Children and 
Adolescents with Cystic Fibrosis', The Journal of Pediatrics, 151(2), pp. 134-139.e1. 
 
Kochavi, B. (2014) '211 Overweight and obesity in the cystic fibrosis Israeli national 
center', Journal of Cystic Fibrosis, 13, Supplement 2(0), p. S100.  
201 
 
 
Kotha K and Clancy J P. (2013) ‘Ivacaftor treatment of cystic fibrosis patients with the 
G551D mutation: a review of the evidence’ Therapeutic Advances in Respiratory Disease 
7: 288 2013 
 
Kulig, M., Nocon, M., Vieth, M., Leodolter, A., Jaspersen, D., Labenz, J., Meyer-Sabellek, 
W., Stolte, M., Lind, T., Malfertheiner, P. and Willich, S.N. (2004) 'Risk factors of 
gastroesophageal reflux disease: methodology and first epidemiological results of the 
ProGERD study', Journal of Clinical Epidemiology, 57(6), pp. 580-589. 
 
Kraemer, R., A. RÜDeberg, B. Hadorn and E. Rossi (1978). "RELATIVE 
UNDERWEIGHT IN CYSTIC FIBROSIS AND ITS PROGNOSTIC VALUE." Acta 
Pædiatrica 67(1): 33-37. 
 
Laszlo, G. (2006) 'Standardisation of lung function testing: helpful guidance from the 
ATS/ERS Task Force', Thorax, 61, pp. 744-746 
 
Ledson, M.J., Tran, J. and Walshaw, M.J. (1998) 'Prevalence and mechanisms of gastro-
oesophageal reflux in adult cystic fibrosis patients.', Journal of the Royal Society of 
Medicine, 91, pp. 7-9. 
 
Laohasiriwong, S., Johnston, N. and Woodson, B.T. (2013) 'Extra-esophageal Reflux, 
NOSE score, and sleep quality in an adult clinic population', The Laryngoscope, 123(12), 
pp. 3233-3238. 
 
Lerín, M., Prados, C., Martínez, M.T., Maíz, L., Girón, R., Solé, A., Cabanillas, J.J. and 
Álvarez-Sala, R. (2014) 'Cystic fibrosis in adult age', Revista Clínica Española (English 
Edition), 214(6), pp. 289-295. 
 
Littlewood, J.M. (1992) 'Gastrointestinal complications in cystic fibrosis', Journal of the 
Royal Society of Medicine, 85(19), pp. 13-19. 
 
Mandal, P., Morice, A.H., Chalmers, J.D. and Hill, A.T. (2013) 'Symptoms of airway 
reflux predict exacerbations and quality of life in bronchiectasis', Respiratory Medicine, 
107(7), pp. 1008-1013. 
 
Malfroot, A. and Dab, I. (1991) 'New insights on gastro-oesophageal reflux in cystic 
fibrosis by longitudinal follow up.', Archives of Disease in Childhood, 66, pp. 1339-1345. 
 
McNally, P., Ervine, E., Shields, M.D., Dimitrov, B.D., El Nazir, B., Taggart, C.C., 
Greene, C.M., McElvaney, N.G. and Greally, P. (2011) 'High concentrations of pepsin in 
bronchoalveolar lavage fluid from children with cystic fibrosis are associated with high 
interleukin-8 concentrations', Thorax, 66(2), pp. 140-143. 
 
Meyer JH, Lembo A, Elashoff JD, Fass R, Mayer EA. Duodenal fat intensifies the 
perception of heartburn. Gut 2001; 49: 624-628   
 
Meining, A. and Classen, M. (2000) 'The role of diet and lifestyle measures in the 
pathogenesis and treatment of gastroesophageal reflux disease', The American Journal of 
Gastroenterology, 95(10), pp. 2692-2697. 
202 
 
 
Mittal, R.K., Holloway, R.H., Penagini, R., Ashley Blackshaw, L. and Dent, J. (1995) 
'Transient lower esophageal sphincter relaxation', Gastroenterology, 109(2), pp. 601-610. 
Mousa, H. and Woodley, F. (2012) 'Gastroesophageal Reflux in Cystic Fibrosis: Current 
Understandings of Mechanisms and Management', Current Gastroenterology Reports, 
14(3), pp. 226-235. 
 
Moayyedi, P. and Talley, N.J. (2006) 'Gastro-oesophageal reflux disease', The Lancet, 
367(9528), pp. 2086-2100. 
 
Moazzez, R., Bartlett, D. and Anggiansah, A. (2004) 'Dental erosion, gastro-oesophageal 
reflux disease and saliva: how are they related?', Journal of Dentistry, 32(6), pp. 489-494. 
 
Morice, A.H., Faruqi, S., Wright, C.E., Thompson, R. and Bland, J.M. (2011) 'Cough 
Hypersensitivity Syndrome: A Distinct Clinical Entity', Lung, 189(1), pp. 73-79. 
 
Morton, A.M. (2009) 'Symposium 6: Young people, artificial nutrition and transitional 
care The nutritional challenges of the young adult with cystic fibrosis: transition', 
Proceedings of the Nutrition Society, 68(04), pp. 430-440. 
 
Mousa, H. and Woodley, F. (2012) 'Gastroesophageal Reflux in Cystic Fibrosis: Current 
Understandings of Mechanisms and Management', Current Gastroenterology Reports, 
14(3), pp. 226-235. 
 
Murphy DW, Castell DO. Chocolate and heartburn: evidence of increased esophageal acid 
exposure after chocolate ingestion. Am J Gastroenterol. 1988;83:633–636. 
 
Munck, A., G. Bellis, S. Ravilly and F. Huet (2007). "221* Do overweight and obesity 
improve clinical outcome in the French cystic fibrosis population?" Journal of Cystic 
Fibrosis 6, Supplement 1(0): S54. 
 
Nandurkar, S., G. R. Locke, et al. (2004). "Relationship between body mass index, diet, 
exercise and gastro-oesophageal reflux symptoms in a community." Alimentary 
Pharmacology & Therapeutics 20(5): 497-505. 
 
Navarro, J., Rainisio, M., Harms, H.K., Hodson, M.E., Koch, C., Mastella, G., Strandvik, 
B., McKenzie, S.G. and on behalf of the investigators of the European Epidemiologic 
Registry of Cystic, F. (2001) 'Factors associated with poor pulmonary function: cross-
sectional analysis of data from the ERCF', European Respiratory Journal, 18(2), pp. 298-
305. 
 
Nessbaum, E., Maggi, J.C., Mathis, R. and Galant, S.P. (1987) 'Association of lipid-laden 
alveolar macrophages and gastroesophageal reflux in children', Journal of Peadiatrics, 
Feb; 110(2), pp. 190-4. 
 
Nebel OT, Fornes MF, Castell DO. Symptomatic gastroesophageal reflux: incidence and 
precipitating factors. Am J Dig Dis. 1976;21:953–956. 
 
203 
 
Nowak M, Büttner P, Raasch B, Daniell K, McCutchan C, Harrison S (2005) Lifestyle 
changes as a treatment of gastroesophageal reflux disease: a survey of general 
practitioners in North Queensland, Australia.  Ther Clin Risk Manag.1(3):219-24. 
 
Orel, R. and Markovic, S. (2003) 'Bile in the Esophagus: A Factor in the Pathogenesis of 
Reflux Esophagitis in Children', Journal of Pediatric Gastroenterology and Nutrition, 
36(2), pp. 266-273. 
 
Orenstein, D.M., Rosenstein, B.J. and Stern, R.C. (2000) Cystic Fibrosis: Medical Care. 
Philadelphia, USA.: Lippincott Williams & Wilkins. 
O'Sullivan, B. P. and S. D. Freedman (2009). "Cystic fibrosis." The Lancet 373(9678): 
1891-1904. 
 
Palm, K., Sawicki, G. and Rosen, R. (2012) 'The impact of reflux burden on Pseudomonas 
positivity in children with Cystic Fibrosis', Pediatric Pulmonology, 47(6), pp. 582-587. 
 
Panagopoulou, P., M. Fotoulaki, A. Nikolaou and S. Nousia-Arvanitakis (2014). 
"Prevalence of malnutrition and obesity among cystic fibrosis patients." Pediatrics 
International 56(1): 89-94. 
 
Parameswaran, K., Anvari, M., Efthimiadis, A., Kamada, D., Hargreave, F.E. and Allen, 
C.J. (2000) 'Lipid-laden macrophages in induced sputum are a marker of oropharyngeal 
reflux and possible gastric aspiration', European Respiratory Journal, 16(6), pp. 1119-
1122. 
 
Parikh, S., Brownlee, I.A., Robertson, A.G., Manning, N.T., Johnson, G.E., Brodlie, M., 
Corris, P.A., Ward, C. and Pearson, J.P. (2013) 'Are the enzymatic methods currently 
being used to measure bronchoalveolar lavage bile salt levels fit for purpose?', The 
Journal of Heart and Lung Transplantation, 32(4), pp. 418-423. 
 
Pauwels, A., Verleden, S., Farre, R., Vanaudenaerde, B.M., Van Raemdonck, D., Verleden, 
G., Sifrim, D. and Dupont, L.J. (2013) 'The effect of gastric juice on interleukin-8 
production by cystic fibrosis primary bronchial epithelial cells', Journal of Cystic Fibrosis, 
12(6), pp. 700-705. 
 
Pauwels, A., Blondeau, K., Mertens, V., Farré, R., Dupont, L. and Sifrim, D. (2011) 'A 
Distinct Mechanism for Reflux in Patients With Cystic Fibrosis: A Study Using High 
Resolution Manometry-Impedance', Gastroenterology, 140(5, Supplement 1), pp. S-43. 
 
Pauwels, A., Blondeau, K., Dupont, L.J. and Sifrim, D. (2012) 'Mechanisms of Increased 
Gastroesophageal Reflux in Patients With Cystic Fibrosis', Am J Gastroenterol, 107(9), pp. 
1346-1353. 
 
Pier, G.B., Grout, M., Zaidi, T.S., Olsen, J.C., Johnson, L.G., Yankaskas, J.R. and 
Goldberg, J.B. (1996) 'Role of mutant CFTR in hypersusceptibility of cystic fibrosis 
patients to lung infections.', Science., 271, pp. 64-67. 
 
Pearson, J.P and Parikh, S (2011) 'Reviewarticle:refluxanditsconsequences—the laryngeal, 
pulmonaryandoesophagealmanifestations.', Alimentary Pharmacology and Therapeutics 
33, pp. 2-7. 
204 
 
 
Pearson, J P & Brownlee, I A, Stomach – Structure and function, Encyclopedia of human 
nutrition, Volume 4, 2005, pp. 180-190, Academic Press. 
 
Polenakovik, H.M. and Sanville, B. (2013) 'The use of ivacaftor in an adult with severe 
lung disease due to cystic fibrosis (ΔF508/G551D)', Journal of Cystic Fibrosis, 12(5), pp. 
530-531. 
 
Pehl, C., A. Waizenhoefer, et al. (1999). "Effect of low and high fat meals on lower 
esophageal sphincter motility and gastroesophageal reflux in healthy subjects." The 
American Journal of Gastroenterology 94(5): 1192-1196. 
 
Pellegrino, R., Viegi, G., Brusasco, V., Crapo, R.O., Burgos, F., Casaburi, R., Coates, A., 
van der Grinten, C.P.M., Gustafsson, P., Hankinson, J., Jensen, R., Johnson, D.C., 
MacIntyre, N., McKay, R., Miller, M.R., Navajas, D., Pedersen, O.F. and Wanger, J. 
(2005) 'Interpretative strategies for lung function tests', European Respiratory Journal, 
26(5), pp. 948-968. 
Penagini, R., Mangano, M. and Bianchi, P.A. (1998) 'Effect of increasing the fat content 
but not the energy load of a meal on gastro-oesophageal reflux and lower oesophageal 
sphincter motor function', Gut, 42(3), pp. 330-333. 
 
Penagini R (2000) 'Fat and gastro-oesophageal reflux disease.', European Journal of 
Gastroenterology and Hepatology, Dec;12(12), pp. 1343-5. 
 
Phitidis, M.E., Murthy, M., Hunt, N., Jones, G.H., Fox, J., Ledson, M., Greenwood, J. and 
Walshaw, M. (2014) '168 Cystic fibrosis: an ageing condition', Journal of Cystic Fibrosis, 
13, Supplement 2(0), p. S89. 
 
Quintana-Gallego, E., Delgado-Pecellín, I. and Calero Acuña, C. (2014) 'CFTR Protein 
Repair Therapy in Cystic Fibrosis', Archivos de Bronconeumología (English Edition), 
50(4), pp. 146-150. 
 
Quon, B.S. and Aitken, M.L. (2012) 'Cystic Fibrosis: What to Expect now in the Early 
Adult Years', Paediatric Respiratory Reviews, 13(4), pp. 206-214. 
 
Ramsey, B. W., J. Davies, et al. (2011). "A CFTR Potentiator in Patients with Cystic 
Fibrosis and the G551D Mutation." New England Journal of Medicine 365(18): 1663-
1672. 
 
Robertson, A.G.N., Krishnan, A., Ward, C., Pearson, J.P., Small, T., Corris, P.A., Dark, 
J.H., Karat, D., Shenfine, J. and Griffin, S.M. (2012) 'Anti-reflux surgery in lung 
transplant recipients: outcomes and effects on quality of life', European Respiratory 
Journal, 39(3), pp. 691-697. 
 
Robinson, N.B. and DiMango, E. (2014) 'Prevalence of Gastroesophageal Reflux in Cystic 
Fibrosis and Implications for Lung Disease', Annals of the American Thoracic Society, 
11(6), pp. 964-968. 
 
205 
 
Robinson, P.J., Smith, A.L. and Sly, P. (1990) 'Duodenal pH in cystic fibrosis and its 
relationship to fat malabsorption.', Digestive Diseases & Sciences, Oct;35(10), pp. 1299-
304. 
 
Ronkainen, J. and Agréus, L. (2013) 'Epidemiology of reflux symptoms and GORD', Best 
Practice & Research Clinical Gastroenterology, 27(3), pp. 325-337. 
 
Rosaida MS, Goh KL. (2004) Gastro-oesophageal reflux disease, reflux oesophagitis and 
non-erosive reflux disease in a multiracial Asian population: a prospective, endoscopy 
based study. Eur J Gastroenterol Hepatol. 16: 495-501 
 
Ruhl, C. E. and J. E. Everhart (1999). "Overweight, but Not High Dietary Fat Intake, 
Increases Risk of Gastroesophageal Reflux Disease Hospitalization: The NHANES I 
Epidemiologic Followup Study." Annals of Epidemiology 9(7): 424-435. 
 
Ruigómez, A., García Rodríguez, L.A., Wallander, M.A., Johansson, S., Graffner, H. and 
Dent, J. (2004) 'Natural history of gastro-oesophageal reflux disease diagnosed in general 
practice', Alimentary Pharmacology & Therapeutics, 20(7), pp. 751-760. 
 
Ruigomez, A., Wallander, M.-A., Lundborg, P., Johansson, S. and Garcia-Rodriguez, L. 
(2008) 'T1981 Gastroesophageal Reflux Disease in Children and Adolescents in Primary 
Care: Incidence, Prevalence and Treatment Patterns', Gastroenterology, 134(4, 
Supplement 1), pp. A-593. 
 
Reznikov, L.R., Abou Alaiwa, M.H., Dohrn, C.L., Gansemer, N.D., Diekema, D.J., Stoltz, 
D.A. and Welsh, M.J.(2014) 'Antibacterial properties of the CFTR potentiator ivacaftor', 
Journal of Cystic Fibrosis, (0). 
 
Sabati, A.A., Kempainen, R.R., Milla, C.E., Ireland, M., Schwarzenberg, S.J., Dunitz, J.M. 
and Khan, K.M. (2010) 'Characteristics of gastroesophageal reflux in adults with cystic 
fibrosis', Journal of Cystic Fibrosis, 9(5), pp. 365-370. 
 
Saberi-Firoozi Mehdi, Yazdanbakhsh Mohammad A, Heidari Seyed-Taghi, 
Khademolhosseini Farnaz, Mehrabani Davood (2007) Correlation of gastroesophageal 
reflux disease with positive family history and headache in Shiraz city, Southern Iran.  
Saudi J Gastroenterol.13;  4, 176-179  
 
Sagel, S.D., Chmiel, J.F. and Konstan, M.W. (2007) 'Sputum Biomarkers of Inflammation 
in Cystic Fibrosis Lung Disease', Proceedings of the American Thoracic Society, 4(4), pp. 
406-417. 
 
Saiman, L. and Prince, A. (1993) 'Pseudomonas aeruginosa pili bind to asialoGM1 which 
is increased on the surface of cystic fibrosis epithelial cells', The Journal of Clinical 
Investigation, 92(4), pp. 1875-1880. 
 
Salvatore, D., Buzzetti, R., Baldo, E., Furnari, M.L., Lucidi, V., Manunza, D., Marinelli, I., 
Messore, B., Neri, A.S., Raia, V. and Mastella, G. (2012) 'An overview of international 
literature from cystic fibrosis registries. Part 4: Update 2011', Journal of Cystic Fibrosis, 
11(6), pp. 480-493. 
 
206 
 
Savarino, E., Carbone, R., Marabotto, E., Furnari, M., Sconfienza, L., Ghio, M., Zentilin, 
P. and Savarino, V. (2013) 'Gastro-oesophageal reflux and gastric aspiration in idiopathic 
pulmonary fibrosis patients', European Respiratory Journal, 42(5), pp. 1322-1331. 
 
Scott, R.B., O'Loughlin, E.V. and Gall, D.G. (1985) 'Gastroesophageal reflux in patients 
with cystic fibrosis', The Journal of Pediatrics, 106(2), pp. 223-227. 
 
Sagel, S.D., Chmiel, J.F. and Konstan, M.W. (2007) 'Sputum Biomarkers of Inflammation 
in Cystic Fibrosis Lung Disease', Proceedings of the American Thoracic Society, 4(4), pp. 
406-417. 
 
Sharma, R., Florea, V.G., Bolger, A.P., Doehner, W., Florea, N.D., Coats, A.J.S., Hodson, 
M.E., Anker, S.D. and Henein, M.Y. (2001) 'Wasting as an independent predictor of 
mortality in patients with cystic fibrosis', Thorax, 56(10), pp. 746-750. 
 
 
Shapiro, M., C. Green, et al. (2007). "Assessment of dietary nutrients that influence 
perception of intra-oesophageal acid reflux events in patients with gastro-oesophageal 
reflux disease." Alimentary Pharmacology & Therapeutics 25(1): 93-101. 
 
Shanks, K.K., Guang, W., Kim, K.C. and Lillehoj, E.P. (2010) 'Interleukin-8 Production 
by Human Airway Epithelial Cells in Response to Pseudomonas aeruginosa Clinical 
Isolates Expressing Type a or Type b Flagellins', Clinical and Vaccine Immunology, 17(8), 
pp. 1196-1202. 
 
Sheikh, S.I., Ryan-Wenger, N.A. and McCoy, K.S. (2013) 'Outcomes of surgical 
management of severe GERD in patients with cystic fibrosis', Pediatric Pulmonology, 
48(6), pp. 556-562. 
 
 
Sifrim, D. and Holloway, R. (2001) 'Transient lower esophageal sphincter relaxations: 
how many or how harmful[quest]', Am J Gastroenterol, 96(9), pp. 2529-2532. 
 
Simmonds, N. J. (2013). "Ageing in Cystic Fibrosis and Long-term Survival." Paediatric 
Respiratory Reviews 14, Supplement 1(0): 6-9. 
Simmonds, N.J., Cullinan, P. and Hodson, M.E. (2009) 'Growing old with cystic fibrosis – 
The characteristics of long-term survivors of cystic fibrosis', Respiratory Medicine, 103(4), 
pp. 629-635. 
 
Simon, M. I. S. S., M. Drehmer and S. S. Menna-Barreto (2009). "Association between 
nutritional status and dietary intake in patients with cystic fibrosis." Associação entre o 
estado nutricional e a ingestão dietética em pacientes com fibrose cística 35(10): 966-972. 
 
Sinaasappel, M., M. Stern, J. Littlewood, S. Wolfe, G. Steinkamp, H. G. M. Heijerman, E. 
Robberecht and G. Döring (2002). "Nutrition in patients with cystic fibrosis: a European 
Consensus." Journal of Cystic Fibrosis 1(2): 51-75. 
Smyth, A. and Elborn, J.S. (2008) 'Exacerbations in cystic fibrosis: 3 · Management', 
Thorax, 63(2), pp. 180-184. 
 
207 
 
Smyth, A.R., Bell, S.C., Bojcin, S., Bryon, M., Duff, A., Flume, P., Kashirskaya, N., 
Munck, A., Ratjen, F., Schwarzenberg, S.J., Sermet-Gaudelus, I., Southern, K.W., Taccetti, 
G., Ullrich, G. and Wolfe, S. (2014) 'European Cystic Fibrosis Society Standards of Care: 
Best Practice guidelines', Journal of Cystic Fibrosis, 13, Supplement 1(0), pp. S23-S42. 
 
Stack, M., M. Mahony and C. Boyle (2007). "220 Obesity in childhood cystic fibrosis." 
Journal of Cystic Fibrosis 6, Supplement 1(0): S54. 
 
Stallings, V. A., L. J. Stark, K. A. Robinson, A. P. Feranchak and H. Quinton (2008). 
"Evidence-Based Practice Recommendations for Nutrition-Related Management of 
Children and Adults with Cystic Fibrosis and Pancreatic Insufficiency: Results of a 
Systematic Review." Journal of the American Dietetic Association 108(5): 832-839. 
 
Stephenson, A. L., L. A. Mannik, S. Walsh, M. Brotherwood, R. Robert, P. B. Darling, R. 
Rosane Nisenbaum, J. Moerman and S. Stanojevic (2013). "Longitudinal trends in 
nutritional status and the relation between lungfunction and BMI in cystic fibrosis: a 
population-based cohort study." Am J Clin Nutr 97: 872-827. 
 
Starosta, V., Kitz, R., Hartl, D., Marcos, V., Reinhardt, D. and Griese, M. (2007) 
'BRonchoalveolar pepsin, bile acids, oxidation, and inflammation in children with 
gastroesophageal reflux disease*', CHEST Journal, 132(5), pp. 1557-1564. 
 
Steinkamp, G. and Wiedemann, B. (2002) 'Relationship between nutritional status and 
lung function in cystic fibrosis: cross sectional and longitudinal analyses from the German 
CF quality assurance (CFQA) project', Thorax, 57(7), pp. 596-601. 
 
 
Stovold, R., Forrest, I.A., Corris, P.A., Murphy, D.M., Smith, J.A., Decalmer, S., Johnson, 
G.E., Dark, J.H., Pearson, J.P. and Ward, C. (2007) 'Pepsin, a Biomarker of Gastric 
Aspiration in Lung Allografts', American Journal of Respiratory and Critical Care 
Medicine, 175(12), pp. 1298-1303. 
 
Strugala, V., McGlashan, J.A., M.G, W., Morice, A.H., Granier, B. and Dettmar, P.W. 
(2007) 'Detection of pepsin using a non-invasive lateral flow test for the diagnosis of 
extra-oesophageal reflux - results of a pilot study', Gut, Suppl III, p. A212. 
 
Tasker, A., Dettmar, P.W., Panetti, M., Koufman, J.A., Birchall, J.P. and Pearson, J.P. 
(2002) 'Reflux of gastric juice and glue ear in children', The Lancet, 359(9305), p. 493. 
 
Thomson, A. and A. Harris (2008). Cystic Fibrosis The Facts, Oxford University Press, 
2008. 
 
Thomas B. and Bishop J, (2007) Manual of Dietetic Practice, 4
th
 Edition. Oxford, 
Blackwell Publishing LTD 
 
Tsui, L.C., Buchwald, M., Barker, D., Braman, J.C., Knowlton, R., Schumm, J.W., Eiberg, 
H., Mohr, J., Kennedy, D. and Plavsic, N. (1985) 'Cystic fibrosis locus defined by a 
genetically linked polymorphic DNA marker', Science., 230(4729), pp. 1054-7. 
 
208 
 
van der Doef, H.P.J., Arets, H.G.M., Froeling, S.P., Westers, P. and Houwen, R.H.J. (2009) 
'Gastric Acid Inhibition for Fat Malabsorption or Gastroesophageal Reflux Disease in 
Cystic Fibrosis: Longitudinal Effect on Bacterial Colonization and Pulmonary Function', 
The Journal of Pediatrics, 155(5), pp. 629-633. 
 
Van Goor F, Hadida S, Grootenhuis P D J, Burton B, Cao D, Neuberger T, Turnbull A, 
Singh A, Joubran J, Hazlewood A, Zhou J, McCartney J, Arumugam V, Decker C, Yang J, 
Young C, Olsonb E R, Winec J J, Frizzelld R A, Ashlocke M, Negulescua P. (2009) 
‘Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770.’ 
PNAS 106 , 44: 18825–18830 
 
Van Goor F, Yu H, Burton B, Hoffman B J. (2013) ‘Effect of ivacaftor on CFTR forms 
with missense mutations associated with defects in protein processing or function.’ Journal 
of Cystic Fibrosis IN PRESS 
 
van Pinxteren B, Numans M, Lau J, de Wit NJ, Hungin APS, Bonis PAL: Short-term 
treatment of gastroesophageal reflux disease. A systematic review and meta-analysis of 
the effect of acid-suppressant drugs in empirical treatment and in endoscopy-negative 
patients. J Gen Intern Med 2003, 18:755-763. 
 
Vakil, N. (2010). "Disease definition, clinical manifestations, epidemiology and natural 
history of GERD." Best Practice & Research Clinical Gastroenterology 24(6): 759-764. 
 
Vemulapalli, R. (2008). "Diet and lifestyle modifications in the management of 
gastroesophageal reflux disease." Nutrition in Clinical Practice 23(3): 293-298. 
Veeze, H.J. (1995) 'Diagnosis of cystic fibrosis', The Netherlands Journal of Medicine, 
46(6), pp. 271-274. 
 
Vinocur, C.D., Marmon, L., Schidlow, D.V. and Weintraub, W.H. (1985) 
'Gastroesophageal reflux in the infant with cystic fibrosis', The American Journal of 
Surgery, 149(1), pp. 182-186. 
 
Wang, Y., Goulart, R.A. and Pantanowitz, L. (2010) 'Oil Red O Staining in 
Cytopathology', Diagnostic Cytopathology, 39(4), pp. 272-3. 
 
Wang JH, Luo JY, Dong L, Gong J, Tong M. Epidemiology of gastroesophageal reflux 
disease: a general population-based study in Xi’an of Northwest China. World J 
Gastroenterol 2004; 10: 1647-1651    
 
Waugh, A., Grant, A.W., Chambers, G., Ross, J.S. and Wilson, K.J.W. (2006) Ross and 
Wilson anatomy and physiology in health and illness. Churchill Livingstone. 
 
Weusten, B.L., Akkermans, L.M., vanBerge-Henegouwen, G.P. and Smout, A.J. (1995) 
'Dynamic characteristic of gastro-oesophageal reflux in ambulatory patients with gastro-
oesophageal reflux disease and normal control subjects.', Scand J Gastroenterol., 
Aug;30(8), pp. 731-7. 
 
Webster-Gandy, J., A. Madden and M. Holdsworth (2012). Oxford Handbook of Nutrition 
and Dietetics, OUP Oxford. 
 
209 
 
White, H., A. M. Morton, D. G. Peckham and S. P. Conway (2004). "Dietary intakes in 
adult patients with cystic fibrosis–do they achieve guidelines?" Journal of Cystic Fibrosis 
3(1): 1-7. 
 
WHO. (1998). "International Obesity Task Force. Obesity: preventing and managing the 
global epidemic. Report of the WHO consultation on obesity, Geneva, 3-5th June  1998." 
Geneva: WHO, 1998. 
 
Wilson, D. C. and P. B. Pencharz (1998). "Nutrition and cystic fibrosis." Nutrition 14(10): 
792-795.  
 
Woodley, F., Machado, R., Hayes, D., Jr., Lorenzo, C., Kaul, A., Skaggs, B., McCoy, K.,  
Patel, A. and Mousa, H. (2014) 'Children with Cystic Fibrosis Have Prolonged Chemical 
Clearance of Acid Reflux Compared to Symptomatic Children Without Cystic Fibrosis', 
Digestive Diseases and Sciences, 59(3), pp. 623-630. 
 
Yankaskas, J. R., B. C. Marshall, B. Sufian, R. H. Simon and D. Rodman (2004). "Cystic 
fibrosis adult care*: Consensus conference report." CHEST Journal 125(1_suppl): 1S-39S. 
  
W, Chiaw P K and Bear C E. (2011) ‘Probing Conformational Rescue Induced by a 
Chemical Corrector of F508del-Cystic Fibrosis Transmembrane Conductance Regulator 
(CFTR) Mutant.’ Journal of Biological Chemistry 286, 28: 24714-24725 
 
Yu H, Burton B, Huang C J, Worley J, Cao D, Johnson J P, Urrutia A, Joubran J, 
Seepersaud, Sussky S K, Hoffman B J, Van Goor F. (2012) ‘Ivacaftor potentiation of 
multiple CFTR channels with gating mutations.’ Journal of Cystic Fibrosis 11: 237–245 
 
Zerbib, F., Bruley Des Varannes, S., Roman, S., Pouderoux, P., Artigue, F., Chaput, U., 
Mion, F., Caillol, F., Verin, E., Bommelaer, G., DucrottÉ, P., Galmiche, J.P. and Sifrim, D. 
(2005) 'Normal values and day-to-day variability of 24-h ambulatory oesophageal 
impedance-pH monitoring in a Belgian–French cohort of healthy subjects', Alimentary 
Pharmacology & Therapeutics, 22(10), pp. 1011-1021. 
 
Zerbib, F., Sifrim, D., Tutuian, R., Attwood, S. and Lundell, L. (2013) 'Modern medical 
and surgical management of difficult-to-treat GORD', Jornal of United European 
Gastroenterol, Feb;1(1), pp. 21-31. 
 
Zheng, Z., H. Nordenstedt, et al. (2007). "Lifestyle Factors and Risk for Symptomatic 
Gastroesophageal Reflux in Monozygotic Twins." Gastroenterology 132(1): 87-95. 
  
 
 
 
 
 
 
210 
 
8.0 Appendix 
8.1 Appendix 1 Ethical approval and NHS R&D approval 
 
211 
 
 
 
 
 
212 
 
8.2 Appendix 2 Patient information sheet and consent form 
 
 
 
 
213 
 
 
 
 
 
 
 
214 
 
8.3 Appendix 3 Questionnaire(s) 
1 The DeMeester reflux questionnaire 
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2. The Reflux Symptom Index (RSI) 
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3. The Hull Airway Reflux Questionnaire (HARQ) 
 
Within the last month, how did the following problems affect you?  
                                                                                     0 = no problem  5= severe/frequent 
problem 
 0 1 2 3 4 5 
Hoarseness or problem with your voice       
Clearing your throat       
The feeling of something dripping down the back 
of your nose or throat 
      
Retching or vomiting when you cough       
cough or shortness of breath on first lying down or 
bending over 
      
chest tightness or wheeze when coughing       
heartburn, indigestion, stomach acid coming up (or 
medication =5) 
      
A tickle in your throat, or a lump in your throat       
cough or shortness of breath with eating (during or 
soon after) 
      
cough or shortness of breath when you get out of 
bed in the morning 
      
cough or shortness of breath brought on by singing 
or speaking (telephone) 
      
coughing more when awake rather than asleep       
a strange taste in your mouth       
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8.5 Appendix 5 Abstracts 
 
Gastric aspiration into the CF lung; relationship with reflux symptoms and lung function 
G.L. Crossfield
1
, A. Krishnan
2
, J. Lordan
3
, S. Bourke
4
, A. Anderson
4
, P.W. Dettmar
5
, I.A. Brownlee
6
, 
C. Ward
7
, J.P. Pearson
1 
 
1
Institute of Cell and Molecular Bioscience, Faculty of Medical Sciences, Newcastle University, 
Newcastle Upon Tyne, United Kingdom, 
2
Northern Oesophago-Gastric Unit, Royal Victoria Infirmary, 
Newcastle Upon Tyne, United Kingdom, 
3
Institute of Transplantation, The Freeman Hospital, 
Newcastle Upon Tyne, United Kingdom, 
4
Royal Victoria Infirmary, Newcastle Upon Tyne, United 
Kingdom, 
5
Technostics Ltd, Daisy Building, 2nd Floor, Castle Hill Hospital, Cottingham, East 
Yorkshire, United Kingdom, 
6
Food and Human Nutrition Department, Nanyang Polytechnic, Newcastle 
University, Singapore, 
7
Institute of Cellular Medicine, Faculty of Medical Sciences, Newcastle 
University, Newcastle Upon Tyne, United Kingdom 
Objectives: Gastro-oesophageal reflux (GOR) is the retrograde movement of gastric contents up the 
oesophagus. This results in both classical and atypical symptoms. GOR is common in CF affecting 35-
81% of patients and it may be associated with deteriorating lung function. We investigated 
microaspiration into the CF lung, characterised symptoms of reflux and compared these parameters 
with lung function. 
 
Methods: FEV1 % predicted was recorded in 37 CF patients (19 male), mean age 29 (range 17-60) 
years. GOR symptom severity was assessed using the DeMeester Reflux score (0-9; < 1 normal) and 
extra oesophageal reflux (EOR) using the Reflux Symptom Index (RSI) score (0-45; < 13 normal). 
Pepsin (ELISA) and total bile acids (TBA) (mass spectrometry) were measured in the sputum of 29 and 
24 CF patients respectively. 
 
Results: Pepsin was identified in 17 of 29 (59%) (median 111ng/ml) and TBA in 23 of 24 (96%) 
(median 0.18µMol/L) patients. RSI scores showed atypical symptoms in 87% of patients, whereas, 
classical symptoms (DeMeester scores) were identified in 43% of patients. 88% pepsin-positive and 
87% TBA- positive patients suffered EOR symptoms, however 53% pepsin-positive and 61% TBA-
positive patients experienced GOR symptoms. FEV1 ranged from 12% to 101% of predicted (median 
43%) but was not correlated with biomarkers or symptoms of reflux.  
 
Conclusion: Gastric and biliary reflux into the lungs are very common in CF patients. EOR symptoms 
may be more closely associated with CF than GOR. Microaspiration of gastric content into the lung 
was not correlated with FEV1 and occurred across the spectrum of disease severity.  
 
Keywords: Gastro-oesophageal reflux, cystic fibrosis, FEV1 
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Overweight and obesity challenges in the Cystic Fibrosis population – a need for 
revision in nutritional advice? By G. L. Crossfield 
1
, A. Krishnan 
2
, S. Bourke 
3
, A. 
Anderson 
3
, A. Gurney 
3
, P.  W. Dettmar 
4
, I. Brownlee 5, C. Ward 
6
 and  J. P. Pearson 
1
, 
1
Institute of Cell and Molecular Bioscience, Faculty of Medical Sciences, Newcastle 
University, Newcastle Upon Tyne, NE2 4HH; 
2
Northern Oesophago-Gastric Unit, Royal 
Victoria Infirmary, Newcastle Upon Tyne, NE1 4LP; 
3
Royal Victoria Infirmary, Newcastle 
Upon Tyne, NE1 4LP; 
4
Technostics Ltd, Daisy Building, 2nd Floor, Castle Hill Hospital, 
Cottingham, East Yorkshire, HU16 5JQ; 
5
Food and Human Nutrition Department, 
Nanyang Polytechnic, Newcastle University, Singapore; 
6
 Institute of Cellular Medicine, 
Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne, NE2 4HH. 
 
Cystic fibrosis (CF) is the most common inherited autosomal recessive disease in 
Caucasian populations leading to pulmonary and digestive complications. CF is often 
associated with malnutrition due to the increased energy demands of chronic lung 
infection and reduced nutritional intake associated with anorexia and fat malabsorption. A 
high fat and high calorie diet is therefore advised. The importance of nutritional care has 
been evident for >3 decades as an increase in Body Mass Index (BMI) has been associated 
with an increase in pulmonary function (FEV1)  and improved  survival. In recent times 
reported overweight and obese BMI scores are increasing and the potential health risks are 
not understood in our ever aging CF population
(1)
. Authors suggested that there were 
lower numbers of homozygous ∆F508 genotypes with a BMI >25. It has been proposed 
that dietary advice may need to be modified for CF patients with a BMI >25 or those 
expressing a heterozygous ∆F508 genotype
(2)
. The aim of the study was to evaluate the 
relationship between CFTR genotype with BMI and pulmonary function in CF patients.        
        Between April 2011 and April 2013 sixty four CF patients (37M/27F, median age 29 
(17-60) years) were recruited from their routine appointments at the adult CF clinic and 
were measured for BMI (km/m
2
). The patients were grouped according to the following 
BMI categories: underweight (UW): <18.5 km/m
2
, normal weight (NW): 18.5-25.0 km/m
2
, 
overweight (OW): 25.1-30.0 km/m
2
 and obese (OB): >30.1 km/m
2
. Lung function (FEV1 % 
predicted) and genotype were recorded at the time of data collection. To evaluate the 
relationship between BMI or pulmonary function with genotype the Kruskal-Wallis 
statistical test was used followed by the Mann Whitney U test.  
        Of the total 64 patients 9% were UW, 72% achieved a NW, 17% were OW, and 1 
patient was OB. Increased BMI scores were associated with improved pulmonary function 
(FEV1 % predicted, mean (range): UW:41 (25–53); NW:45 (12–92); OW:75 (54–110); 
OB:90 (P < 0.05). Twenty of the 64 CF patients were homozygous for the ΔF508 mutation; 
the remaining 44 were heterozygous (ΔF508/other). No association was observed between 
CF genotype status and BMI or pulmonary function. 
     The body weight of the CF population is increasing due to improvements in clinical 
care and today we observe BMI scores reaching OW and OB categories. The potential 
health risks of OW and OB in the CF population are not completely understood but the 
benefits of increased pulmonary function scores regardless of genotype are evident. Long 
term follow up studies are needed before a revision of dietary advice is proposed to CF 
patients. 
 
1. Kastner-Cole D, Palmer CNA, Ogston SA et al. (2005) J Pediatrics 147, 402-404. 
2. Stephenson AL, Mannik LA, Walsh S et al. (2013) Am J Clin Nutr 97, 872-7. 
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Pepsin detection despite the use of acid suppressant medication in patients with 
airway reflux related chronic cough 
Gemma L Crossfield, Warren Jackson, Jennifer Burke,  Andrew D Woodcock, Vicki 
Strugala, Chris Ward, Jeffrey P Pearson, Peter W Dettmar, Alyn H Morice 
Background 
Chronic cough (CC) is an increasing problem that is not easy to treat with medication. 
Associated symptoms include hoarse voice, dysphonia, persistent tickling and irritation of 
the throat or chest. These lead to poor sleeping and eating patterns, loss of vocal 
independence and social isolation all resulting in an impaired quality of life. Airway reflux 
is a common cause of unexplained chronic cough and proton pump inhibitor (PPI) 
medication is commonly prescribed as initial therapy. The following study assessed pepsin 
identification in CC patients as a marker of airway reflux on PPI. 
Methods 
Symptomatic expectorated saliva samples were obtained from 16 patients (6 male/10 
female, 50 years (37–76), Body Mass Index (BMI) 30 (24-44) median (range)) attending 
clinical appointment with symptoms of chronic cough. Pepsin was identified using the 
Peptest
TM
 an in vitro diagnostic medical device specific for human pepsin A (RD Biomed 
Ltd, UK). All patients completed the Hull Airways Reflux Questionnaire (HARQ) to 
determine airway reflux related cough (range 0-70; <13 normal). Patient demographics 
and medication data was provided on sample collection. 
Results 
Fourteen (88%) of the CC patients were positive for pepsin in saliva samples (median 
83ng/ml; range 25–250), providing non-invasive verification of presence of reflux in this 
CC population. Thirteen pepsin positive patients were symptomatic of airway reflux 
related cough according to abnormal HARQ score (median 40; range 25–59) and all were 
taking PPI (20-60mg/d range collected from referral letter and patient questionnaire). The 
median BMI of the pepsin positive patients was 30 (range 25–44).  
Conclusion 
Pepsin was present in 88% of suspected airway reflux related chronic cough patients 
therefore corroborating the diagnosis of reflux. Airway reflux is associated with 
unexplained chronic cough in patients receiving PPI highlighting that symptoms and 
reflux are still present despite acid suppression. Overweight and obese BMI status is a 
common feature of airway reflux related chronic cough patients. A reconsideration of the 
empiric use of acid suppression use maybe warranted for unexplained chronic cough. 
 
Key words: Chronic cough, pepsin, airway reflux, acid suppressants 
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8.6 Appendix 6 ECFS travel grant 
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8.7 Appendix 7 Patient demographics 
Patient 
no 
Sex 
(m/f) 
Age Height 
(m) 
Weight 
(kg) 
BMI 
1 F 23 1.73 65.00 21.70 
2 M 22 1.85 61.70 18.00 
3 F 29 1.60 57.20 22.30 
4 M 29 1.63 61.20 23.00 
5 M 40 1.77 82.80 26.40 
6 M 20 1.77 58.50 18.70 
7 F 24 1.52 55.30 23.90 
8 M 35 1.83 73.02 21.80 
9 F 19 1.47 63.00 29.20 
10 F 60 1.67 56.24 20.10 
11 M 32 1.70 62.00 21.50 
12 F 21 1.50 46.10 20.50 
13 F 23 1.73 62.80 21.00 
14 F 28 1.60 58.50 22.90 
15 M 40 1.77 82.80 26.40 
16 F 24 1.52 53.40 23.00 
17 M 26 1.75 68.03 22.20 
18 M 19 1.67 57.20 20.50 
19 F 59 1.67 54.00 19.40 
20 M 21 1.85 52.00 15.20 
21 M 17 1.72 60.30 20.40 
22 F 34 1.67 58.96 21.10 
23 F 22 1.50 57.70 25.60 
24 F 41 1.65 60.78 22.30 
25 F 31 1.52 52.00 22.50 
26 F 29 1.60 56.30 22.00 
27 M 44 1.67 56.20 20.20 
28 F 25 1.57 59.42 23.90 
29 M 22 1.85 63.00 18.40 
30 M 32 1.70 51.00 17.60 
31 M 24 1.75 58.00 18.90 
32 M 20 1.72 64.00 21.60 
33 F 19 1.48 46.00 21.00 
34 M 21 1.78 73.00 23.00 
35 M 21 1.73 80.00 26.70 
36 M 34 1.78 63.50 20.00 
37 F 43 1.60 45.00 17.60 
38 F 39 1.65 78.00 28.70 
39 F 17 1.55 48.50 20.20 
40 M 29 1.73 57.20 19.10 
41 M 24 1.73 60.50 20.20 
42 M 23 1.70 54.00 18.70 
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43 M 44 1.83 76.00 22.70 
44 F 30 1.70 66.20 22.90 
45 F 32 1.56 50.20 20.70 
46 M 19 1.70 54.00 18.70 
47 M 20 1.69 68.00 23.80 
48 F 32 1.53 47.00 20.10 
49 M 20 1.15 48.40 21.20 
50 M 22 1.72 79.40 26.80 
51 F 21 1.54 41.40 17.50 
52 F 21 1.66 61.50 22.40 
53 F 17 1.50 47.00 18.80 
54 F 38 1.59 54.00 21.40 
55 F 20 1.46 65.80 30.90 
56 M 23 1.71 57.80 19.80 
57 M 25 1.72 77.00 26.10 
58 M 28 1.70 73.80 25.30 
59 M 24 1.73 67.40 22.50 
60 M 28 1.75 82.80 26.90 
61 M 36 1.81 70.40 21.80 
62 F 25 1.54 55.00 20.30 
63 M 31 1.80 87.00 27.90 
64 M 24 1.80 55.8 17.70 
65 M 43 1.77 69.30 22.10 
66 M 20 1.77 64.40 23.20 
67 F 25 1.54 55.00 23.10 
68 F 42 1.77 63.20 20.10 
69 M 16 1.65 47.50 17.40 
70 F 28 1.55 34.10 14.10 
71 F 24 1.55 43.10 17.90 
72 M 26 1.92 56.40 15.20 
NA F 38 1.52 47.62 20.60 
NA F 39 1.53 36.74 15.70 
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8.8 Appendix 8 Questionnaire scores 
Patient 
no 
DeMeester 
score 
Reflux 
Symptom 
Index 
(RSI) 
Hull Airway 
Reflux Cough 
Questionnaire 
(HARQ) 
 
1 6 31    
2 2 25    
3 4 22    
4 2 11    
5 1 15    
6 2 19    
7 2 14    
8 7 36    
9 5 17    
10 4 21    
11 1 8    
12 1 20    
13 2 29    
14 2 26    
15 1 17    
16 2 14    
17 1 13    
18 0 6    
19 2 17    
20 2 25    
21 0 3    
22 2 20    
23 1 12    
24 5 10    
25 0 19    
26 1 30    
27 1 17    
28 0 23    
29 3 10    
30 3 12    
31 1 24    
32 0 6    
33 0 10    
34 2 11    
35 1 8    
36 2 19    
37 4 43    
38 1 18    
225 
 
39 2 25    
40 0 16    
41 1 11    
42 0 8    
43 0 16    
44 0 19    
45 0 20    
46 2 5    
47 0 8    
48 3 20    
49 1 14 12  
50 1 2 3  
51 1 23 31  
52 0 11 7  
53 1 17 19  
54 2 29 33  
55 5 12 12  
56 2 15 15  
57 0 3 3  
58 1 4 4  
59 0 15 27  
60 1 8 8  
61 1 20    
62 1 0 0  
63 2 14 25  
64 2 9 9  
65 0 16 36  
66 1 9    
67 0 15 26  
68 0 2 1  
69 0 9 15  
70 1 25 44  
71 4 26 42  
72 1 17 32  
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8.10 Appendix 10 Medication 
Patient 
no 
Medication 
1 40mg BD 
2 30mg BD 
3 40mg BD 
4 30mg BD 
5 30mg BD 
6 20mg BD 
7 Ranitidine 300mg OD 
8 20mg BD 
9 20mg BD 
10 30mg OD 
11 15mg OD 
12 omeprazole 20mg od 
13 40mg BD 
14 omeprazole 40mg bd 
15 lansoprazole 30mg bd 
16 omeprazole 20mg bd 
17 lansoprazole 30mg od 
18 omeprazole 20mg bd 
19 lansoprazole 30mg od 
20   
21 omeprazole 10mg bd 
22 no 
23 no 
24 omeprazole 20mg bd 
25 omeprazole 20mg bd 
26 no 
27 Lansoprazole 30mg od 
28 no 
29 no 
30 no 
31   
32 omeprazole 20mg bd 
33 lansoprazole 30mg od 
34 lansoprazole 30mg prn 
35 omeprazole 20mg bd 
36 omeprazole 20mg  
37 no 
38 omeprazole X2 daily 
39 ranitidine 150mg OD 
40 lansoprazole 30mg od 
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41 no 
42 omeprazole 20mg bd 
43 omeprazole 20mg  bd 
44 omeprazole 20mg BD 
45 lansoprazole 30mg od 
46 lansoprazole 30mg bd 
47 no 
48 no 
49 omeprazole 20mg 
50 ranitidine 150mg 
51 lansoprazole 30mg bd 
52 omeprazole 20mg 
53 gaviscon prn/omeprazole 
20mg 
54 lansoprazole 30mg bd 
55 omeprazole 20mg 
56 no 
57 gaviscon prn/omeprazole 
20mg 
58 no 
59 lansoprazole 30mg 
60 no 
61 lansoprazole 30mg 
62 no 
63 no 
64 no 
65 no 
66 lansoprazole 
67 lansoprazole 15mg 
68 no 
69 lansoprazole 20mg 
70 no 
71 omeprazole 20mg/2 
72 lansoprazole 30mg/2 
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8.11 Appendix 11 Pepsin identification and quantification 
Patient 
no 
Pepsin 
ng/ml 
1 0 
2 152 
3 88 
4 0 
5 0 
6 324 
7 196 
8 112 
9 0 
10 80 
11 111 
12 296 
13 320 
14 0 
15 187 
16 0 
17 0 
18 305 
19 0 
20 0 
21 0 
22 0 
23 0 
24 275 
25 0 
26 0 
27 189 
28 147 
29 364 
30 611 
31  
32 831 
33 178 
34 0 
35  
36 800 
37  382 
38  0 
39  0 
40  570 
41  633 
42  489 
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43  920 
44  1025 
45  274 
46  0 
47  231 
48  294 
49  261 
50  0 
51 870 
52  1151 
53  283 
54  178 
55  128 
56  710 
57  116 
58  418 
59  481 
60  611 
61  387 
62  
63  597 
64  515 
65  0 
66  0 
67  246 
68  464 
69  782 
70  382 
71 270 
72 350 
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8.12 Appendix 12 Bile acid identification and quantification 
Patient 
no 
TBA 
µMol/L 
G-
DHC 
G-
THC 
T-
DHC 
T-
THC 
Total Free 
LITHOCHOLATE 
1 3.168 0.64 1.6 0.08 0.88 3.2 0.32 
2 0.2348 0 0.08 0 0.08 0.16 0.16 
3 0.11 0 0 0 0.08 0.08 0 
4 0.144 0 0.08 0 0.08 0.16 0.16 
5 0.0428 0 0 0 0 0 0.08 
6 0.1288 0.08 0 0 0.08 0.16 0.48 
7 0.374 0.24 0.08 0 0 0.32 0.24 
8 0.3216 0.16 0.16 0 0.08 0.4 0.24 
9 0.1268 0 0 0.08 0 0.08 0.24 
10 0.2744 0.16 0 0.08 0.08 0.32 0.48 
11 0.192 0 0 0 0 0 0.4 
12 0.2336 0.08 0 0.08 0.08 0.24 0.3824 
13 0 0 0 0 0 0 0.94 
14 2.42 1.44 0.48 0.32 0.24 2.48 0.9424 
15 0.0896 0 0 0 0 0 0.2176 
16 0.1208 0 0.08 0 0 0.08 0.228 
17 0.0856 0 0 0 0.08 0.08 2.0984 
18 0.2216 0.08 0.08 0 0 0.16 0.7184 
19 0.3056 0.16 0 0.16 0 0.32 0.532 
20 0.792 0.16 0.08 0.56 0.08 0.88 0.448 
21 0.2216 0.08 0.08 0 0 0.16 0.2064 
22 0.4216 0.24 0.08 0.08 0 0.4 0.4128 
23 0.1832 0.08 0.08 0 0.08 0.24 0.7704 
24 1.0488 0.8 0.16 0.08 0 1.04 0.584 
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8.13 Appendix 13 Pulmonary function 
Patient 
no 
FEV1 FEV1 
pred % 
FVC FVC 
pred % 
ratio L 
1 1.05 30 1.4 34 0.75 
2 2.55 51 4.95 84 0.52 
3 1.35 42 2.35 63 0.57 
4 1.6 43 3.1 72 0.52 
5 2.25 54 4.65 93 0.48 
6 2.1 48 4.56 88 0.46 
7 0.35 12 0.35 11 1.00 
8 1.55 36 2.05 40 0.76 
9 2.2 87 2.65 90 0.83 
10 0.91 36 1.52 50 0.60 
11 1.2 30 2.4 52 0.50 
12 0.95 36 1.5 47 0.63 
13 2.2 47 3.3 59 0.67 
14 1.35 41 2.35 62 0.57 
15 2.3 55 4.7 94 0.49 
16 0.7 25 1.2 36 0.58 
17 3.4 80 4.7 93 0.72 
18 1.05 25 2 41 0.53 
19 0.75 29 1.5 49 0.50 
20 2.2 48 3.65 71 0.60 
21 2.1 47 4 72 0.53 
22 0.9 26 1.3 34 0.69 
23 1.8 67 3.3 105 0.55 
24 1.75 57 2.5 66 0.70 
25 1.45 52 1.8 54 0.81 
26 2.5 83 3.15 91 0.79 
27 0.8 27 1.9 55 0.42 
28 1.25 43 1.7 53 0.74 
29 2.2 47 3.3 59 0.67 
30 1.35 32 1.95 40 0.69 
31 2.55 59 3.05 59 0.84 
32          
33          
34 1.93 42 3.36 60 0.57 
35 4.15 101 5.24 109 0.79 
36 1.4 35 3.6 71 0.39 
37          
38 1.9 60 2.4 68 0.79 
39 1 38 1.25 41 0.80 
40 1.45 33 2.59 50 0.56 
41 0.74 19 2.1 49 0.35 
42 3 69 4.65 91 0.65 
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43 1.7 43 2.45 48 0.69 
44          
45 0.95 34 1.5 46 0.63 
46 2.06 54 2.95 65 0.70 
47 3.35 82 3.97 83 0.84 
48 1.15 41 1.3 40 0.88 
49 2.05 92 2.4 92 0.85 
50 4.51 110 5.73 119 0.79 
51 0.85 28 1.6 47 0.53 
52 3 90 3.95 100 0.76 
53 1.94 87 2.2 89 0.88 
54 0.95 35 2.38 78 0.40 
55 2.3 90 2.6 89 0.88 
56 0.8 19 1.75 35 0.46 
57 3.7 88 4.9 99 0.76 
58 2.85 70 4.7 99 0.61 
59 2.75 64 3.8 74 0.72 
60 2.75 64 4 78 0.69 
61 1.4 32 2.1 40 0.67 
62 1.75 54 2.9 78 0.60 
63 3.05 69 4.3 83 0.71 
64 3.25 53 3.75 71 0.87 
65           
66 2.1 58 3.96 93 0.53 
67           
68 1.4 39 3.2 100 0.44 
69           
70           
71 0.9 30 1.3 38 0.69 
72 2.15 56 2.7 59 0.80 
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8.14 Appendix 14 Genetics 
Patient 
no 
genetic mutation 
1 (?508/-) 
2 (?508/?508) 
3 (?508/N1303K) 
4 (?508/?508) 
5 (?508/?508) 
6 (?508/NMD) 
7 (?508/2184delA) 
8 (?508) 
9 (?508/9551D) 
10 (?508/D1152H) 
11 (?508) 
12 ?F508/ ?F508 
13  
14 ?F508/ N1303K 
15 ?F508/ ?F508 
16 ?F508/ 2184DELA A 
17 1145INSTC/ 3659DEL C 
18 ?F508/ ?F508 
19 ?F508/ 01152H 
20  
21 ?F508/ ?F508 
22 ?F508/ ?F508 
23 ?F508/ ?F508 
24 ?F508/ P67l 
25 ?F508/ E60X 
26 ?F508/ 1154 
27 ?F508/ ? 
28 ?F508/ ?F508 
29 ?F508/ ?F508 
30 ?F508/ ?F508 
31  
32  
33  
34 ?F508/ ?F508 
35 ?F508/G551D 
36 ?F508/ ?1507 
37  
38 ?F508/c.3140-26A.G 
39 ?F508/ ?F508 
40 ?F508/ ?F508 
41 ?F508/ R560T 
42 ?F508/A1507 
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43 ?F508/ ?F508 
44  
45 ?F508/ ?F508 
46 ?F508/ ?F508 
47 ?F508/R56OT 
48 ?F508/E6OX 
49 ?F508/G551D 
50 ?F508/G551D 
51 ?F508/G551D 
52 ?F508/G551D 
53 ?F508/G551D 
54 ?F508/G551D 
55 ?F508/G551D 
56 ?F508/G551D 
57 ?F508/G551D 
58 ?F508/G551D 
59 ?F508/G551D 
60 ?F508/G551D 
61 ?F508/? 
62 ?F508/?F508 
63 ?F508/?F508 
64 ?F508/621+1G>T 
65  
66 ?F508/R117H-5T 
67  
68 ^ F508/P67L 
69   
70   
71 ^ F508/^ F508 
72 ^ F508/^ F508 
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8.15 Appendix 15 Inflammatory analysis 
patient 
no 
IL8 
ng/ml 
IL6 
pg/ml 
1 12 0 
2 4.5 0 
3 9 0 
4 14 0 
5 4.5 78 
6 17 0 
7 7.5 0 
8 8 0 
9 8 0 
10 6 266 
11 9 70 
12 3.1  
13 10 32 
14 1 0 
15   
16 27 105 
17   
18   
19   
20 24 0 
21 2 0 
22 5 0 
23   
24 6 0 
25 14 0 
26 19 105 
27 8 0 
28 14 166 
29 6 0 
30 10 0 
31   
32 17 0 
33 16 0 
34 14 0 
35   
36 4 0 
37 12 0 
38 2 0 
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39 19 0 
40 3 0 
41 5 244 
42 19 58 
43 23 0 
44 8 0 
45 5 0 
46 9 0 
47 2 0 
48 11 0 
49 7 290 
50 10 249 
51  4  
52 9 0 
53 15 94 
54 2 0 
55 16 0 
56 11 87 
57 3 0 
58 4 0 
59 11 0 
60 9 107 
61 35 0 
62   
63 12 41 
64 30 0 
65 8 0 
66 17 704 
67 8 0 
68 14 0 
69 5 0 
70 7 0 
71  3  0 
72  4  0 
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Patient no Neutrophils % Eosinophils % Macrophages % Lymphocytes % 
1 100 0 0 0 
2 100 0 0 0 
3 99 0 0 1 
4 100 0 0 0 
5 100 0 0 0 
6 99.4 0 0 0.6 
7 100 0 0 0 
8 99.4 0 0 0.6 
9 99.2 0.8 0 0 
10 100 0 0 0 
11 100 0 0 0 
12 99.6 0.4 0 0 
12 100 0 0 0 
14 97.2 0 1.6 1.2 
16 100 0 0 0 
17 100 0 0 0 
18 100 0 0 0 
19 99.4 0 0 0.6 
20 99.8 0 0 0.2 
22 100 0 0 0 
23 100 0 0 0 
24 100 0 0 0 
25 100 0 0 0 
26 99.4 0.6 0 0 
27 100 0 0 0 
28 99.8 0 0 0.2 
29 100 0 0 0 
34 100 0 0 0 
35 100 0 0 0 
36 100 0 0 0 
37 100 0 0 0 
49 100 0 0 0 
51 100 0 0 0 
53 99 0 1 0 
56 100 0 0 0 
60 100 0 0 0 
 
 
        
 
